sore B-PHE
; O
pain B-PHE
; O
to O
ache B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
( O
Powder O
insufflation O
for O
pharyngitis B-PHE
and O
diphtheria B-PHE
) O
. O

-DOCSTART- O


NRP409 O
is O
presumed O
to O
work O
like O
the O
endogenous O
thyroid B-PHE
hormone I-PHE
thyroxine B-PHE
( O
T O
4 O
, O
a O
tetra-iodinated O
tyrosine O
derivative O
) O
. O

In O
the O
liver B-PHE
and O
kidney B-PHE
, O
T O
4 O
is O
converted O
to O
T O
3, O
the O
active O
metabolite B-PHE
. O

In O
order O
to O
increase O
solubility O
, O
the O
thyroid B-PHE
hormones I-PHE
attach O
to O
thyroid O
hormone O
binding O
proteins O
, O
thyroxin-binding B-PHE
globulin I-PHE
, O
and O
thyroxin-binding B-PHE
prealbumin I-PHE
( O
transthyretin B-PHE
) O
. O

Transport O
and O
binding O
to O
thyroid O
hormone O
receptors O
in O
the O
cytoplasm O
and O
nucleus O
then O
takes O
place O
. O

Thus O
by O
acting O
as O
a O
replacement O
for O
natural O
thyroxine B-PHE
, O
symptoms O
of O
thyroxine B-PHE
deficiency I-PHE
are O
relieved O
. O

-DOCSTART- O


cold B-PHE
sweating I-PHE
at O
night O

-DOCSTART- O


To O
lower O
blood B-PHE
pressure I-PHE
, O
supplement O
liver B-PHE
and O
kidney B-PHE
, O
strengthen O
sinews B-PHE
and O
bones B-PHE
, O
quiet O
fetus O
. O

-DOCSTART- O


edema B-PHE

-DOCSTART- O


high B-PHE
fever I-PHE
due O
to O
shaking B-PHE
chills I-PHE
during O
fever B-PHE

-DOCSTART- O


pain B-PHE
with O
1 O
hernia B-PHE
2 O
diseases B-PHE
of I-PHE
genitalia I-PHE
3 O
. O
severe O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE

-DOCSTART- O


Both O
tolterodine O
and O
its O
active O
metabolite O
, O
5-hydroxymethyltolterodine O
, O
act O
as O
competitive O
antagonists O
at O
muscarinic O
receptors O
. O

This O
antagonism O
results O
in O
inhibition O
of O
bladder B-PHE
contraction I-PHE
, O
decrease O
in O
detrusor B-PHE
pressure I-PHE
, O
and O
an O
incomplete O
emptying O
of O
the O
bladder B-PHE
. O

-DOCSTART- O


regulate O
menstruation B-PHE

-DOCSTART- O


To O
promote O
contraction O
and O
stem O
desertion O
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


smallpox B-PHE

-DOCSTART- O


profuse B-PHE
metrorrhagia I-PHE

-DOCSTART- O


Treatment O
of O
bdominal O
pain B-PHE
and O
constipation B-PHE
due O
to O
cold B-PHE
or O
retention B-PHE
of I-PHE
food I-PHE
in O
the O
intestines O
. O

-DOCSTART- O


suffering B-PHE
from O
diarrhea B-PHE
and O
having O
a O
stomachache B-PHE

-DOCSTART- O


To O
regulate O
cold B-PHE
and O
heat B-PHE
, O
regulate O
the O
functions B-PHE
of I-PHE
the I-PHE
stomach I-PHE
and O
lower O
down O
the O
adverse O
rising O
energy O
. O

-DOCSTART- O


cataract B-PHE
and O
nebula B-PHE

-DOCSTART- O


Used O
principally O
as O
an O
analgesic O
. O

-DOCSTART- O


Retention O
of O
moisture O
, O
dermatological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
caused O
by O
heat B-PHE
toxin I-PHE

-DOCSTART- O


dispel O
wind B-PHE

-DOCSTART- O


General O
woman O
, O
Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Leukemia B-PHE

-DOCSTART- O


injury B-PHE
by I-PHE
knife I-PHE

-DOCSTART- O


Atopic B-PHE
Dermatitis I-PHE

-DOCSTART- O


Chinese O
herbal O
medicine O
( O
CHM O
) O
, O
either O
in O
single O
herb O
or O
in O
herbal O
formula O
, O
has O
been O
used O
to O
treat O
insomnia B-PHE
for O
more O
than O
2000 O
years O
. O

A O
systematic O
review O
including O
Chinese O
and O
English O
literature O
of O
randomized O
controlled O
trials O
was O
conducted O
to O
examine O
the O
efficacy O
, O
safety O
, O
and O
composition O
of O
CHM O
for O
insomnia B-PHE
. O

Among O
the O
217 O
studies O
we O
have O
reviewed O
, O
only O
eight O
had O
a O
Jadad O
score O
>= O
3, O
and O
seven O
out O
of O
these O
eight O
studies O
had O
at O
least O
one O
domain O
with O
high O
risks O
of O
bias O
. O

Meta-analyses O
of O
the O
studies O
with O
Jadad O
score O
>= O
3 O
found O
that O
CHM O
was O
similar O
to O
Western O
medication O
( O
three O
studies O
) O
and O
placebo O
( O
three O
studies O
) O
in O
treating O
insomnia B-PHE
. O

Due O
to O
the O
poor O
methodological O
quality O
of O
the O
studies O
and O
the O
small O
number O
of O
trials O
included O
in O
meta-analyses O
, O
the O
current O
evidence O
is O
insufficient O
to O
support O
the O
efficacy O
of O
CHM O
for O
insomnia B-PHE
. O

The O
frequency O
of O
adverse O
events O
associated O
with O
CHM O
was O
similar O
to O
that O
of O
placebo O
, O
but O
lower O
than O
with O
Western O
medication O
. O

Gui O
Pi O
Tang O
was O
the O
most O
commonly O
used O
standardized O
formula O
, O
while O
Suan O
Zao O
Ren O
( O
Ziziphus O
jujuba O
) O
was O
the O
most O
frequently O
used O
single O
herb O
. O

Further O
studies O
with O
a O
double-blind O
placebo-controlled O
design O
are O
needed O
to O
accurately O
determine O
the O
benefits O
and O
risks O
of O
CHM O
for O
insomnia B-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
disinhibit O
water O
and O
harmonize O
center O
, O
quicken O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


disharmony B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
stomach I-PHE
a O
morbid B-PHE
condition I-PHE
marked O
by O
poor B-PHE
appetite I-PHE
, O
loose B-PHE
stools I-PHE
and O
other O
symptoms O
of O
indigestion B-PHE
. O

-DOCSTART- O


For O
stablizing O
period O
, O
controlling O
urine B-PHE
and O
reducing O
heavy B-PHE
blood-flow I-PHE

-DOCSTART- O


refers O
to O
the O
dream-disturbed O
sleep O

-DOCSTART- O


Enzalutamide O
is O
indicated O
for O
the O
treatment O
of O
patients O
with O
metastatic B-PHE
castration-resistant I-PHE
prostate I-PHE
cancer I-PHE
who O
have O
previously O
received O
docetaxel O
. O

-DOCSTART- O


protracted O
dysentery B-PHE
; O
chronic B-PHE
dysentery I-PHE
; O
prolonged O
dysentery B-PHE

-DOCSTART- O


Chronic B-PHE
Renal I-PHE
Failure I-PHE

-DOCSTART- O


Respiratory B-PHE
Distress I-PHE

-DOCSTART- O


infraumbilical B-PHE
cold I-PHE
pain I-PHE

-DOCSTART- O


It O
means O
not O
shiny O
hair O

-DOCSTART- O


Malaria B-PHE
infection I-PHE

-DOCSTART- O


ulcerative B-PHE
gingivitis I-PHE

-DOCSTART- O


Asthma B-PHE

-DOCSTART- O


vomiting B-PHE
due O
to O
heat B-PHE
in O
the O
stomach O

-DOCSTART- O


To O
tonify O
Qi O
and O
strengthen O
the O
spleen B-PHE
. O

To O
consolidate O
the O
Chong B-PHE
channel I-PHE
and O
control O
the O
blood B-PHE
. O

-DOCSTART- O


ETI-204 O
is O
an O
affinity-enhanced O
, O
de-immunized O
antibody O
, O
which O
means O
that O
its O
ability O
to O
bind O
to O
its O
target O
pathogen O
has O
been O
strengthened O
and O
that O
elements O
that O
might O
cause O
an O
immune B-PHE
response I-PHE
have O
been O
removed O
. O

ETI-204 O
targets O
and O
binds O
to O
Protective O
Antigen O
, O
which O
prevents O
the O
anthrax B-PHE
toxins I-PHE
from O
binding O
to O
and O
entering O
the O
cells O
in O
the O
body O
, O
thereby O
preventing O
death B-PHE
. O

-DOCSTART- O


Emergence B-PHE
Agitation I-PHE

-DOCSTART- O


Muscle B-PHE
Weakness I-PHE

-DOCSTART- O


Didanosine O
is O
converted O
to O
the O
active O
triphosphate O
form O
, O
which O
is O
incorporated O
into O
DNA O
and O
inhibits O
DNA B-PHE
elongation I-PHE
. O

-DOCSTART- O


Colonic B-PHE
Cancer I-PHE
. O

-DOCSTART- O


menorrhagia B-PHE
; O
abnormally O
profuse B-PHE
menstruation I-PHE

-DOCSTART- O


Lymphoma B-PHE
, I-PHE
Non-Hodgkin I-PHE

-DOCSTART- O


Cholangiocarcinoma B-PHE

-DOCSTART- O


affection O
due O
to O
wind-heat B-PHE
; O
common O
cold B-PHE
of O
the O
wind-heat B-PHE
type O
; O
flu B-PHE
caused O
by O
wind B-PHE
and O
heat B-PHE

-DOCSTART- O


Pralnacasan O
inhibits O
interleukin-1beta B-PHE
converting I-PHE
enzyme I-PHE
( O
ICE B-PHE
) O
, O
an O
enzyme B-PHE
that O
regulates O
the O
production B-PHE
of I-PHE
IL-1 I-PHE
and I-PHE
IFN I-PHE
gamma I-PHE
- I-PHE
intercellular I-PHE
mediators I-PHE
that O
initiate O
and O
sustain O
the O
process O
of O
inflammation B-PHE
. O

Inhibiting O
ICE B-PHE
may O
be O
an O
effective O
strategy O
for O
curtailing O
damaging O
inflammatory O
processes O
common O
to O
a O
number O
of O
acute O
and O
chronic O
conditions O
, O
such O
as O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
and O
osteoarthritis B-PHE
. O

-DOCSTART- O


Treatment O
of O
edema B-PHE
, O
oliguria B-PHE
, O
arthritis B-PHE
with O
contracture B-PHE
of O
joints O
, O
diarrhea B-PHE
due O
to O
diminished B-PHE
function I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
lung B-PHE
abscess I-PHE
, O
appendicitis B-PHE
, O
verruca B-PHE
plana I-PHE
. O

-DOCSTART- O


Epinastine O
has O
a O
multiaction O
effect O
that O
inhibits O
the O
allergic B-PHE
response I-PHE
in O
3 O
ways O
: O
1 O
stabilizes O
mast B-PHE
cells I-PHE
by O
preventing O
mast B-PHE
cell I-PHE
degranulation I-PHE
to O
control O
the O
allergic B-PHE
response I-PHE
, O
2 O
prevents O
histamine B-PHE
binding O
to O
both O
the O
H1- O
and O
H O
2-receptors O
to O
stop O
itching B-PHE
and O
provide O
lasting B-PHE
protection I-PHE
, O
and O
3 O
prevents O
the O
release B-PHE
of I-PHE
proinflammatory I-PHE
chemical I-PHE
mediators I-PHE
from O
the O
blood B-PHE
vessel I-PHE
to O
halt O
progression O
of O
the O
allergic B-PHE
response I-PHE
. O

-DOCSTART- O


Parkinsons B-PHE
Disease I-PHE

-DOCSTART- O


1 O
For O
cases O
with O
paralysis B-PHE
of I-PHE
lower I-PHE
limbs I-PHE
and O
feverish B-PHE
sensation I-PHE
of O
joints O
, O
which O
are O
attritbutive O
to O
deficiency O
of O
kidney-yin O
, O
omit O
menthae O
, O
Ziziphi O
jujubae O
and O
add O
carapax O
trionycis O
and O
ramulus O
mori O
to O
benefit O
kidney-yin O
and O
eliminate O
asthenic B-PHE
heat I-PHE
. O

-DOCSTART- O


cold B-PHE
and O
heat B-PHE
; O

cold B-PHE
syndrome I-PHE
and O
heat B-PHE
syndrome I-PHE
two O
of O
the O
eight O
principles O
in O
analysing O
and O
differentiating O
pathological O
conditions O
; O

cold B-PHE
caused O
by O
excess O
of O
Eum O
, O
and O
heat B-PHE
caused O
by O
excess O
of O
Yang O
. O

chills B-PHE
and O
fever B-PHE

cold B-PHE
pathogene I-PHE
and O
heat B-PHE
pathogene I-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
; O
dyspepsia B-PHE

-DOCSTART- O


Adult B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


promote O
menstruation B-PHE

-DOCSTART- O


stop O
thirst B-PHE

-DOCSTART- O


weakness B-PHE
of O
the O
waist O

-DOCSTART- O


terminate O
lactation B-PHE

-DOCSTART- O


To O
relieve O
cough B-PHE
and O
promote O
expectoration B-PHE
, O
to O
promote O
digestion B-PHE
and O
remove O
stagnancy B-PHE
of I-PHE
food I-PHE
, O
and O
to O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation B-PHE
of I-PHE
AMP-activated I-PHE
protein I-PHE
kinase I-PHE
( O
AMPK O
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin B-PHE
signaling I-PHE
, O
whole B-PHE
body I-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and I-PHE
fats I-PHE
. O

Pioglitazone O
activates O
peroxisome B-PHE
proliferator-activated I-PHE
receptor I-PHE
gamma I-PHE
( O
PPAR-gamma B-PHE
) O
, O
a O
ligand-activated B-PHE
transcription I-PHE
factor I-PHE
, O
thereby O
inducing O
cell B-PHE
differentiation I-PHE
and O
inhibiting O
cell B-PHE
growth I-PHE
and O
angiogenesis B-PHE
. O

-DOCSTART- O


food B-PHE
damage I-PHE
; O

injury B-PHE
due O
to O
improper O
diet O
; O

eating O
food O
much O
injury B-PHE
of O
spleen O
and O
stomach O

-DOCSTART- O


The O
authors O
report O
the O
3 O
months O
treatment O
of O
51 O
cases O
of O
breast B-PHE
proliferation I-PHE
disease I-PHE
with O
modified O
Xiao O
Yao O
San O
and O
Er O
Chen O
decoction O
, O
an O
effective O
rate O
being O
0.961 O
. O

In O
each O
patient O
before O
and O
after O
treatment O
, O
saliva B-PHE
estradiol I-PHE
( O
SE2 B-PHE
) O
, O
saliva B-PHE
progesterone I-PHE
( O
SP B-PHE
) O
, O
saliva B-PHE
testosterone I-PHE
( O
ST B-PHE
) O
and O
plasma B-PHE
prolactin I-PHE
( O
PRL B-PHE
) O
concentrations O
were O
monitored O
and O
breast O
molybdenum O
- O
target O
X O
- O
ray O
films O
were O
taken O
. O

The O
results O
showed O
that O
after O
treatment O
, O
SE2 B-PHE
concentrations I-PHE
declined O
very O
significantly O
( O
P O
less O
than O
0.001 O
) O
; O
SP B-PHE
concentrations I-PHE
declined O
significantly O
( O
P O
less O
than O
0.05 O
) O
; O
PRL B-PHE
concentrations I-PHE
declined O
very O
significantly O
( O
P O
less O
than O
0.005 O
) O
, O
but O
ST B-PHE
concentrations I-PHE
did O
not O
change O
significantly O
. O

Breast O
molybdenum O
- O
target O
X O
- O
ray O
films O
showed O
absorption O
of O
proliferation O
masses O
in O
21 O
cases O
. O

These O
indicated O
that O
the O
medicine O
could O
regulate O
endocrine B-PHE
system I-PHE
, O
perhaps O
through O
suppressing O
secretion B-PHE
of I-PHE
PRL I-PHE
, O
decreasing O
prolactin B-PHE
antagonist I-PHE
action I-PHE
to O
follicular B-PHE
stimulating I-PHE
hormone I-PHE
so O
as O
to O
restore O
follicle B-PHE
function I-PHE
, O
and O
could O
regulate O
pituitary O
- O
follicle O
axis O
and O
make O
the O
axis O
normal O
. O

-DOCSTART- O


To O
enrich O
yin O
and O
supplement O
kidney B-PHE
, O
clear O
lung B-PHE
and O
moisten O
dryness B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


stomachache B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE
( O
M7 B-PHE
) O

-DOCSTART- O


To O
transform O
dampness B-PHE
and O
promote O
water B-PHE
metabolism I-PHE
. O

-DOCSTART- O


yellowish B-PHE
complexion I-PHE

-DOCSTART- O


Seasonal B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


relieve O
Clonorchiasis B-PHE
toxin I-PHE

-DOCSTART- O


wind-toxic B-PHE
pathogen O

-DOCSTART- O


Binding O
of O
dalbavancin O
to O
the O
D-Ala-D-Ala O
prevents O
the O
incorporation O
of O
the O
NAM/NAG-peptide O
subunits O
into O
the O
peptidoglycan O
matrix O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
remove O
obstruction O
of O
the O
collaterals O
, O
and O
relieve O
spasms B-PHE
and O
convulsions B-PHE
. O

-DOCSTART- O


a O
symptom O
of O
fingers B-PHE
being I-PHE
cold I-PHE
although O
the O
temperature O
is O
not O

-DOCSTART- O


disperse O
carbuncle B-PHE
swelling B-PHE

-DOCSTART- O


For O
bacterial B-PHE
infections I-PHE
of O
eyes O

-DOCSTART- O


function O

-DOCSTART- O


Reserpine's O
mechanism O
of O
action O
is O
through O
inhibition O
of O
the O
ATP/Mg2+ O
pump O
responsible O
for O
the O
sequestering O
of O
neurotransmitters B-PHE
into O
storage O
vesicles O
located O
in O
the O
presynaptic B-PHE
neuron I-PHE
. O

Trichlormethiazide O
appears O
to O
block O
the O
active O
reabsorption O
of O
chloride O
and O
possibly O
sodium O
in O
the O
ascending O
loop B-PHE
of I-PHE
Henle I-PHE
, O
altering O
electrolyte O
transfer O
in O
the O
proximal B-PHE
tubule I-PHE
. O

-DOCSTART- O


Pain B-PHE
Due O
to O
Certain O
Specified O
Procedures O

-DOCSTART- O


Juvenile B-PHE
Idiopathic I-PHE
Arthritis I-PHE

-DOCSTART- O


To O
transform O
water O
and O
reduce O
edema B-PHE

-DOCSTART- O


dispel O
wind B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
condition I-PHE
of I-PHE
the I-PHE
kidney I-PHE
marked O
by O
lumbago B-PHE
and O
lack B-PHE
of I-PHE
strength I-PHE
, O
threatened B-PHE
abortion I-PHE
, O
hypertension B-PHE
. O

-DOCSTART- O


pain B-PHE
of O
genitals O
among O
men O
and O
women O

-DOCSTART- O


Heat B-PHE
vexation I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
vomiting B-PHE
nausea I-PHE
, O
vacuity B-PHE
heat I-PHE
cough I-PHE
, O
dry B-PHE
stool I-PHE
, O
swelling B-PHE
of I-PHE
welling I-PHE
abscess I-PHE
, O
welling B-PHE
abscess I-PHE
and O
flat B-PHE
abscess I-PHE
with O
swelling B-PHE
sore I-PHE
. O

-DOCSTART- O


Treament O
of O
edema B-PHE
or O
retained O
fluid O
with O
abdominal B-PHE
distension I-PHE
, O
oliguria B-PHE
and O
constipation B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
external O
use O
for O
ringworm B-PHE
and O
verrucous B-PHE
vegetations I-PHE
. O

-DOCSTART- O


1 O
An O
active O
component O
, O
anisaldehyde O
, O
increases O
the O
effect O
of O
streptomycin B-PHE
on O
experimental O
tuberculosis B-PHE
in O
mice O
. O
Accelerating O
gastrointestinal B-PHE
peristalsis I-PHE
, O
and O
promoting O
eliminating B-PHE
of I-PHE
flatus I-PHE
. O
Eliminating O
phlegm B-PHE
. O

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
short B-PHE
, I-PHE
rapid I-PHE
and I-PHE
interrupted I-PHE
breathing I-PHE
. O

-DOCSTART- O


neck B-PHE
stiffness I-PHE
; O
neck B-PHE
rigidity I-PHE
; O
rigidity B-PHE
of I-PHE
the I-PHE
neck I-PHE
; O
rigid B-PHE
neck I-PHE

-DOCSTART- O


Beginning O
stage O
of O
rash B-PHE
, O
fever B-PHE
, O
cough B-PHE
, O
alternating O
cold B-PHE
and I-PHE
hot I-PHE
feeling I-PHE

-DOCSTART- O


mania-withdrawal B-PHE
; O

mania B-PHE
; O

manic-depressive B-PHE
psychosis I-PHE

-DOCSTART- O


Yokukansan O
inhibits O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
: O
the O
role O
of O
a O
A-adrenoceptor B-PHE
. O

-DOCSTART- O


Milnacipran O
is O
used O
to O
treat O
moderate O
to O
severe O
clinical B-PHE
depression I-PHE
but O
this O
indication O
is O
not O
yet O
FDA-approved O
in O
the O
USA O
. O

Milnacipran O
is O
labelled O
for O
the O
treatment O
of O
fibromyalgia B-PHE
pain I-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews O
and O
quicken O
blood B-PHE
, O
relieve O
cough B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O

-DOCSTART- O


Treatment O
of O
pains B-PHE
caused O
by O
blood B-PHE
stagnation I-PHE
. O

-DOCSTART- O


Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic B-PHE
cancer I-PHE
and O
lymphoma B-PHE
. O

-DOCSTART- O


Rikkunshito O
improves O
globus B-PHE
sensation I-PHE
in O
patients O
with O
proton-pump O
inhibitor-refractory O
laryngopharyngeal B-PHE
reflux I-PHE
. O

-DOCSTART- O


Treatment O
of O
stagnation O
of O
qi O
in O
the O
liver B-PHE
and O
stomach B-PHE
manifested O
by O
distending O
pain B-PHE
in O
the O
chest O
and O
hypochodria B-PHE
, O
fullness B-PHE
and O
stuffiness B-PHE
sensation O
in O
the O
epigastrium O
, O
vomiting B-PHE
and O
belching B-PHE
, O
cough B-PHE
with O
copious O
expectoration B-PHE
. O

-DOCSTART- O


To O
induce O
subsidence O
of O
swelling B-PHE
and O
remove O
toxic B-PHE
substances O
, O
to O
cause O
purgation B-PHE
. O

-DOCSTART- O


papule B-PHE

-DOCSTART- O


stop O
itching B-PHE

-DOCSTART- O


Parkinson B-PHE
Disease I-PHE

-DOCSTART- O


Treatment O
of O
impotence B-PHE
and O
seminal O
emission O
, O
mass B-PHE
in O
the O
abdomen B-PHE
, O
scrofula B-PHE
, O
traumatic B-PHE
injuries I-PHE
, O
external O
use O
for O
carbuncles B-PHE
and O
boils O
. O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
palpitation B-PHE
and O
severe O
palpitation B-PHE
. O

-DOCSTART- O


harmonize O
acute B-PHE
and I-PHE
chronic I-PHE
disease I-PHE
of O
center O

-DOCSTART- O


epigastric O
fullness O
; O
stuffiness B-PHE
in O
the O
gastric O
region O

-DOCSTART- O


In O
order O
to O
investigate O
the O
characteristic O
of O
optical O
properties O
of O
Asian O
dust O
particles O
, O
the O
atmospheric O
aerosol O
vertical O
profile O
was O
measured O
with O
the O
multi-wavelength O
LIDAR O
system O
, O
at O
the O
Gosan O
super O
site O
( O
33 O
degrees O
17'N O
, O
126 O
degrees O
10'E O
) O
in O
Jeju O
Island O
, O
Korea O
, O
during O
the O
ACE-Asia O
intensive O
observation O
period O
, O
11 O
42798 O
May O
2001 O
. O

An O
air O
mass O
backward O
trajectory O
analysis O
, O
using O
Hysplit-4 O
, O
was O
carried O
out O
to O
track O
the O
aerosol O
plume O
, O
with O
high O
mass O
loading O
, O
from O
the O
Chinese O
desert O
regions O
during O
the O
period O
of O
Asian O
dust O
storm O
events O
. O

Vertical O
atmospheric O
aerosol O
profiles O
on O
three O
major O
Asian O
dust O
storm O
event O
days O
, O
22 O
March O
and O
13 O
and O
26 O
April O
2001 O
, O
have O
been O
analyzed O
. O

The O
LIDAR-derived O
aerosol O
optical O
depth O
values O
were O
compared O
with O
those O
measured O
by O
a O
collocated O
sunphotometer O
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cataracts B-PHE
, O
eye B-PHE
disorders I-PHE
/ I-PHE
infections I-PHE
, O
glaucoma B-PHE
, O
and O
macular B-PHE
degeneration I-PHE
. O

-DOCSTART- O


Baker's B-PHE
Cyst I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Others O

-DOCSTART- O


prolapse B-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


the O
disease B-PHE
that O
liver O
and O
spleen O
become O
swollen B-PHE
and O
enlarged B-PHE

-DOCSTART- O


release O
muscles B-PHE

-DOCSTART- O


arthralgia B-PHE
and O
myalgia B-PHE
; O
pain B-PHE
in O
the O
muscles O
and O
bones O

-DOCSTART- O


the O
heat B-PHE
syndrome I-PHE
syndrome O
due O
to O
attack O
of O
pathogenic O
heat B-PHE
or O
hyperactivity B-PHE
of O
Yanggi O
, O
usually O
seen O
in O
infectious B-PHE
disease I-PHE
and O
those O
caused O
by O
abnormal O
hyperactivity I-PHE
of O
the O
body O
, O
with O
manifestation O
such O
as O
fever B-PHE
, O
fidgets B-PHE
, O
flushed B-PHE
face I-PHE
, O
congested B-PHE
eyes I-PHE
dry B-PHE
mouth I-PHE
and I-PHE
throat I-PHE
, O
red O
and O
dry B-PHE
lip I-PHE
thirst B-PHE
with O
preference O
for O
cold O
drink O
, O
constipation B-PHE
, O
scanty O
dark B-PHE
urine I-PHE
reddened B-PHE
tongue I-PHE
with O
dry B-PHE
brow I-PHE
or O
black O
coating O
, O
and O
rapid B-PHE
pulse I-PHE
. O

-DOCSTART- O


spitting B-PHE
pus I-PHE
and I-PHE
blood I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
obesity B-PHE
. O

-DOCSTART- O


the O
low B-PHE
back I-PHE
and I-PHE
knees I-PHE
being I-PHE
aching I-PHE
and I-PHE
limp I-PHE
( O
i O
. O
e O
. O
, O
weak O
) O

-DOCSTART- O


To O
dispel O
damp B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


SP-01A O
is O
an O
HIV B-PHE
oral O
entry O
inhibitor O
drug O
. O

In O
order O
for O
viruses B-PHE
to O
reproduce O
, O
they O
must O
infect O
or O
hi-jack O
a O
cell O
, O
and O
use O
it O
to O
make O
new O
viruses B-PHE
. O

Just O
as O
your O
body O
is O
constantly O
making O
new O
skin B-PHE
cells I-PHE
, O
or O
new O
blood B-PHE
cells I-PHE
, O
each O
cell O
often O
makes O
new O
proteins O
in O
order O
to O
stay O
alive O
and O
to O
reproduce O
itself O
. O

Viruses B-PHE
hide O
their O
own O
DNA O
in O
the O
DNA O
of O
the O
cell O
, O
and O
then O
, O
when O
the O
cell O
tries O
to O
make O
new O
proteins O
, O
it O
accidentally O
makes O
new O
viruses B-PHE
as O
well O
. O

HIV B-PHE
mostly O
infects O
cells O
in O
the O
immune B-PHE
system I-PHE
. O

-DOCSTART- O


Arrhythmia B-PHE

-DOCSTART- O


As O
an O
anthelmintic O
for O
tapeworm O
and O
hookworm O
, O
more O
effective O
than O
that O
of O
tetrachloroethylene O
. O

-DOCSTART- O


conjunctival B-PHE
congestion I-PHE

-DOCSTART- O


night B-PHE
blindness I-PHE
. O
Visual B-PHE
disorder I-PHE
at O
night O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
motility B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


bruise B-PHE

-DOCSTART- O


incised B-PHE
wound I-PHE

-DOCSTART- O


To O
relieve O
rheumatic B-PHE
conditions I-PHE
, O
to O
strengthen O
the O
tendons B-PHE
and O
bones B-PHE
, O
and O
to O
arrest O
bleeding B-PHE
. O

-DOCSTART- O


promote O
all O
vessels B-PHE

-DOCSTART- O


constrain O
the O
lung B-PHE

-DOCSTART- O


Phenylpropanolamine O
acts O
directly O
on O
alpha- O
and O
, O
to O
a O
lesser O
degree O
, O
beta-adrenergic O
receptors O
in O
the O
mucosa B-PHE
of I-PHE
the I-PHE
respiratory I-PHE
tract I-PHE
. O

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
increase O
food B-PHE
intake I-PHE

-DOCSTART- O


Adult B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE
With O
t(9;22)(q34;q11.2 O
) O
; O
BCR-ABL1 O

-DOCSTART- O


Uncomplicated B-PHE
Falciparum I-PHE
Malaria I-PHE

-DOCSTART- O


Myelodysplastic B-PHE
Syndromes I-PHE

-DOCSTART- O


restlessness B-PHE
and O
thirst B-PHE
; O

polydipsia B-PHE

-DOCSTART- O


Saengmaeksan O
inhibits O
inflammatory B-PHE
mediators I-PHE
by O
suppressing O
RIP-2 B-PHE
/ I-PHE
caspase-1 I-PHE
activation I-PHE
. O

-DOCSTART- O


general O
weakness B-PHE
and O
weight B-PHE
loss I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
free O
network B-PHE
vessels I-PHE
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
, O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


cooling O
throat B-PHE

-DOCSTART- O


Relief O
of O
mild O
to O
moderate O
pain B-PHE

-DOCSTART- O


Despite O
the O
development O
of O
radiotherapy O
machines O
and O
technologies O
, O
a O
proportion O
of O
patients O
suffer O
from O
radiation-induced B-PHE
lymphedema I-PHE
. O

Saireito O
( O
SRT O
) O
is O
a O
traditional O
Japanese O
herbal O
medicine O
that O
has O
been O
used O
for O
treating O
edema B-PHE
and O
inflammation B-PHE
in O
conditions O
such O
as O
nephritic B-PHE
disease I-PHE
. O

This O
study O
investigated O
the O
effect O
of O
SRT O
on O
lymphedema B-PHE
caused O
by O
radiotherapy O
. O

Four O
patients O
were O
treated O
with O
SRT O
at O
a O
dose O
of O
9 O
g/day O
. O

The O
severity O
of O
lymphedema B-PHE
was O
evaluated O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4 O
and O
Numerical O
Rating O
Scale O
before O
and O
after O
SRT O
treatment O
. O

After O
the O
treatment O
with O
SRT O
, O
2 O
of O
4 O
patients O
( O
0.5 O
) O
showed O
apparent O
improvement O
in O
lymphedema B-PHE
. O

One O
of O
the O
cases O
had O
difficulty O
in O
wearing O
the O
custom-made O
thermoplastic O
cast O
, O
but O
after O
SRT O
administration O
, O
he O
could O
wear O
the O
mask O
easily O
. O

One O
case O
decided O
to O
stop O
taking O
SRT O
3 O
days O
after O
initiation O
because O
cough B-PHE
and O
fever B-PHE
appeared O
. O

In O
conclusion O
, O
it O
is O
important O
to O
control O
the O
side O
effects O
of O
radiotherapy O
, O
which O
leads O
to O
improved O
tumor B-PHE
control I-PHE
rates I-PHE
. O

Prospective O
randomized O
studies O
are O
necessary O
to O
confirm O
the O
findings O
of O
this O
case O
series O
study O
. O

-DOCSTART- O


Zuo O
Jin O
Wan O
( O
ZJW O
) O
, O
a O
typical O
traditional O
Chinese O
medicine O
( O
TCM O
) O
formula O
, O
has O
been O
identified O
to O
have O
anticancer B-PHE
activity I-PHE
in O
recent O
studies O
. O

In O
this O
study O
, O
we O
determined O
the O
underlying O
mechanism O
of O
ZJW O
in O
the O
reversal O
effect O
of O
multidrug O
resistance O
on O
colorectal B-PHE
cancer I-PHE
in O
vitro O
and O
in O
vivo O
. O

Our O
results O
showed O
that O
ZJW O
significantly O
enhanced O
the O
sensitivity O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
, O
SGC7901/DDP O
, O
and O
Bel/Fu O
MDR O
cells O
. O

Moreover O
, O
combination O
of O
chemotherapy O
with O
ZJW O
could O
reverse O
the O
drug O
resistance O
of O
HCT116/L-OHP B-PHE
cells I-PHE
, O
increase O
the O
sensitivity O
of O
HCT116/L-OHP B-PHE
cells I-PHE
to O
L-OHP O
, O
DDP O
, O
5-Fu O
, O
and O
MMC O
in O
vitro O
, O
and O
inhibit O
the O
tumor B-PHE
growth I-PHE
in O
the O
colorectal O
MDR O
cancer O
xenograft O
model O
. O

ICP-MS O
results O
showed O
that O
ZJW O
could O
increase O
the O
concentration O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
cells O
in O
a O
dose-dependent O
manner O
. O

Furthermore O
, O
we O
showed O
that O
ZJW O
could O
reverse O
drug O
resistance O
of O
colorectal B-PHE
cancer I-PHE
cells O
by O
decreasing O
P-gp B-PHE
level I-PHE
in O
vitro O
and O
in O
vivo O
, O
which O
has O
been O
represented O
as O
one O
of O
the O
major O
mechanisms O
that O
contribute O
to O
the O
MDR O
phenotype O
. O

Our O
study O
has O
provided O
the O
first O
direct O
evidence O
that O
ZJW O
plays O
an O
important O
role O
in O
reversing O
multidrug O
resistance O
of O
human B-PHE
colorectal I-PHE
cancer I-PHE
and O
may O
be O
considered O
as O
a O
useful O
target O
for O
cancer O
therapy O
. O

-DOCSTART- O


To O
arrest O
bleeding B-PHE
by O
reducing O
heat B-PHE
in O
blood O
, O
to O
remove O
heat B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


syphilis B-PHE
; O
strawberry O
sores B-PHE
; O
syphilitic B-PHE
skin I-PHE
disease I-PHE

-DOCSTART- O


Appears O
to O
preferentially O
bind O
to O
mycobacterial B-PHE
DNA I-PHE
leading O
to O
disruption B-PHE
of I-PHE
the I-PHE
cell I-PHE
cycle I-PHE
and O
eventually O
kills O
the O
bacterium B-PHE
. O

-DOCSTART- O


hemiplegia B-PHE

-DOCSTART- O


the O
body O
is O
fatigued O
and O
cannot O
walk O
because O
of O
a O
flaccidity B-PHE
of I-PHE
lower I-PHE
limbs I-PHE

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
and O
promote O
virility B-PHE
, O
to O
reduce O
modulation O
, O
and O
to O
induce O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
externally O
. O

-DOCSTART- O


Warfarin O
inhibits O
vitamin B-PHE
K I-PHE
reductase I-PHE
, O
resulting O
in O
depletion O
of O
the O
reduced O
form O
of O
vitamin B-PHE
K I-PHE
which O
reduces O
the O
thrombogenicity B-PHE
of I-PHE
clots I-PHE
. O

Heparin O
binds O
to O
antithrombin O
III O
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin B-PHE
and O
other O
activated O
clotting B-PHE
factors I-PHE
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization B-PHE
of I-PHE
fibrinogen I-PHE
to O
fibrin O
and O
the O
subsequent O
formation B-PHE
of I-PHE
clots I-PHE
. O

-DOCSTART- O


Cholelithiasis B-PHE
, O
infection B-PHE
of I-PHE
the I-PHE
biliary I-PHE
tract I-PHE
, O
cholecystitis B-PHE
. O

-DOCSTART- O


Dermatitis B-PHE
, I-PHE
Atopic I-PHE

-DOCSTART- O


As O
GABA B-PHE
is O
an O
inhibitory O
neurotransmitter O
, O
this O
results O
in O
increased O
inhibition O
of O
the O
ascending O
reticular B-PHE
activating I-PHE
system I-PHE
. O

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

ABT-751 O
binds O
to O
the O
colchicine-binding O
site O
on O
beta-tubulin O
and O
inhibits O
the O
polymerization O
of O
microtubules O
, O
thereby O
preventing O
tumor B-PHE
cell I-PHE
replication I-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of I-PHE
the I-PHE
eyes I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE

-DOCSTART- O


Acute B-PHE
Adrenal I-PHE
Insufficiency I-PHE

-DOCSTART- O


Inecalcitol O
is O
an O
analogue O
of O
calcitriol O
, O
the O
naturally O
active O
metabolite O
of O
vitamin O
D O
. O

Calcitriol O
and O
their O
analogues O
activate O
the O
vitamin O
D O
receptor O
( O
VDR O
) O
. O

Vitamin O
D O
has O
a O
major O
role O
in O
regulating O
calcium B-PHE
absorption I-PHE
from O
the O
gut O
, O
storage O
in O
mineral O
form O
in O
the O
bones O
, O
and O
excretion B-PHE
by O
the O
kidney O
and O
effectively O
prevents O
rickets B-PHE
in O
infants O
. O

Vitamin O
D O
and O
calcitriol O
can O
cause O
hypercalcemia B-PHE
at O
high O
or O
frequently O
repeated O
doses O
; O
in O
turn O
, O
hypercalcemia B-PHE
can O
cause O
kidney B-PHE
toxicity I-PHE
by O
accumulation O
of O
calcium-containing O
micro-crystals O
and O
heart B-PHE
and I-PHE
muscle I-PHE
dysfunction I-PHE
by O
impairing O
contractions O
. O

The O
mechanism O
of O
action O
is O
currently O
unknown O
, O
but O
it O
is O
proposed O
that O
inecalcitol O
exerts O
its O
superagonistic O
action O
through O
enhancing O
coactivator O
binding O
by O
the O
VDR O
. O

-DOCSTART- O


The O
herbal O
medicine O
Tokishakuyakusan O
increases O
fetal O
blood B-PHE
glucose I-PHE
concentrations I-PHE
and O
growth B-PHE
hormone I-PHE
levels I-PHE
and O
improves O
intrauterine B-PHE
growth I-PHE
retardation I-PHE
induced O
by O
N(omega)-nitro-L-arginine O
methyl O
ester O
. O

-DOCSTART- O


1 O
Interrupting O
pregnancy B-PHE
. O

2 O
Its O
active O
component O
, O
trichosanthin O
, O
is O
effective O
on O
placental B-PHE
trophocytic I-PHE
tumor I-PHE
. O

3 O
. O
Bacteriostatic B-PHE
. O

-DOCSTART- O


Endometrial B-PHE
Cancer I-PHE

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
increased O
food B-PHE
intake I-PHE

-DOCSTART- O


Weak B-PHE
and I-PHE
reduced I-PHE
yin I-PHE
blood I-PHE
after O
treatment O
, O
exterior B-PHE
evil I-PHE
, O
loss B-PHE
of I-PHE
blood I-PHE
, O
cold B-PHE
and O
period O
, O
headache B-PHE
, O
hot B-PHE
body I-PHE
, O
feeling O
slightly O
cold B-PHE
, O
no B-PHE
sweating I-PHE
. O

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
syndrome I-PHE
of O
the O
kidney O
marked O
by O
back B-PHE
pain I-PHE
, O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
and O
looseness B-PHE
of I-PHE
teeth I-PHE
, O
traumatic B-PHE
injury I-PHE
, O
bone B-PHE
fracture I-PHE
, O
external O
use O
for O
alopecia B-PHE
areata I-PHE
, O
vitiligo B-PHE
. O

-DOCSTART- O


major O
red O
and O
white O
dysentery B-PHE

-DOCSTART- O


1 O
Hypotensive B-PHE
2 O
Promoting O
phagocytosis B-PHE
of I-PHE
mononuclear I-PHE
phagocytes I-PHE
. O

Sedative O
and O
diuretic O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from I-PHE
the I-PHE
lung I-PHE
, O
relieve O
cough B-PHE
and O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


1)a O
disease O
due O
to O
reducing O
wind B-PHE
pathogen O
of O
the O
heart B-PHE
2) O
mental B-PHE
problem I-PHE
due O
to O
disorder O
of O
opening O
the O
heart O
by O
phlegm B-PHE
. O

-DOCSTART- O


upper O
diabetes B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
colorectal B-PHE
cancer I-PHE
. O

-DOCSTART- O


linear O
lump B-PHE
of I-PHE
scrofula I-PHE

-DOCSTART- O


settle O
the O
pain B-PHE
and O
tranquilize O

-DOCSTART- O


Enteritis B-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of O
rectum O
, O
emission O
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Zidovudine O
inhibits O
the O
activity B-PHE
of I-PHE
HIV-1 I-PHE
reverse I-PHE
transcriptase I-PHE
( O
RT O
) O
via O
DNA B-PHE
chain I-PHE
termination I-PHE
after O
incorporation O
of O
the O
nucleotide B-PHE
analogue I-PHE
. O

-DOCSTART- O


Saireito O
(a O
Chinese O
herbal O
drug O
) O
decreases O
inhibitory O
effect O
of O
prednisolone O
and O
accelerates O
the O
recovery O
of O
rat O
hypothalamic-pituitary-adrenal O
axis O
. O

-DOCSTART- O


Tropicamide O
acts O
by O
blocking O
the O
responses O
of O
the O
iris B-PHE
sphincter I-PHE
muscle I-PHE
to O
the O
iris B-PHE
and I-PHE
ciliary I-PHE
muscles I-PHE
to O
cholinergic B-PHE
stimulation I-PHE
, O
producing O
dilation B-PHE
of O
the O
pupil O
and O
paralysis B-PHE
of O
the O
ciliary O
muscle O
. O

Hydroxyamphetamine O
is O
a O
sympathomimetic O
drug O
, O
that O
is O
, O
a O
drug O
that O
stimulates O
the O
sympathetic B-PHE
nervous I-PHE
system I-PHE
as O
an O
agonist O
of O
human O
TAAR1 O
. O

-DOCSTART- O


Cetuximab O
competitively O
inhibits O
epidermal O
growth O
factor O
and O
TGF B-PHE
alpha I-PHE
, O
thereby O
reducing O
their O
effects O
on O
cell B-PHE
growth I-PHE
and O
metastatic B-PHE
spread I-PHE
. O

Fluorouracil O
metabolites O
incorporate O
into O
both O
RNA B-PHE
and O
DNA B-PHE
; O
inhibits O
synthesis B-PHE
of I-PHE
DNA I-PHE
, O
incorporation O
into O
RNA B-PHE
results O
in O
major O
effects O
on O
both O
RNA B-PHE
processing O
and O
functions O
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Maturation B-PHE

-DOCSTART- O


swelling B-PHE
of O
the O
lips O
; O
swollen B-PHE
lips I-PHE

-DOCSTART- O


Breech B-PHE
Presentation I-PHE
in O
Pregnancy O

-DOCSTART- O


HIV B-PHE
Infection I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
health I-PHE
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Memory B-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


dyspnea B-PHE
due O
to O
the O
kidney B-PHE
deficiency I-PHE

-DOCSTART- O


Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Memory B-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Quality O
of O
life O
, O
UV B-PHE
protection I-PHE
, O
Others O
, O
Man O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Motivation O
, O
Strength B-PHE
and O
power B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
, O
Hemostatic B-PHE
function I-PHE
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
dermatological B-PHE
systems I-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


1.To O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
, O
expel O
wind B-PHE
and O
alleviate O
pain B-PHE
. O

2 O
. O
To O
relieve O
asthma B-PHE
. O

-DOCSTART- O


Pulmonary B-PHE
Disease I-PHE
, I-PHE
Chronic I-PHE
Obstructive I-PHE

-DOCSTART- O


Diminshing O
the O
toxicity B-PHE
of I-PHE
kanamycin I-PHE
to O
guinea-pig's O
cochlea B-PHE
. O

the O
levels O
of O
serum B-PHE
cholesterol I-PHE
and O
triglyceride B-PHE
. O

Hindering O
the O
formation O
of O
arteriosclerotic B-PHE
deposits O
in O
the O
vessels O
. O

-DOCSTART- O


protracted O
diarrhea B-PHE
; O
chronic B-PHE
diarrhea I-PHE
; O
prolonged O
diarrhea B-PHE

-DOCSTART- O


Tourette B-PHE
Disorder I-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

Prazosin O
acts O
by O
inhibiting O
the O
postsynaptic O
alpha(1)-adrenoceptors O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

This O
inhibits O
the O
vasoconstrictor B-PHE
effect I-PHE
of O
circulating O
and O
locally O
released O
catecholamines B-PHE
, O
resulting O
in O
peripheral B-PHE
vasodilation I-PHE
. O

Oxymetazoline O
is O
a O
direct O
acting O
sympathomimetic O
amine O
, O
which O
acts O
on O
alpha-adrenergic O
receptors O
in O
the O
arterioles O
of O
the O
conjunctiva O
and O
nasal O
mucosa O
. O

-DOCSTART- O


Cyclosporine O
binds O
to O
cyclophilin O
which O
inhibits O
lymphokine B-PHE
production I-PHE
and O
interleukin B-PHE
release I-PHE
, O
shows O
potent O
immunosuppressant O
medication O
. O

-DOCSTART- O


Repeated O
administration O
of O
Yokukansan O
inhibits O
DOI B-PHE
- I-PHE
induced I-PHE
head I-PHE
- I-PHE
twitch I-PHE
response I-PHE
and O
decreases O
expression O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
2A O
receptors O
in O
the O
prefrontal O
cortex O
. O

-DOCSTART- O


abdominal B-PHE
pain I-PHE
and O
tenesmus B-PHE

-DOCSTART- O


stroke B-PHE
; O
sudden B-PHE
wind-stroke I-PHE
a O
sudden O
and O
severe O
attack O
, O
as O
of O
apoplexy B-PHE

-DOCSTART- O


Glucagon O
binds O
the O
glucagon O
receptor O
, O
a O
G O
protein-coupled O
receptor O
located O
in O
the O
plasma B-PHE
membrane I-PHE
, O
which O
then O
initiates O
a O
dual O
signaling O
pathway O
using O
both O
adenylate O
cyclase O
activation O
and O
increased O
intracellular B-PHE
calcium I-PHE
. O

Adenylate O
cyclase O
manufactures O
cAMP O
( O
cyclic O
AMP O
) O
, O
which O
activates O
protein B-PHE
kinase I-PHE
A I-PHE
( O
cAMP-dependent B-PHE
protein I-PHE
kinase I-PHE
) O
. O

This O
enzyme B-PHE
, O
in O
turn O
, O
activates O
phosphorylase B-PHE
kinase I-PHE
, O
which O
, O
in O
turn O
, O
phosphorylates O
glycogen B-PHE
phosphorylase I-PHE
, O
converting O
into O
the O
active O
form O
called O
phosphorylase B-PHE
A I-PHE

Phosphorylase O
A O
is O
the O
enzyme O
responsible O
for O
the O
release O
of O
glucose-1-phosphate O
from O
glycogen O
polymers O
. O

This O
yields O
glucose O
molecules O
to O
be O
released O
into O
the O
blood O
. O

Glucagon O
receptors O
are O
found O
in O
the O
liver B-PHE
, O
kidney B-PHE
, O
brain B-PHE
and O
pancreatic B-PHE
islet I-PHE
cells I-PHE
. O

The O
glucagon O
mediated O
signals O
lead O
to O
an O
increase O
in O
insulin B-PHE
excretion I-PHE

-DOCSTART- O


Acute B-PHE
Myelogenous I-PHE
Leukemia I-PHE

-DOCSTART- O


miasma O
1 O
pestilential B-PHE
pathogene I-PHE
2 O
malaria B-PHE

-DOCSTART- O


disliking O
wind B-PHE
syndrome I-PHE
due O
to O
external B-PHE
and I-PHE
internal I-PHE
injury I-PHE
. O

-DOCSTART- O


Therapeutic O
effects O
of O
Saireito O
( O
chai-ling-tang O
) O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
on O
lymphedema B-PHE
caused O
by O
radiotherapy O
: O
a O
case O
series O
study O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
kill O
worms B-PHE
and O
relieve O
itch B-PHE
, O
resolve B-PHE
toxin I-PHE
and O
close O
sores B-PHE
. O

-DOCSTART- O


restore O
depression B-PHE
and O
dissipate O
bind O

-DOCSTART- O


dispel O
the O
effects O
of O
alcohol O

-DOCSTART- O


Symptoms O
associated O
with O
stagnation O
of O
liver O
qi O
, O
stagnated O
qi O
truned O
into O
fire O
, O
insufficient O
yin O
blood O

-DOCSTART- O


Allosteric O
interactions O
between O
central O
benzodiazepine O
receptors O
and O
gamma-aminobutyric O
acid O
( O
GABA O
) O
receptors O
potentiate O
the O
effects O
of O
GABA O
. O

-DOCSTART- O


OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
value O
of O
intraoperative O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
( O
SBB O
) O
. O

So O
far O
, O
only O
a O
few O
studies O
have O
reported O
about O
the O
usefulness O
of O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
. O

METHODS O
: O
Between O
1998 O
and O
2003 O
, O
155 O
SBBs O
were O
performed O
in O
153 O
patients O
with O
micro-Doppler O
( O
81 O
males O
, O
72 O
females O
, O
mean O
age O
: O
59 O
years O
) O
. O

All O
operations O
were O
performed O
using O
a O
ZD-frame O
and O
a O
multiplanar O
computer O
tomography-guided O
trajectory O
planning O
system O
( O
Leibinger O
SPP O
) O
. O

A O
16 O
MHz O
micro-Doppler O
probe O
( O
diameter O
1 O
mm O
, O
DWL O
) O
was O
used O
in O
all O
cases O
to O
explore O
the O
area O
of O
biopsy O
before O
the O
tissue O
probes O
were O
taken O
. O

Serial O
biopsies O
( O
mean O
, O
6 O
samples O
) O
were O
taken O
with O
the O
Sedan O
side-cutting O
cannula O
(n O
= O
145 O
) O
or O
the O
small O
forceps O
(n O
= O
10 O
) O
. O

We O
evaluated O
the O
number O
of O
intraoperative O
detectable O
vessel O
signals O
by O
micro-Doppler O
, O
intraoperative O
bleedings B-PHE
as O
well O
as O
bleedings B-PHE
detected O
by O
postoperative O
CT O
( O
which O
was O
performed O
in O
all O
cases O
) O
. O

We O
compared O
our O
results O
according O
to O
bleeding B-PHE
- O
related O
complications O
with O
the O
data O
of O
stereotactic O
biopsy O
series O
from O
the O
recent O
literature O
. O

RESULTS O
: O
A O
conclusive O
histopathological O
diagnosis O
was O
achieved O
in O
150/153 O
patients O
( O
98 O
% O
) O
. O

A O
re-biopsy O
had O
to O
be O
undertaken O
in O
2 O
cases O
. O

In O
98 O
biopsies O
( O
63 O
% O
) O
, O
no O
vessel O
could O
be O
detected O
with O
the O
micro-Doppler O
. O

In O
the O
remainder O
, O
a O
signal O
of O
arterial B-PHE
vessels I-PHE
was O
detected O
in O
22 O
( O
14 O
%) O
and O
a O
signal O
of O
venous B-PHE
vessels I-PHE
in O
35 O
cases O
( O
23 O
% O
) O
. O

Detection O
of O
a O
vessel B-PHE
in O
the O
micro-Doppler O
led O
to O
a O
change O
of O
the O
biopsy O
site O
in O
each O
case O
within O
the O
same O
trajectory O
. O

Biopsy-related O
bleedings B-PHE
were O
detected O
in O
4 O
cases O
( O
2.6 O
% O
) O
. O

Among O
these O
, O
the O
only O
bleeding B-PHE
which O
occurred O
without O
any O
signs O
of O
vessels B-PHE
in O
the O
micro-Doppler O
happened O
in O
a O
case O
of O
a O
melanoma B-PHE
. O

The O
overall O
biopsy-related O
permanent O
morbidity O
was O
0.6 O
% O
(n O
= O
1 O
) O
. O

The O
biopsy-related O
mortality O
was O
0 O

CONCLUSIONS O
: O
Despite O
the O
overall O
high O
security O
of O
SBB O
, O
the O
use O
of O
intraoperative O
micro-Doppler O
may O
lead O
to O
an O
additional O
reduction O
of O
the O
risk O
for O
a O
biopsy-related O
bleeding B-PHE
without O
enormous O
expense O
. O

-DOCSTART- O


cold O
dysentery B-PHE

-DOCSTART- O


Antiviral O
Treatment O
of O
Chronic B-PHE
Hepatitis I-PHE
B I-PHE

-DOCSTART- O


dispel O
cold B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


For O
the O
prophylaxis O
of O
organ B-PHE
rejection I-PHE
in O
patients O
receiving O
renal O
transplants O
. O

-DOCSTART- O


Purging B-PHE
by O
moisterizing O

-DOCSTART- O


Zidovudine O
inhibits O
the O
activity B-PHE
of I-PHE
HIV-1 I-PHE
reverse I-PHE
transcriptase I-PHE
( O
RT B-PHE
) O
via O
DNA B-PHE
chain I-PHE
termination I-PHE
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

Efavirenz O
inhibits O
the O
activity B-PHE
of I-PHE
viral I-PHE
RNA-directed I-PHE
DNA I-PHE
polymerase I-PHE
. O

Lamivudine O
is O
a O
synthetic O
nucleoside O
analogue O
and O
this O
nucleoside O
analogue O
is O
incorporated O
into O
viral O
DNA O
by O
HIV B-PHE
reverse I-PHE
transcriptase I-PHE
and O
HBV B-PHE
polymerase I-PHE
, O
resulting O
in O
DNA B-PHE
chain I-PHE
termination I-PHE
. O

-DOCSTART- O


10-Gingerol O
, O
a O
component O
of O
Rikkunshito O
, O
improves O
cisplatin-induced B-PHE
anorexia I-PHE
by O
inhibiting O
acylated B-PHE
ghrelin I-PHE
degradation I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(8;21)(q22;q22 O
) O
; O
RUNX1-RUNX1T1 O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Monoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Intraocular B-PHE
Melanoma I-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Reactivation I-PHE

-DOCSTART- O


Sudden O
stroke O
and O
fulminant O
reversal O
, O
pain B-PHE
in O
heart O
and O
abdomen B-PHE
, O
postpartum O
blood B-PHE
dizziness I-PHE
, O
child O
fright B-PHE
epilepsy I-PHE
, O
wind B-PHE
impediment O
and O
lumbago B-PHE
. O

-DOCSTART- O


Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness B-PHE
and O
fullness B-PHE
sensation O
in O
the O
abdomen O
with O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
damp-heat B-PHE
in O
combination O
with O
cold B-PHE
. O

-DOCSTART- O


Gallbladder B-PHE
Neoplasms I-PHE

-DOCSTART- O


Urinary B-PHE
tract I-PHE
stone I-PHE
marked O
by O
paroxysmal B-PHE
lumbago I-PHE
or O
pain B-PHE
in O
one O
side O
of O
the O
abdomen O
often O
radiating O
to O
pudendum O
, O
or O
accompanied O
by O
fever B-PHE
, O
hematuria B-PHE
, O
urodynia B-PHE
, O
dysuria B-PHE
, O
discontinuance B-PHE
of O
urination O
, O
yellow B-PHE
fur I-PHE
of I-PHE
the I-PHE
tongue I-PHE
and O
taut B-PHE
pulse I-PHE
. O

-DOCSTART- O


Food O
accumulation O
, O
stomachache B-PHE
, O
abdomin B-PHE
al I-PHE
pain I-PHE
. O

-DOCSTART- O


break O
blood B-PHE

-DOCSTART- O


The O
itching B-PHE
sensation I-PHE
due O
to O
eczema B-PHE

-DOCSTART- O


( O
1) O
wind-warm B-PHE
; O
wind-warm B-PHE
pathogen I-PHE
( O
1 O
) O
wind B-PHE
and O
warm O
blended O
as O
a O
pathogenic O
factor O
. O

( O
2 O
) O
wind-warm B-PHE
syndrome I-PHE
acute O
febrile B-PHE
diseases I-PHE
caused O
by O
wind-warm B-PHE
pathogene I-PHE
occurring O
in O
winter O
and O
spring O
, O
characterized O
by O
chills B-PHE
and O
fever B-PHE
, O
thirst B-PHE
sweating I-PHE
, O
cough B-PHE
and O
headache B-PHE
in O
the O
initial O
stage O
, O
and O
then O
, O
delirium B-PHE
and O
maculation B-PHE
in O
the O
following O
stage O
. O

-DOCSTART- O


fever B-PHE
and O
aversion O
to O
cold B-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE

-DOCSTART- O


pyogenic B-PHE
infections I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
signs O
and O
symptoms O
of O
idiopathic O
Parkinson's B-PHE
disease I-PHE
. O

Also O
used O
for O
the O
treatment O
of O
restless B-PHE
legs I-PHE
syndrome I-PHE
. O

-DOCSTART- O


soothe O
the O
sinews B-PHE
and O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


acute B-PHE
arthritis I-PHE
; O
gout B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Quality O
of O
life O
, O
absorption O
, O
Liver B-PHE
health I-PHE
, O
motility O
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


Methyclothiazide O
appears O
to O
block O
the O
active O
reabsorption B-PHE
of I-PHE
chloride I-PHE
and O
possibly O
sodium O
in O
the O
ascending O
loop O
of O
Henle O
, O
altering O
electrolyte O
transfer O
in O
the O
proximal O
tubule O
. O

Pargyline O
is O
a O
monoamine O
oxidase O
B O
( O
MAO-B O
) O
inhibitor O
with O
antihypertensive O
properties O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Quality O
of O
life O
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
woman O
, O
Inflammation B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


Grepafloxacin O
exerts O
its O
antibacterial B-PHE
activity I-PHE
by O
inhibiting O
bacterial B-PHE
topoisomerase I-PHE
II I-PHE
( O
DNA B-PHE
gyrase I-PHE
) O
and O
topoisomerase B-PHE
IV I-PHE
, O
essential O
enzymes O
for O
duplication O
, O
transcription O
, O
and O
repair O
of O
bacterial B-PHE
DNA I-PHE
. O

-DOCSTART- O


Other O
system B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
counteract O
toxicity B-PHE
, O
to O
expel O
intestinal B-PHE
worms I-PHE
, O
stanch O
bleeding B-PHE
. O

-DOCSTART- O


Beta-Thalassemia B-PHE

-DOCSTART- O


constipation B-PHE

-DOCSTART- O


Methotrexate O
anti-tumor O
activity O
is O
a O
result O
of O
the O
inhibition O
of O
folic B-PHE
acid I-PHE
reductase I-PHE
, O
leading O
to O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
and O
inhibition O
of O
cellular B-PHE
replication I-PHE
. O

Golimumab O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
cytokine I-PHE
, O
tumor B-PHE
necrosis I-PHE
factor I-PHE
alpha I-PHE
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Lipid O
profile O

-DOCSTART- O


Untreated O
Childhood B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


The O
precise O
mechanism O
of O
action O
has O
not O
been O
fully O
determined O
, O
but O
the O
main O
mechanism O
of O
fluorouracil O
is O
thought O
to O
be O
the O
binding O
of O
the O
deoxyribonucleotide O
of O
the O
drug O
( O
FdUMP O
) O
and O
the O
folate O
cofactor O
, O
N50-methylenetetrahydrofolate O
, O
to O
thymidylate O
synthase O
( O
TS O
) O
to O
form O
a O
covalently O
bound O
ternary O
complex O
. O

This O
results O
in O
the O
inhibition O
of O
the O
formation B-PHE
of I-PHE
thymidylate I-PHE
from O
uracil O
, O
which O
leads O
to O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cell B-PHE
death I-PHE
. O

Fluorouracil O
can O
also O
be O
incorporated O
into O
RNA B-PHE
in O
place O
of O
uridine O
triphosphate O
( O
UTP O
) O
, O
producing O
a O
fraudulent B-PHE
RNA I-PHE
and O
interfering O
with O
RNA B-PHE
processing I-PHE
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


yellow B-PHE
or I-PHE
reddish I-PHE
urine I-PHE
; O
dark B-PHE
urine I-PHE

-DOCSTART- O


Postpartum B-PHE
bleeding I-PHE
, O
migraine B-PHE
. O

-DOCSTART- O


penis B-PHE
ulceration I-PHE

-DOCSTART- O


Cardiac B-PHE
carbuncle I-PHE
has O
half O
conscious O
, O
stuffiness B-PHE
in O
the O
heart O
, O
and O
forgetting O
well O
when O
something O
occurred O
. O

-DOCSTART- O


Adult B-PHE
Pure I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Quality O
of O
life O

-DOCSTART- O


phlegmy B-PHE
fire O
a O
morbid O
condition O
produced O
by O
long-standing O
depression B-PHE
of O
Gi O
which O
turns O
into O
fire O
and O
changes O
the O
body O
fluid O
into O
phlegm B-PHE
, O
usually O
causing B-PHE
mental I-PHE
disturbances O
such O
as O
hysteria B-PHE
, O
mania B-PHE
. O

-DOCSTART- O


AIM O
: O
Zhi O
Zhu O
Wan O
( O
ZZW O
) O
is O
a O
classical O
Chinese O
medical O
formulation O
used O
for O
the O
treatment O
of O
functional O
dyspepsia B-PHE
that O
attributed O
to O
Spleen B-PHE
- I-PHE
deficiency I-PHE
Syndrome I-PHE
. O

ZZW O
contains O
Atractylodes O
Rhizome O
and O
Fructus O
Citrus O
Immaturus O
, O
the O
later O
originates O
from O
both O
Citrus O
aurantium O
L. O
( O
BZZW O
) O
and O
Citrus O
sinensis O
Osbeck O
( O
RZZW O
) O
. O

The O
present O
study O
is O
designed O
to O
elucidate O
disparities O
in O
the O
clinical O
efficacy O
of O
two O
ZZW O
varieties O
based O
on O
the O
pharmacokinetics O
of O
naringenin O
and O
hesperetin O
. O

MEHTOD O
: O
After O
oral O
administration O
of O
ZZWs O
, O
blood O
sample O
was O
collected O
from O
healthy O
volunteers O
at O
designed O
time O
points O
. O

Naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
by O
RP-HPLC O
, O
pharmacokinetic O
parameters O
were O
processed O
using O
mode-independent O
methods O
with O
WINNONLIN O
. O

RESULTS O
: O
After O
oral O
administration O
of O
BZZW O
, O
both O
naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
, O
and O
demonstrated O
similar O
pharmacokinetic O
parameters O
. O

Ka O
was O
0.384+/-0.165 O
and O
0.401+/-0.159 O
, O
T(1/2(ke))(h O
) O
was O
5.491+/-3.926 O
and O
5.824+/-3.067 O
, O
the O
AUC O
( O
mg/Lh O
) O
was O
34.886+/-22.199 O
and O
39.407+/-19.535 O
for O
naringenin O
and O
hesperetin O
, O
respectively O
. O

However O
, O
in O
the O
case O
of O
RZZW O
, O
only O
hesperetin O
was O
found O
in O
plasma O
, O
but O
the O
pharmacokinetic O
properties O
for O
hesperetin O
in O
RZZW O
was O
different O
from O
that O
in O
BZZW O
. O

T(max O
) O
for O
hesperetin O
in O
RZZW O
is O
about O
8.515h O
, O
and O
its O
C(max O
) O
is O
much O
larger O
than O
that O
of O
BZZW O
. O

Moreover O
, O
it O
was O
eliminated O
slowly O
as O
it O
possessed O
a O
much O
larger O
AUC O
value O
. O

CONCLUSION O
: O
The O
distinct O
therapeutic O
orientations O
of O
the O
Chinese O
medical O
formula O
ZZWs O
with O
different O
Fructus O
Citrus O
Immaturus O
could O
be O
elucidated O
based O
on O
the O
pharmacokinetic O
parameters O
of O
constituents O
after O
oral O
administration O
. O

-DOCSTART- O


Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Eye B-PHE
health I-PHE
, O
Eye B-PHE
health I-PHE
, O
Others O
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Strength O
and O
power O
, O
Intelligence B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


dizziness B-PHE
and O
palpitation B-PHE
due O
to O
congested B-PHE
fluids I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Fat B-PHE
storage I-PHE
and O
oxidation O

-DOCSTART- O


inner O
impairment B-PHE

-DOCSTART- O


Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Menopausal B-PHE
woman I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Metabolism B-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Woman O
, O
Quality O
of O
life O
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Liver B-PHE
, O
Others O
, O
Kids O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Liver B-PHE
health I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Intelligence B-PHE
, O
Overall O
CVD B-PHE
, O
General O
woman O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


tonify O
the O
kidney B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Inflammation B-PHE
, O
Other O
system O
health O
, O
Others O

-DOCSTART- O


The O
anti-inflammatory B-PHE
effects I-PHE
of O
diclofenac O
are O
believed O
to O
be O
due O
to O
inhibition O
of O
both O
leukocyte B-PHE
migration I-PHE
and O
the O
enzyme B-PHE
cylooxygenase I-PHE
( O
COX-1 B-PHE
and O
COX-2 B-PHE
) O
, O
leading O
to O
the O
peripheral O
inhibition O
of O
prostaglandin B-PHE
synthesis I-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
strengthen O
the O
muscles B-PHE
and O
tendon B-PHE
, O
regulate O
the O
function O
between O
qi O
and O
blood O
. O

-DOCSTART- O


promote O
blood B-PHE
vessel I-PHE

-DOCSTART- O


For O
appendicitis B-PHE
, O
used O
together O
with O
same O
dose O
of O
pills O
of O
Radix O
et O
Rhizoma O
Rhei O
and O
Rhizoma O
Coptidis O
, O
or O
mixed O
with O
same O
dose O
of O
Cinnabaris O
, O
applying O
on O
point O
Lanwei O
( O
Extra33 O
) O
. O

-DOCSTART- O


Heavy B-PHE
flow I-PHE
in I-PHE
period I-PHE
due O
to O
blood B-PHE
stagnation I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
liver B-PHE
cancer I-PHE
. O

-DOCSTART- O


Hyperactivity B-PHE
of O
the O
liver-yang O
, O
hypertension B-PHE
, O
dizziness B-PHE
, O
vertigo B-PHE
, O
insomnia B-PHE
, O
amnesia B-PHE
. O

-DOCSTART- O


moisten B-PHE
face I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Mood O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Inflammation B-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


diarrhea B-PHE
due O
to O
dysfunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE

-DOCSTART- O


harmonize O
the O
stomach B-PHE

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
, O
invigorate O
yang O
, O
replenish O
the O
vital B-PHE
essence I-PHE
and O
reinforce O
the O
marrow B-PHE

-DOCSTART- O


To O
benefit O
qi O
and O
revitalize O
blood B-PHE
; O
To O
nourish O
yin O
and O
tonify O
yang O

-DOCSTART- O


For O
the O
treatment O
of O
essential B-PHE
hypertension I-PHE
, O
alone O
or O
as O
an O
adjunct O
. O

Also O
for O
the O
management O
of O
severe B-PHE
hypertension I-PHE
when O
the O
drug O
cannot O
be O
given O
orally O
or O
when O
blood B-PHE
pressure I-PHE
must O
be O
lowered O
immediately O
, O
congestive B-PHE
heart I-PHE
failure I-PHE
( O
in O
combination O
with O
cardiac O
glycosides O
and O
diuretics O
and O
/ O
or O
with O
isosorbide O
dinitrate O
) O
, O
and O
hypertension B-PHE
secondary I-PHE
to O
pre-eclampsia B-PHE
/ O
eclampsia B-PHE
. O

-DOCSTART- O


the O
stagnation B-PHE
of O
Gi O
a O
morbid B-PHE
condition I-PHE
due O
to O
impeded B-PHE
circulation I-PHE
of O
Gi O
that O
leads O
to O
a O
local B-PHE
obstruction I-PHE
, O
manifested O
by O
distension B-PHE
or O
pain B-PHE
in O
the O
affected O
part O
. O

-DOCSTART- O


facial B-PHE
hemiparalysis I-PHE
due O
to O
wind B-PHE
stroke I-PHE

-DOCSTART- O


The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin O
and O
other O
activated O
clotting O
factors O
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization O
of O
fibrinogen O
to O
fibrin O
and O
the O
subsequent O
formation B-PHE
of I-PHE
clots I-PHE
. O

-DOCSTART- O


This O
is O
a O
syndrome O
that O
the O
both O
cheeks O
of O
children O
turn O
red O
. O

-DOCSTART- O


exogenous B-PHE
febrile I-PHE
disease I-PHE
of O
four O
seasons O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
dispel O
stasis B-PHE
, O
regulate O
menstruation B-PHE
and O
relieve O
pain B-PHE
, O
nourish O
blood B-PHE
and O
quiet O
spirit O
, O
cool O
blood B-PHE
and O
disperse O
welling O
abscess B-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
to O
kill O
parasites B-PHE
, O
and O
to O
relieve O
itching B-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Quality O
of O
life O
, O
Inflammation B-PHE
, O
Protective O
immunity B-PHE
, O
Others O

-DOCSTART- O


invigorate O
the O
spleen B-PHE

-DOCSTART- O


Alzheimer's B-PHE
Disease I-PHE

-DOCSTART- O


Quality O
of O
life O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Mood O

-DOCSTART- O


spitting O
bloody B-PHE
pus I-PHE
; O

cough B-PHE
with O
bloody B-PHE
pus I-PHE

-DOCSTART- O


stop O
dysentery B-PHE

-DOCSTART- O


palpitation B-PHE

-DOCSTART- O


Hochuekkito O
, O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
and O
its O
Polysaccharide O
Portion O
Stimulate O
G B-PHE
- I-PHE
CSF I-PHE
Secretion I-PHE
from O
Intestinal O
Epithelial O
Cells O
. O

-DOCSTART- O


stranguria B-PHE
due O
to O
heat B-PHE
; O
heat-type B-PHE
stranguria I-PHE

-DOCSTART- O


old O
ulceration B-PHE

-DOCSTART- O


1 O
To O
relieve O
carbuncle B-PHE
and O
drain B-PHE
pus I-PHE
. O

For O
the O
early O
stage O
of O
carbuncle B-PHE
or O
carbuncle B-PHE
with O
unruptured O
abscess B-PHE
. O

2 O
To O
expel O
wind B-PHE
and O
kill O
parasites B-PHE
. O

For O
tinea B-PHE
infection I-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


For O
tonifying O
blood B-PHE

-DOCSTART- O


Anti-inflammatory B-PHE
activity I-PHE
of O
Gumiganghwaltang O
through O
the O
inhibition O
of O
nuclear B-PHE
factor-kappa I-PHE
B I-PHE
activation I-PHE
in O
peritoneal O
macrophages O
. O

-DOCSTART- O


pain B-PHE
from I-PHE
cramped I-PHE
tendons I-PHE
and I-PHE
bones I-PHE

-DOCSTART- O


a O
stomachache B-PHE
due O
to O
exhaustion O
of O
vital O
energy O

-DOCSTART- O


deficiency O
of O
the O
Yang O
of O
the O
spleen B-PHE
and O
the O
kidney B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
remove O
toxic B-PHE
materials I-PHE
; O
To O
tonify O
kidney B-PHE
and O
revitalize O
blood B-PHE

-DOCSTART- O


Blood B-PHE
activation I-PHE
and O
injury B-PHE
healing I-PHE

-DOCSTART- O


hemicrania B-PHE
; O
migraine B-PHE
; O
megrim B-PHE

-DOCSTART- O


1 O
For O
cases O
of O
menorrhagia B-PHE
accompanied O
with O
listlessness B-PHE
and O
pale B-PHE
complexion I-PHE
due O
to O
deficiency B-PHE
of I-PHE
vital I-PHE
energy I-PHE
Radix O
Ginseng O
Jilin O
to O
invigorate O
vital B-PHE
energy I-PHE
and O
control O
blood B-PHE
of O
profuse O
uterine B-PHE
bleeding I-PHE
leading O
to O
deadly O
coldness B-PHE
of I-PHE
limbs I-PHE
and O

-DOCSTART- O


Fructus O
Crataegi O
( O
charred O
) O
: O
Has O
more O
digestant O
action O
and O
is O
particularly O
useful O
for O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
and O
diarrhea B-PHE
with O
inadequate B-PHE
discharge I-PHE
from I-PHE
the I-PHE
bowels I-PHE
. O

-DOCSTART- O


Woman O
, O
Eldery O
, O
menopausal B-PHE
woman I-PHE
, O
Others O

-DOCSTART- O


Rapamycin O
binds O
to O
the O
immunophilin B-PHE
FK I-PHE
Binding I-PHE
Protein-12 I-PHE
( O
FKBP-12 B-PHE
) O
to O
generate O
an O
immunosuppressive B-PHE
complex I-PHE
that O
binds O
to O
and O
inhibits O
the O
activation B-PHE
of I-PHE
the I-PHE
mammalian I-PHE
Target I-PHE
Of I-PHE
Rapamycin I-PHE
( O
mTOR B-PHE
) O
, O
a O
key O
regulatory O
kinase B-PHE
. O

This O
results O
in O
inhibition O
of O
T B-PHE
lymphocyte I-PHE
activation I-PHE
and I-PHE
proliferation I-PHE
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-PHE
( O
IL-2 B-PHE
, O
IL-4 B-PHE
, O
and O
IL-15 B-PHE
) O
stimulation O
and O
inhibition O
of O
antibody B-PHE
production I-PHE
. O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

This O
agent O
inhibits O
TK B-PHE
encoded O
by O
the O
bcr-abl O
oncogene O
as O
well O
as O
receptor O
TKs O
encoded O
by O
the O
c-kit O
and O
platelet-derived O
growth O
factor O
receptor O
( O
PDGFR O
) O
oncogenes O
. O

Biochemical O
analyses O
raise O
the O
possibility O
that O
inhibition O
of O
4E-BP1 B-PHE
phosphorylation I-PHE
may O
be O
particularly O
important O
for O
the O
synergistic O
effects O
of O
PTK O
inhibitor O
/ O
rapamycin O
combinations O
. O

-DOCSTART- O


convulsion B-PHE
; O

epilepsy B-PHE

-DOCSTART- O


general O
edema B-PHE
with O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Gi O
( O
Qi O
) O
and O
blood B-PHE

-DOCSTART- O


Acne B-PHE
Vulgaris I-PHE

-DOCSTART- O


Gramicidin O
D O
binds O
and O
inserts O
itself O
into O
bacterial B-PHE
membranes I-PHE
and O
results O
in O
membrane B-PHE
disruption I-PHE
and O
permeabilization O
, O
which O
leads O
to O
cell B-PHE
death I-PHE
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane O
permeability O
and O
causing O
cell B-PHE
death I-PHE
. O

Neomycin O
is O
a O
bactericidal O
aminoglycoside O
antibiotic O
that O
binds O
to O
the O
30S O
ribosome O
of O
susceptible O
organisms O
. O

Binding O
interferes O
with O
mRNA B-PHE
binding I-PHE
and O
acceptor B-PHE
tRNA I-PHE
sites I-PHE
and O
results O
in O
the O
production O
of O
non-functional O
or O
toxic B-PHE
peptides I-PHE
. O

-DOCSTART- O


To O
dispel O
phlegm B-PHE
, O
to O
restore O
consciousness B-PHE
, O
and O
to O
reduce O
modulation B-PHE
and O
cause O
the O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
and O
cause O
diuresis B-PHE
. O

-DOCSTART- O


Chronic B-PHE
hepatitis I-PHE

-DOCSTART- O


This O
paper O
was O
designed O
to O
study O
metabonomic O
characters O
of O
the O
hepatotoxicity O
induced O
by O
alcohol O
and O
the O
intervention O
effects O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
classic O
traditional O
Chinese O
medicine O
formula O
for O
treatment O
of O
jaundice B-PHE
and O
liver B-PHE
disorders I-PHE
in O
China O
. O

Urinary O
samples O
from O
control O
, O
alcohol- O
and O
YCHT-treated O
rats O
were O
analyzed O
by O
ultra-performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time-of-flight O
mass O
spectrometry O
( O
UPLC/ESI-QTOF-MS O
) O
in O
positive O
ionization O
mode O
. O

The O
total O
ion O
chromatograms O
obtained O
from O
the O
control O
, O
alcohol- O
and O
YCHT-treated O
rats O
were O
easily O
distinguishable O
using O
a O
multivariate O
statistical O
analysis O
method O
such O
as O
the O
principal O
components O
analysis O
( O
PCA O
) O
. O

The O
greatest O
difference O
in O
metabolic O
profiling O
was O
observed O
from O
alcohol-treated O
rats O
compared O
with O
the O
control O
and O
YCHT-treated O
rats O
. O

The O
positive O
ions O
m/z O
664.3126 O
( O
9 O
min O
) O
was O
elevated O
in O
urine O
of O
alcohol-treated O
rats O
, O
whereas O
, O
ions O
m/z O
155.3547 O
( O
10.96 O
min O
) O
and O
708.2932 O
( O
9.01 O
min O
) O
were O
at O
a O
lower O
concentration O
compared O
with O
that O
in O
urine O
of O
control O
rats O
, O
however O
, O
these O
ions O
did O
not O
indicate O
a O
statistical O
difference O
between O
control O
rats O
and O
YCHT-treated O
rats O
. O

The O
ion O
m/z O
664.3126 O
was O
found O
to O
correspond O
to O
ceramide O
( O
d18:1/25:0 O
) O
, O
providing O
further O
support O
for O
an O
involvement O
of O
the O
sphingomyelin O
signaling O
pathway O
in O
alcohol B-PHE
hepatotoxicity I-PHE
and O
the O
intervention O
effects O
of O
YCHT O
. O

-DOCSTART- O


abdominal B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
parasitosis I-PHE
; O
abdominal B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
ascariasis I-PHE

-DOCSTART- O


deficiency B-PHE
of I-PHE
the I-PHE
heart I-PHE
; O
deficiency B-PHE
syndrome I-PHE
of I-PHE
the I-PHE
heart I-PHE
including O
deficiency B-PHE
of I-PHE
blood I-PHE
and O
Eum O
, O
and O
insufficiency O
of O
Gi O
and O
Yang O
of O
the O
heart O

-DOCSTART- O


galactostasis B-PHE
; O
hypogalactia B-PHE
; O
scant B-PHE
breast I-PHE
; O
inadequacy B-PHE
of I-PHE
lactation I-PHE

-DOCSTART- O


Pregnancy B-PHE
Outcome O

-DOCSTART- O


disperse O
wart B-PHE

-DOCSTART- O


Follitropin O
alpha O
is O
a O
recombinant O
form O
of O
endogenous O
follicle O
stimulating O
hormone O
( O
FSH O
) O
. O

FSH O
binds O
to O
the O
follicle O
stimulating O
hormone O
receptor O
which O
is O
a O
G-coupled O
transmembrane O
receptor O
. O

Binding O
of O
the O
FSH O
to O
its O
receptor O
seems O
to O
induce O
phosphorylation B-PHE
and O
activation B-PHE
of I-PHE
the I-PHE
PI3K I-PHE
( O
Phosphatidylinositol-3-kinase O
) O
and O
Akt O
signaling O
pathway O
, O
which O
is O
known O
to O
regulate O
many O
other O
metabolic O
and O
related O
survival/maturation O
functions O
in O
cells O
. O

-DOCSTART- O


Vaginitis B-PHE

-DOCSTART- O


Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Mood O

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
promote O
the O
stomach B-PHE

-DOCSTART- O


nocturnal B-PHE
enuresis I-PHE
and O
frequency B-PHE
of I-PHE
micturition I-PHE

-DOCSTART- O


jaundice B-PHE
related O
to O
immoderate O
drinking O
; O
alcoholic B-PHE
jaundice I-PHE
one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

jaundice B-PHE
caused O
by O
endogenous O
damp-heat B-PHE
due O
to O
indulging O
in O
alcohol O
, O
manifested O
as O
yellowish B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
, O
chest B-PHE
distress I-PHE
, O
anorexia B-PHE
, O
nausea B-PHE
and O
vomiting B-PHE

-DOCSTART- O


Treatment O
of O
fever B-PHE
with O
constipation B-PHE
, O
retention O
of O
the O
feces O
and O
abdominal B-PHE
pain I-PHE
, O
dysentery B-PHE
with O
inadequate O
discharge O
from O
the O
bowels B-PHE
, O
jaundice B-PHE
caused O
by O
damp-heat B-PHE
, O
haematemesis B-PHE
, O
epistaxis B-PHE
, O
inflammation B-PHE
of O
eye O
and O
swelling B-PHE
of O
the O
throat O
due O
to O
heat B-PHE
in O
the O
blood O
, O
appendicitis B-PHE
with O
abdominal B-PHE
pain I-PHE
, O
boils B-PHE
, O
sores B-PHE
and O
abscess B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
traumatic B-PHE
injuries I-PHE
, O
hemorrhage B-PHE
from O
the O
upper B-PHE
gastrointestinal I-PHE
tract I-PHE
. O

External O
use O
for O
scalds B-PHE
and O
burns.Radixet O
Rhizoma O
Rhei O
( O
stir-fried O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
swelling B-PHE
of O
the O
throat O
and O
painful O
swelling B-PHE
of O
the O
gums O
. O

Radix O
et O
Rhizoma O
Rhei O
( O
prepared O
) O
Boils B-PHE
, O
sores B-PHE
and O
abscess B-PHE
. O

Radix O
et O
Rhizoma O
Rhei O
( O
carbonized O
) O
Hemorrhage B-PHE
with O
blood B-PHE
stasis I-PHE
due O
to O
heat B-PHE
in O
the O
blood O
. O

-DOCSTART- O


Diarrhea B-PHE
, O
Malnutrition B-PHE

-DOCSTART- O


Menstrual B-PHE
discomfort I-PHE
, O
feelings O
of O
heat B-PHE
, O
flushed B-PHE
face I-PHE
, O
irritability B-PHE

-DOCSTART- O


Schizophrenia B-PHE

-DOCSTART- O


regurgitation B-PHE
; O
frequent B-PHE
vomiting I-PHE

-DOCSTART- O


For O
promoting O
diuresis B-PHE
and O
desolving O
inflammation B-PHE
. O

-DOCSTART- O


jaundice B-PHE
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
and O
dark B-PHE
yellow I-PHE
colored I-PHE
urine I-PHE
, O
and O
classified O
into O
two O
types O
, O
Yang B-PHE
jaundice I-PHE
and O
Eum B-PHE
jaundice I-PHE
; O

one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

-DOCSTART- O


Post-operative B-PHE
Pain I-PHE

-DOCSTART- O


Angiotensin B-PHE
II I-PHE
is O
a O
small O
hormone O
in O
the O
body O
and O
part O
of O
the O
RAS B-PHE
. O

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
of I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
, O
lassitude B-PHE
, O
palpitation B-PHE
, O
arrhythmia B-PHE
. O

-DOCSTART- O


tenesmus B-PHE

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
free O
menstruation B-PHE
( O
raw O
) O
, O
transform O
stasis B-PHE
and O
stanch O
bleeding B-PHE
( O
scorch-fry O
) O
. O

-DOCSTART- O


Bradycardia B-PHE
, O
sick B-PHE
sinus I-PHE
syndrome I-PHE
, O
angina B-PHE
and O
cardiac B-PHE
insufficiency I-PHE
, O
arrhythmia B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
pain B-PHE
in O
lumbus O
and O
legs O
, O
numbness B-PHE
of I-PHE
limbs I-PHE
, O
sprain B-PHE
from O
knocks B-PHE
and O
falls B-PHE
, O
sequel O
of O
poliomyelitis B-PHE
. O

-DOCSTART- O


Fenretinide O
treatment O
may O
cause O
ceramide B-PHE
to O
build O
up O
in O
tumor B-PHE
cells I-PHE
and O
is O
associated O
with O
the O
accumulation O
of O
reactive B-PHE
oxygen I-PHE
species I-PHE
, O
resulting O
in O
cell B-PHE
death I-PHE
through O
apoptosis B-PHE
and/or O
necrosis B-PHE
. O

Sodium O
butyrate O
( O
NaB O
) O
, O
a O
short O
chain O
fatty O
acid O
, O
is O
a O
HDAC O
inhibitor O
and O
induces O
growth B-PHE
arrest I-PHE
and O
apoptosis B-PHE
in O
a O
variety O
of O
human O
cancer O
cells O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
or I-PHE
rheumatoid I-PHE
arthrits I-PHE
with O
muscular B-PHE
contracture I-PHE
and O
severe O
joint B-PHE
pain I-PHE
, O
fever B-PHE
recurring O
daily O
in O
the O
afternoon O
, O
fever B-PHE
in O
infants O
with O
malnutrition B-PHE
. O

-DOCSTART- O


headache B-PHE
due O
to O
adverse O
rising O
of O
phlegm B-PHE

-DOCSTART- O


To O
relax O
the O
bowels B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
benefit O
vital B-PHE
energy I-PHE
to O
control O
blood B-PHE
. O

-DOCSTART- O


Graft B-PHE
Versus I-PHE
Host I-PHE
Disease I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
, O
and O
to O
remove O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
. O

-DOCSTART- O


Rheumatoid B-PHE
Arthritis I-PHE

-DOCSTART- O


Type B-PHE
1 I-PHE
Diabetes I-PHE
Mellitus I-PHE

-DOCSTART- O


This O
is O
carbuncle B-PHE
and O
cellulites B-PHE
occurred I-PHE
on I-PHE
the I-PHE
back I-PHE
. O

-DOCSTART- O


Hypoglycemia B-PHE

-DOCSTART- O


swelling B-PHE
and O
pain B-PHE
of O
the O
anus O

-DOCSTART- O


Neostigmine O
is O
used O
for O
the O
symptomatic O
treatment O
of O
myasthenia B-PHE
gravis I-PHE
by O
improving O
muscle B-PHE
tone I-PHE
. O

-DOCSTART- O


Vaginal B-PHE
discharge I-PHE
, O
strangury B-PHE
syndrome I-PHE
, O
swelling B-PHE
toxin I-PHE
of O
clove B-PHE
sore I-PHE
, O
parotitis B-PHE
, O
mastitis B-PHE
, O
lymphrnoditis B-PHE
. O

-DOCSTART- O


Chunghyuldan O
( O
Daio-Orengedokuto O
in O
Japanese O
) O
( O
CHD O
) O
has O
been O
used O
as O
an O
antihyperlipidemic B-PHE
and O
antiischemic B-PHE
agent I-PHE
in O
Korea O
. O

To O
evaluate O
in O
vitro O
the O
efficacy O
of O
Chunghyuldans O
( O
CHDs O
) O
metabolized O
with O
and O
without O
human B-PHE
intestinal I-PHE
microflora I-PHE
against O
brain B-PHE
ischemia I-PHE
, O
we O
investigated O
its O
anti-inflammatory B-PHE
effect I-PHE
on O
LPS-induced O
RAW264.7 O
cells O
. O

Both O
metabolized O
CHD O
( O
MCHD O
) O
and O
CHD O
showed O
antioxidant B-PHE
activities I-PHE
in O
vitro O
, O
and O
inhibited O
nitric O
oxide O
( O
NO O
) O
and O
prostaglandin B-PHE
E2 I-PHE
( O
PGE2 B-PHE
) O
productions O
in O
lipopolysaccharide O
( O
LPS)-induced O
RAW264.7 O
cells O
. O

These O
also O
inhibited O
enzyme B-PHE
activities I-PHE
and O
protein B-PHE
expressions I-PHE
of O
inducible O
NO B-PHE
synthase I-PHE
and O
cyclooxygenase-2 B-PHE
in O
LPS-induced O
RAW264.7 O
cells O
. O

MCHD-inhibitory O
activity O
against O
NO B-PHE
and I-PHE
PGE2 I-PHE
productions I-PHE
in O
LPS-induced O
RAW264.7 O
cells O
was O
more O
potent O
than O
those O
of O
CHD O
. O

These O
results O
suggest O
that O
CHD O
may O
show O
potent O
anti-inflammatory B-PHE
activity I-PHE
in O
vivo O
and O
can O
improve O
brain B-PHE
ischemia I-PHE
. O

-DOCSTART- O


relieve O
throat B-PHE

-DOCSTART- O


a O
disease O
that O
menstruation B-PHE
is O
not O
even O
due O
to O
coldness B-PHE

-DOCSTART- O


1 O
Sennoside O
A O
is O
the O
component O
for O
purgation O
. O

2 O
. O
Promoting O
biliary B-PHE
secretion I-PHE
and O
enhancing O
the O
amount O
of O
bilirubin B-PHE
and O
bile B-PHE
acid I-PHE
. O

3 O
. O
Rhein O
and O
Emodin O
exert O
bacteriostatic O
effect O
by O
inhibting O
the O
synthesis B-PHE
of I-PHE
DNA I-PHE
, O
RNA O
and O
protein O
in O
bacteria O

4 O
. O
Emodin O
is O
a O
component O
for O
hypotensive B-PHE

5 O
. O
Oral O
use O
of O
its O
extract O
reduces O
the O
raio O
of O
serum B-PHE
cholesterol I-PHE
and O
total O
phospholipid B-PHE
in O
rabbits O
with O
hypercholesterolemia B-PHE
. O

6 O
. O
Chrysophanol O
, O
an O
other O
active O
component O
, O
exerts O
a O
hemostatic B-PHE
effect I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
engender O
liquid O
, O
moisten O
dryness B-PHE
and O
harmonize O
center O
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Ulcerative B-PHE
Colitis I-PHE

-DOCSTART- O


1 O
Its O
aqueous O
infusion O
exerts O
a O
significant O
diuretic B-PHE
effect I-PHE
in O
experimental O
animals O
. O

2 O
Shortening O
clotting B-PHE
time O
and O
bleeding B-PHE
time O
, O
and O
decreasing O
the O
permeability O
of O
blood O
vessels O
. O

3 O
Inhibiting O
the O
growth O
of O
Staphylococcus B-PHE
aureus I-PHE
and O
Bacillus B-PHE
dysenteriae I-PHE
. O

-DOCSTART- O


discharge O
heat B-PHE
and O
cool O
blood B-PHE

-DOCSTART- O


Its O
decoction O
inhibits O
the O
development O
of O
egg-white O
induced O
arthritis B-PHE
in O
mice O
. O

-DOCSTART- O


calm O
five B-PHE
viscera I-PHE

-DOCSTART- O


Stage O
IV O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


move O
wind B-PHE
Gi(Qi O
) O

-DOCSTART- O


nocturnal B-PHE
emission I-PHE
; O
emission B-PHE
; O
spermatorrhea B-PHE
; O
seminal B-PHE
emission I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body O
weight O
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Endocrine O
& O
reproductive B-PHE
systems I-PHE
, O
Intelligence O
, O
Dermatological B-PHE
systems I-PHE
health O
, O
Eldery O
, O
Overall O
CVD O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
menopausal B-PHE
woman I-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


To O
reinforce O
qi O
and O
invigorate O
the O
function O
of O
the O
spleen B-PHE
and O
the O
lung B-PHE
. O

-DOCSTART- O


To O
remove O
damp-heat B-PHE
, O
quench O
fire B-PHE
and O
counteract O
toxicity B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
goitre B-PHE
with O
pain B-PHE
, O
epigastric B-PHE
pain I-PHE
and O
distension B-PHE
due O
to O
indigestion B-PHE
. O

-DOCSTART- O


The O
ingredients O
of O
this O
prescription O
are O
all O
bitter O
in O
taste O
and O
cold O
in O
nature O
, O
so O
that O
the O
fire O
purging O
and O
detoxifying O
effect O
is O
very O
strong O
. O

Since O
the O
bitter-cold O
drugs O
are O
liable O
to O
damage O
yin-energy O
, O
the O
prescription O
is O
only O
used O
for O
cases O
when O
the O

-DOCSTART- O


relaxing O
apoplexy B-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
resolve O
stasis B-PHE

-DOCSTART- O


Woman O
, O
Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Menopausal B-PHE
woman I-PHE
, O
Eye B-PHE
health I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
sleep B-PHE
, O
Inflammation B-PHE
, O
Other O
system B-PHE
health I-PHE
, O
Memory B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
post O
delivery O
, O
Hypersensitivity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Eye B-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Diet B-PHE
cardiovascular I-PHE
disease I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Liver B-PHE
, O
Others O
, O
vigilance B-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Homocysteine B-PHE
metabolism I-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
activation B-PHE
, O
attention B-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Liver B-PHE
health I-PHE
, O
Eldery O
, O
Strength B-PHE
and O
power B-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
Strength B-PHE
and O
power B-PHE
Reproductive I-PHE
systems I-PHE
, O
Arousal B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Man O
, O
sleep B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
stanch O
bleeding B-PHE
and O
disperse O
swelling B-PHE
, O
kill O
worms B-PHE
. O

-DOCSTART- O


CYT006-AngQb O
is O
a O
therapeutic O
vaccine O
designed O
to O
instruct O
the O
patient's O
immune B-PHE
system I-PHE
to O
produce O
a O
specific O
anti-angiotensin B-PHE
II I-PHE
antibody I-PHE
response I-PHE
. O

-DOCSTART- O


Metabolic O
urinary O
profiling O
of O
alcohol B-PHE
hepatotoxicity I-PHE
and I-PHE
intervention I-PHE
effects O
of O
Yin O
Chen O
Hao O
Tang O
in O
rats O
using O
ultra O
- O
performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time O
- O
of O
- O
flight O
mass O
spectrometry O
. O

-DOCSTART- O


Insulin O
glargine O
is O
is O
a O
long-acting O
basal O
insulin O
analogue O
and O
binds O
to O
the O
insulin O
receptor O
, O
the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

Insulin O
glulisine O
is O
a O
biosynthetic O
, O
rapid-acting O
human O
insulin O
analogue O
which O
differs O
from O
native O
human O
insulin O
in O
that O
the O
amino O
acid O
arginine O
at O
position O
B3 O
is O
replaced O
by O
lysine O
and O
the O
lysine O
at O
position O
B29 O
is O
replaced O
by O
glutamic O
acid O
. O

-DOCSTART- O


Menstrual B-PHE
disorder I-PHE
, O
postpartum B-PHE
abdominal I-PHE
pain I-PHE
due O
to O
stasis B-PHE
obstruction I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disinhibit O
damp B-PHE
. O

-DOCSTART- O


the O
upper O
emaciation B-PHE
; O
lung B-PHE
diabetes I-PHE

-DOCSTART- O


wind B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthralgia B-PHE
due O
to O
wind B-PHE
arthritis I-PHE
mainly O
due O
to O
pathogenic B-PHE
wind I-PHE
, O
marked O
by O
swelling B-PHE
and O
migratory B-PHE
pain I-PHE
in O
the O
joints O
of O
the O
limbs O
. O

-DOCSTART- O


reinforce O
the O
kidney B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
pricking B-PHE
pain I-PHE
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O


Complicated O
Skin O
and O
Skin B-PHE
Structure I-PHE
Infections I-PHE

-DOCSTART- O


Macular B-PHE
Degeneration I-PHE

-DOCSTART- O


For O
the O
treatment O
and O
management O
of O
congestive B-PHE
cardiac I-PHE
insufficiency I-PHE
, O
arrhythmias B-PHE
and O
heart B-PHE
failure I-PHE
. O

-DOCSTART- O


Pseudoephedrine O
relaxes O
bronchial B-PHE
smooth I-PHE
muscle I-PHE
by O
stimulating O
beta2-adrenergic O
receptors O
. O

-DOCSTART- O


Treament O
of O
looseness B-PHE
of I-PHE
teeth I-PHE
, O
premature B-PHE
greying I-PHE
of I-PHE
hair I-PHE
and I-PHE
beard I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
aching B-PHE
and I-PHE
weakness I-PHE
of I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
hematuria B-PHE
and O
diarrhea B-PHE
with O
bloody B-PHE
stools I-PHE
due O
to O
heat B-PHE
in I-PHE
the I-PHE
blood I-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
. O

-DOCSTART- O


reinforce O
blood B-PHE

-DOCSTART- O


Serious O
heat B-PHE
in O
lung O
and O
stomach O
, O
epidemic B-PHE
infectious I-PHE
diseases I-PHE
, O
fever B-PHE
, O
dizziness B-PHE
, O
aching B-PHE
of O
limbs O
, O
cough B-PHE
with O
copious B-PHE
phlegm I-PHE
, O
sore B-PHE
throat I-PHE
, O
epistaxis B-PHE
, O
haemoptysis B-PHE
, O
dryness B-PHE
of I-PHE
mouth I-PHE
and I-PHE
tongue I-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
pain B-PHE
in O
a O
waist O
and O
the O
side O
. O

-DOCSTART- O


( O
1 O
) O
precordial B-PHE
pain I-PHE
; O
intermittent O
cardiac B-PHE
pain I-PHE
( O
2 O
) O
epigastric B-PHE
pain I-PHE

-DOCSTART- O


fluid B-PHE
retention I-PHE
; O

phlegm B-PHE
and O
retained B-PHE
fluid I-PHE
; O

congested B-PHE
fluids I-PHE

-DOCSTART- O


hematuria B-PHE
with I-PHE
pain I-PHE
; O
stranguria B-PHE
with I-PHE
hematuria I-PHE
; O
painful O
urination B-PHE
with I-PHE
blood I-PHE

-DOCSTART- O


abortion B-PHE

-DOCSTART- O


Purging O
by O
pressure O
and O
by O
removing O
liquid O

-DOCSTART- O


1 O
Application O
to O
cass O
of O
early O
stage O
of O
superficial O
pyogenic O
infection O
with O
local O
signs O
of O
inflammation B-PHE
, O
chilliness B-PHE
, O
fever B-PHE
, O
bitter B-PHE
mouth I-PHE
, O
constipation B-PHE
, O
oliguria B-PHE
, O
red B-PHE
tongue I-PHE
with O
white O
fur O
and O
rapid B-PHE
pulse I-PHE
. O
2 O
Also O
indicated O
for O
cases O
of O
urticaria B-PHE
and O
e O

-DOCSTART- O


To O
activate O
blood B-PHE
circulation I-PHE
, O
eliminate O
stasis B-PHE
, O
promote O
the O
subsidence B-PHE
of I-PHE
swelling I-PHE
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


To O
clear O
liver B-PHE
and O
brighten O
eyes B-PHE
. O

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
cardiovascular B-PHE
disorders I-PHE
and O
inflammatory B-PHE
disorders I-PHE
( O
unspecified O
) O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


pricking B-PHE
pain I-PHE

-DOCSTART- O


Weak O
stomach O
qi O
, O
noise B-PHE
in I-PHE
stomach I-PHE
, O
diarrhea B-PHE
, O
stagnation B-PHE
of I-PHE
water I-PHE
, O
dry B-PHE
vomiting I-PHE
, O
annoyment B-PHE

-DOCSTART- O


Infant B-PHE
, I-PHE
Newborn I-PHE
, I-PHE
Diseases I-PHE

-DOCSTART- O


Besifloxacin O
is O
a O
bactericidal O
fluroquinolone-type O
antibiotic O
that O
inhibits O
bacterial B-PHE
enzymes I-PHE
, O
DNA B-PHE
gyrase I-PHE
and O
topoisomerase B-PHE
IV I-PHE
. O

By O
inhibiting O
DNA B-PHE
gyrase I-PHE
, O
DNA B-PHE
replication O
, O
transcription O
, O
and O
repair O
is O
impaired O
. O

By O
inhibiting O
topoisomerase B-PHE
IV I-PHE
, O
decatenation O
during O
cell O
devision O
is O
impaired O
. O

Inhibiting O
these O
two O
targets O
also O
slows O
down O
development O
of O
resistance O
. O

-DOCSTART- O


convulsive B-PHE
disease I-PHE
; O
epilepsy B-PHE
induced O
by O
frightening O

-DOCSTART- O


Specifically O
, O
dalbavancin O
prevents O
incorporation O
of O
N-acetylmuramic B-PHE
acid I-PHE
( O
NAM B-PHE
) O
- O
and O
N-acetylglucosamine B-PHE
( O
NAG B-PHE
) O
- O
peptide O
subunits O
from O
being O
incorporated O
into O
the O
peptidoglycan O
matrix O
; O
which O
forms O
the O
major O
structural O
component O
of O
Gram-positive O
cell O
walls O
. O

-DOCSTART- O


DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Overall O
CVD B-PHE
, O
Others O

-DOCSTART- O


Cyclandelate O
produces O
peripheral B-PHE
vasodilation I-PHE
by O
a O
direct O
effect O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

Pharmacological O
action O
may O
be O
due O
to O
calcium-channel O
antagonism O
. O

-DOCSTART- O


Cholestyramine O
binds O
bile B-PHE
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
, O
a O
Chinese O
prescription O
, O
inhibits O
both O
herpes B-PHE
simplex I-PHE
virus I-PHE
type-1 I-PHE
and I-PHE
type-2 I-PHE
infections I-PHE
in O
vitro O
. O

-DOCSTART- O


Treatment O
of O
palpitation B-PHE
and O
insomnia B-PHE
, O
convulsion B-PHE
, O
epilepsy B-PHE
, O
nebula B-PHE
, O
skin B-PHE
ulcerations I-PHE
difficult O
to O
heal O
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
Kaposi's B-PHE
sarcoma I-PHE
and O
cancer B-PHE
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

Abraxane O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-PHE
breast I-PHE
cancer I-PHE
and O
locally O
advanced B-PHE
or I-PHE
metastatic I-PHE
non-small I-PHE
cell I-PHE
lung I-PHE
cancer I-PHE
. O

-DOCSTART- O


Acute B-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Carcinoma B-PHE
of I-PHE
mammary I-PHE
glands I-PHE
, O
nasopharyngeal B-PHE
carcinoma I-PHE
, O
carcinoma B-PHE
of I-PHE
salivary I-PHE
gland I-PHE
, O
scrofula B-PHE
, O
swelling B-PHE
of I-PHE
skin I-PHE
, O
pain B-PHE
wind I-PHE
. O

-DOCSTART- O


To O
cause O
diuresis B-PHE
, O
to O
invigorate O
the O
spleen B-PHE
function I-PHE
, O
and O
to O
calm O
the O
mind B-PHE
. O

-DOCSTART- O


clear O
heat B-PHE
and O
calm O
the O
fetus O

-DOCSTART- O


Damp-heat B-PHE
dysentery I-PHE
, O
enteritis B-PHE
and O
diarrhea B-PHE
. O

-DOCSTART- O


dry B-PHE
cough I-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


For O
clearing O
weakness B-PHE
and O
heat B-PHE

-DOCSTART- O


Exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
Glucagon-Like O
Peptide-1 O
( O
GLP-1 O
) O
. O

Incretins B-PHE
enhance O
glucose-dependent B-PHE
insulin I-PHE
secretion I-PHE
and O
exhibit O
other O
antihyperglycemic B-PHE
actions I-PHE
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

The O
GLP-1 B-PHE
system I-PHE
increases O
insulin B-PHE
secretion I-PHE
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-PHE
insulin I-PHE
levels I-PHE
during O
fasting O
. O

The O
drug O
also O
moderates O
peak O
serum B-PHE
glucagon I-PHE
levels I-PHE
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-PHE
release I-PHE
in O
response O
to O
hypoglycemia O
. O

Secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-PHE
of I-PHE
gastric I-PHE
emptying I-PHE
and O
decreases O
food B-PHE
intake I-PHE
, O
mitigating O
the O
potential O
severity B-PHE
of I-PHE
hyperglycemic I-PHE
events I-PHE
after O
meals O
. O

-DOCSTART- O


Intelligence O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
parkinson's B-PHE
disease I-PHE
. O

-DOCSTART- O


Good O
evidence O
exists O
that O
this O
drug O
bind O
strongly O
, O
but O
reversibly O
, O
to O
DNA B-PHE
, O
interfering O
with O
synthesis B-PHE
of I-PHE
RNA I-PHE
( O
prevention O
of O
RNA B-PHE
polymerase I-PHE
elongation I-PHE
) O
and O
, O
consequently O
, O
with O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
paralysis B-PHE
, O
painful O
wound B-PHE
from O
knocks O
and O
falls O
, O
tetanus O
. O

-DOCSTART- O


Halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
A2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

It O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis B-PHE
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins B-PHE
and O
leukotrienes B-PHE
by O
inhibiting O
the O
release O
of O
their O
common O
precursor O
arachidonic B-PHE
acid I-PHE
. O

Arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
A2 O
. O

The O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

After O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
GRE O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

The O
DNA O
bound O
receptor O
then O
interacts O
with O
basic O
transcription B-PHE
factors I-PHE
, O
causing O
the O
increase O
in O
expression B-PHE
of I-PHE
specific I-PHE
target I-PHE
genes I-PHE
. O

-DOCSTART- O


fetal B-PHE
irritability I-PHE
; O
threatened B-PHE
abortion I-PHE
; O
excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE
. O

-DOCSTART- O


Cisplatin O
complexes O
react O
in O
vivo O
, O
binding O
to O
and O
causing O
crosslinking O
of O
DNA B-PHE
which O
ultimately O
triggers O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
. O

Gemcitabine O
is O
converted O
intracellularly O
to O
the O
active O
metabolites O
difluorodeoxycytidine O
di- O
and O
triphosphate O
( O
dFdCDP O
, O
dFdCTP O
) O
. O

dFdCDP O
inhibits O
ribonucleotide B-PHE
reductase I-PHE
, O
thereby O
decreasing O
the O
deoxynucleotide O
pool O
available O
for O
DNA B-PHE
synthesis I-PHE
; O
dFdCTP O
is O
incorporated O
into O
DNA B-PHE
, O
resulting O
in O
DNA B-PHE
strand I-PHE
termination I-PHE
and O
apoptosis B-PHE
. O

-DOCSTART- O


For O
breaking O
blood B-PHE
and O
desolving O
stasis B-PHE

-DOCSTART- O


A O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
HPLC-HG-AFS O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic O
species O
( O
As(III) O
) O
, O
dimethylarsinic O
acid O
( O
DMA O
) O
, O
monomethylarsonic O
acid O
( O
MMA O
) O
and O
arsenate O
As(V) O
in O
dog O
plasma O
. O

Good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/L O
KH(2)PO(4 O
) O
( O
pH O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0mL/min O
. O

The O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/mL O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/mL O
for O
As O
( O
III O
) O
, O
DMA O
, O
MMA O
and O
As O
( O
V O
) O
, O
respectively O
. O

The O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
Realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgAs/kg O
) O
alone O
or O
Niu O
Huang O
Jie O
Du O
Pian O
(a O
patent O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgAs/kg O
) O
, O
respectively O
. O

DMA O
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
As(V O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

No O
traces O
of O
MMA O
and O
As(III O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

The O
main O
pharmacokinetic O
parameters O
found O
for O
DMA O
p.o O
. O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
were O
as O
follows O
: O
C(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/mL O
, O
T(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
AUC(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/mL O
, O
AUC(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/mL O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

The O
influence O
of O
compounding O
in O
Niu O
Huang O
Jie O
Du O
Pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
DMA O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
damp B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
and O
to O
cause O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


Treatment O
of O
headache B-PHE
and O
dizziness B-PHE
, O
costal B-PHE
and I-PHE
abdomina I-PHE
pain I-PHE
, O
spasmodic B-PHE
pain I-PHE
of O
the O
limbs O
, O
anemia B-PHE
, O
menstrual B-PHE
disorders I-PHE
, O
spontaneous O
sweating B-PHE
and O
night B-PHE
sweating I-PHE
. O

-DOCSTART- O


Mounting O
qi O
( O
hernia B-PHE
) O
, O
profuse B-PHE
menstruation I-PHE
. O

-DOCSTART- O


arrest O
cough B-PHE
and O
relieve O
asthms B-PHE

-DOCSTART- O


acute O
infantile B-PHE
convulsion I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
wind-cold B-PHE

-DOCSTART- O


Cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-PHE
, O
vomiting B-PHE
nausea B-PHE
, O
diarrhea B-PHE
, O
cold B-PHE
mounting O
, O
dysmenorrhea B-PHE
, O
urethral B-PHE
stone I-PHE
, O
swelling B-PHE
pain I-PHE
of O
sore O
and O
boil O
. O

-DOCSTART- O


To O
reduce O
swelling B-PHE
and O
promote O
healing B-PHE
. O

-DOCSTART- O


Acute B-PHE
Viral I-PHE
Bronchiolitis I-PHE

-DOCSTART- O


AIDS B-PHE
With O
Tuberculosis B-PHE

-DOCSTART- O


Red B-PHE
eyes I-PHE
with O
gall O
, O
pulmonary O
welling O
abscess B-PHE
, O
diarrhea B-PHE
, O
dysentery B-PHE
, O
leukorrhea B-PHE
, O
postpartum O
blood B-PHE
stasis I-PHE
abdominal B-PHE
pain I-PHE
, O
indigestion B-PHE
, O
nephritis B-PHE
with O
edema B-PHE
, O
cirrhosis B-PHE
with O
ascites B-PHE
, O
swelling B-PHE
toxin O
of O
welling B-PHE
abscess I-PHE
and O
sore B-PHE
. O

-DOCSTART- O


promote O
the O
intestine B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
cool O
blood B-PHE
; O

To O
benefit O
qi O
and O
contain O
blood B-PHE
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


For O
treatment O
and O
management O
of O
epilepsy B-PHE
and O
seizures B-PHE
associated O
with O
Lennox-Gastaut B-PHE
syndrome I-PHE
, O
a O
difficult-to-treat O
form O
of O
childhood B-PHE
epilepsy I-PHE
. O

-DOCSTART- O


Hemophilia B-PHE
A I-PHE

-DOCSTART- O


sore B-PHE

-DOCSTART- O


general O
swelling B-PHE
and O
small B-PHE
amount I-PHE
urine I-PHE

-DOCSTART- O


1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-PHE
wounds I-PHE
with O
hemorrhage B-PHE
( O
topical O
use O
) O
. O

2 O
Applicable O
to O
cases O
of O
angina B-PHE
pectoris I-PHE
which O
are O
attributive O
to O
retention O
of O
blood B-PHE
stasis I-PHE
. O

3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O


Hypertension B-PHE
, O
kidney B-PHE
vacuity I-PHE
lumbago I-PHE
, O
weakness B-PHE
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O


ADHD B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


excessive B-PHE
thought I-PHE
; O
anxiety O

-DOCSTART- O


To O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-PHE
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
chronic B-PHE
coughing I-PHE
and O
inflammation B-PHE
in O
urination O
. O

-DOCSTART- O


Intelligence B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


a O
symptom O
of O
having O
muscular B-PHE
flaccidity I-PHE
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-PHE
of I-PHE
nourishment I-PHE
in O
organs O
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-PHE
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-PHE
cell I-PHE
phagocytosis I-PHE
. O

Anti-inflammation B-PHE
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O


To O
move O
qi O
, O
precipitate O
qi O
, O
relieve O
pain B-PHE
, O
disperse O
distention O
, O
free O
milk O
. O

-DOCSTART- O


Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 O
relaxation O
time O
, O
thus O
producing O
an O
increase O
in O
signal O
intensity O
. O

Gadodiamide O
does O
not O
cross O
the O
intact O
blood-brain B-PHE
barrier I-PHE
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
lesions B-PHE
that O
have O
not O
caused O
an O
abnormal O
blood-brain B-PHE
barrier I-PHE
( O
e.g O
. O
, O
cysts B-PHE
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-PHE
vascularity I-PHE
or O
disruption B-PHE
of I-PHE
the I-PHE
blood-brain I-PHE
barrier I-PHE
allows O
accumulation O
of O
gadodiamide B-PHE
in I-PHE
lesions I-PHE
such O
as O
neoplasms B-PHE
, O
abscesses B-PHE
, O
and O
subacute B-PHE
infarcts I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
regurgitation B-PHE

-DOCSTART- O


Inhibited O
urination B-PHE
, O
dribbling O
pain B-PHE
of O
urination O
, O
edema B-PHE
, O
bloody B-PHE
urine I-PHE
, O
damp-heat B-PHE
dysentery I-PHE
, O
asthma B-PHE
, O
sore B-PHE
swollen I-PHE
throat I-PHE
, O
toxin B-PHE
swelling I-PHE
of O
sores O
, O
wind-damp B-PHE
pain I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
bleeding B-PHE
knife O
wound O
. O

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
bloat I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


swelling B-PHE
and O
bearing-down B-PHE
pain I-PHE
of O
unilateral O
testis O
; O
unilateral O
swelling B-PHE
of I-PHE
the I-PHE
testis I-PHE

-DOCSTART- O


Boils B-PHE
and O
carbuncles B-PHE
. O

-DOCSTART- O


release O
the O
exterior O
and O
dispel O
wind B-PHE

-DOCSTART- O


Treatment O
of O
weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
lung I-PHE
manifested O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
, O
palpitation B-PHE
, O
anorexia B-PHE
, O
loose B-PHE
stools I-PHE
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
. O

-DOCSTART- O


inflammation B-PHE
of O
the O
throat O
; O
sore B-PHE
throat I-PHE
; O
hoarse B-PHE
voice I-PHE
; O
aphonia B-PHE

-DOCSTART- O


Its O
aqueous O
infusion O
inhibits O
the O
growth B-PHE
of I-PHE
skin I-PHE
fungi I-PHE
such O
as O
Trichophyton B-PHE
violaceum I-PHE
. O

-DOCSTART- O


To O
enrich O
the O
blood B-PHE
, O
to O
activate O
blood B-PHE
circulation I-PHE
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O


Chronic B-PHE
Fatigue I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
following O
mild-to-moderate B-PHE
infections I-PHE
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-PHE
bacterial I-PHE
exacerbations I-PHE
of I-PHE
chronic I-PHE
bronchitis I-PHE
, O
secondary B-PHE
bacterial I-PHE
infection I-PHE
of O
acute B-PHE
bronchitis I-PHE
, O
community B-PHE
- I-PHE
acquired I-PHE
pneumonia I-PHE
, O
pharyngitis B-PHE
/ O
tonsilitis B-PHE
, O
and O
uncomplicated B-PHE
skin I-PHE
and O
skin B-PHE
structure I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from O
the O
lung O
and O
relieve O
sore B-PHE
throat I-PHE
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
water O
and O
disperse O
edema B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
. O

-DOCSTART- O


post B-PHE
delivery I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Woman O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE
, O
Others O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Hemostatic B-PHE
function I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


pull O
up O
toxicity B-PHE
and O
regenerate O
flesh B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
of O
a O
retarded B-PHE
child I-PHE
. O

There O
are O
five O
symptoms O
including O
slow B-PHE
stand I-PHE
, O
delayed O
development O
in O
walking O
, O
retardation O
in O
hair-growing O
, O
delayed B-PHE
development I-PHE
in O
growth O
of O
teeth O
, O
and O
delayed B-PHE
development I-PHE
of O
speech O
in O
an O
infant O
. O

-DOCSTART- O


Pulmonary O
Aspiration O

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
reinforce O
blood B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
; O
hemostasis B-PHE

-DOCSTART- O


freckles B-PHE
on O
face O

-DOCSTART- O


Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-PHE
of I-PHE
neutrophils I-PHE
in O
the O
bone O
marrow O
. O

-DOCSTART- O


Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene B-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased B-PHE
cell I-PHE
proliferation I-PHE
, O
and O
inhibition B-PHE
of I-PHE
tumorigenesis I-PHE
. O

-DOCSTART- O


Heart B-PHE
Failure I-PHE
. O

-DOCSTART- O


juvenile O
onset O
smallpox B-PHE
poison O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation B-PHE

-DOCSTART- O


pain B-PHE
in O
ear O

-DOCSTART- O


Numbness B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
aching B-PHE
of O
the O
joints O
and O
menstrual B-PHE
disorders I-PHE
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
fullness B-PHE
and I-PHE
pain I-PHE
in I-PHE
the I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O


Treatment O
of O
hemoptysis B-PHE
, O
hematemesis B-PHE
, O
epistaxis B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
pricking O
pain B-PHE
in O
the O
chest O
and O
abdomen O
, O
traumatic B-PHE
swelling I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O


deficiency B-PHE
and I-PHE
chills I-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


frequent B-PHE
vomiting I-PHE

-DOCSTART- O


epigastric O
twisting O
pain B-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
protease I-PHE
enzyme I-PHE
. O

-DOCSTART- O


Statin O
Therapy O

-DOCSTART- O


TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin O
, O
a O
potent O
mediator O
of O
blood O
vessel O
constriction O
and O
growth O
of O
smooth O
muscle O
in O
vascular B-PHE
walls I-PHE
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-PHE
arterial I-PHE
hypertension I-PHE
. O

TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O


insulin O
sensitivity O
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Quality O
of O
life O
, O
Menopausal B-PHE
woman O
, O
Eldery O
, O
Liver B-PHE
health I-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Bone B-PHE
metabolism/density B-PHE
, O
Memory O
, O
Liver O
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


swelling B-PHE
of O
the O
foot O
; O
edema B-PHE
of O
foot O

-DOCSTART- O


Obesity B-PHE
and O
Obesity-related B-PHE
Medical O
Conditions O

-DOCSTART- O


frost B-PHE
bite I-PHE
; O
chilblain B-PHE
; O
frostbite B-PHE

-DOCSTART- O


Migraine B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
taxation O
damage O
in O
lumbar B-PHE
muscle I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Stage O
IV O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
heparin-induced B-PHE
thrombocytopenia I-PHE

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


For O
cooling O
blood B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


chest O
and O
hypochondriac O
pain O

-DOCSTART- O


This O
is O
bleeding B-PHE
due O
to O
an O
external B-PHE
wound I-PHE
. O

-DOCSTART- O


glad O
and O
misten B-PHE
complexion I-PHE

-DOCSTART- O


Treatment O
of O
taeniasis B-PHE
, O
ancylostomiasis B-PHE
, O
ascariasis B-PHE
, O
intestinal B-PHE
parasitosis I-PHE
with O
abdominal B-PHE
pain I-PHE
or O
with O
infantile B-PHE
malnutrition I-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
subcutaneous I-PHE
nodes I-PHE

-DOCSTART- O


For O
desolving O
phlegm B-PHE
, O
stopping O
cougth B-PHE
, O
and O
soothing O
breathing B-PHE

-DOCSTART- O


Roundworm B-PHE

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


fever B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-PHE
colorectal I-PHE
carcinoma I-PHE
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O


Rheumatism B-PHE
numbness I-PHE
, O
damp-heat B-PHE
itchy I-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
menstruant O
morbidity O
. O

-DOCSTART- O


To O
soothe O
the O
liver B-PHE
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-PHE
and O
toxic O
materials O
. O

-DOCSTART- O


new O
and O
old O
cough B-PHE

-DOCSTART- O


To O
supplement O
blood B-PHE
and O
quicken O
blood B-PHE
, O
free O
channels B-PHE
and O
quicken O
network B-PHE
vessels I-PHE
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Edema B-PHE
due O
to O
deficiency B-PHE
in I-PHE
the I-PHE
kidney I-PHE
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-PHE
and O
cough B-PHE
. O

-DOCSTART- O


leukorrhea B-PHE
with O
pruritis B-PHE
vulva I-PHE

-DOCSTART- O


Liver O
Transplantation O

-DOCSTART- O


To O
regulate O
menstruation B-PHE
, O
replenish O
blood B-PHE
and O
regulate O
qi O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


To O
supplement O
blood B-PHE
, O
quicken B-PHE
blood I-PHE
, O
strengthen O
lumbus B-PHE
and O
knees B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
abdominal B-PHE
distension I-PHE
and O
pain B-PHE
caused O
by O
retention O
of O
undigested O
food O
. O

-DOCSTART- O


To O
eliminate O
toxic B-PHE
material I-PHE
, O
promote O
pus B-PHE
drainage I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Papillary B-PHE
serous I-PHE
endometrial I-PHE
cancer I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE
, O
Pediatric O

-DOCSTART- O


1 O
To O
remove O
blood B-PHE
stasis I-PHE
and O
alleviate O
pain B-PHE
. O

For O
stomachache B-PHE
, O
headache B-PHE
, O
toothache B-PHE
, O
trauma B-PHE
and O
rheumatism O
. O

2 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
. O

For O
sorethroat B-PHE
, O
aphthae B-PHE
, O
carbuncle B-PHE
, O
burn B-PHE
, O
snake B-PHE
bite I-PHE
, O
dysentery B-PHE
and O
diarrhea B-PHE
. O

3 O
To O
relax O
the O
muscles O
. O

As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-PHE
and O
surgical O
operation O
. O

-DOCSTART- O


Chloramphenicol O
reversibly O
binds O
to O
the O
L16 B-PHE
protein I-PHE
of O
the O
50S B-PHE
subunit I-PHE
of I-PHE
bacterial I-PHE
ribosomes I-PHE
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase B-PHE
I I-PHE
, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular B-PHE
DNA I-PHE
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-PHE
molecules I-PHE
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human B-PHE
mucosa I-PHE
. O

-DOCSTART- O


pulmonary B-PHE
carbuncle I-PHE
; O
lung B-PHE
abscess I-PHE

-DOCSTART- O


a O
disease O
that O
tendons B-PHE
and O
bones B-PHE
become O
dry O

-DOCSTART- O


vomiting B-PHE

-DOCSTART- O


Yang O
poison B-PHE
; O
extreme O
heat B-PHE
; O
symptoms O
due O
to O
extreme O
heat B-PHE

-DOCSTART- O


the O
steaming B-PHE
of I-PHE
bone I-PHE
and O
tidal O
fever B-PHE

-DOCSTART- O


1 O
Byak-angelicin O
contained O
in O
its O
root O
can O
dilate O
the O
coronary B-PHE
arteries I-PHE
. O

2 O
Stimulating O
the O
respiratory B-PHE
center I-PHE
, O
vasomotor B-PHE
center I-PHE
and O
nervus B-PHE
vagus I-PHE
. O

3 O
Its O
decoction O
exerts O
bacteriostatic B-PHE
effect I-PHE
. O

4 O
Imperatorin O
, O
another O
active O
component O
, O
is O
effective O
for O
psoriasis B-PHE
. O

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Others O

-DOCSTART- O


Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard B-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


To O
pacify O
the O
liver B-PHE
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-PHE
; O

To O
stop O
bleeding B-PHE

-DOCSTART- O


gingivitis B-PHE
; O
epulis B-PHE

-DOCSTART- O


kill O
worms B-PHE

-DOCSTART- O


HER2-overexpressing O
breast B-PHE
cancer I-PHE

-DOCSTART- O


ischuria B-PHE
; O
dysuria B-PHE
; O
retention B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Juzentaihoto O
Failed O
to O
Augment O
Antigen-Specific O
Immunity B-PHE
but O
Prevented O
Deterioration B-PHE
of O
Patients' O
Conditions O
in O
Advanced O
Pancreatic B-PHE
Cancer I-PHE
under O
Personalized O
Peptide O
Vaccine O
. O

-DOCSTART- O


To O
break O
blood B-PHE
and O
desolve O
stagnation B-PHE
; O
To O
benefit O
qi O

-DOCSTART- O


Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme B-PHE
acetylcholinesterase I-PHE
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-PHE
disease I-PHE
. O

-DOCSTART- O


Effects O
of O
Hachimijiogan O
on O
dopamine O
, O
serotonin O
and O
vasoactive O
intestinal O
peptide O
in O
plasma O
and O
hypothalamus O
in O
sulpiride-induced O
hyperprolactinemic O
rats O
. O

-DOCSTART- O


Chronic B-PHE
Heart I-PHE
Failure I-PHE

-DOCSTART- O


Treatment O
of O
carbuncle B-PHE
and O
boil B-PHE
at O
the O
early O
stage O
or O
formation B-PHE
of I-PHE
abscess I-PHE
difficult O
to O
burst B-PHE
, O
external O
use O
for O
scabies B-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


oppressed B-PHE
feeling I-PHE
and O
fullness B-PHE
in O
the O
chest O
and O
diaphragm O

-DOCSTART- O


Spontaneous O
external B-PHE
bleeding I-PHE
, O
hematochezia B-PHE
, O
headache B-PHE
, O
dizziness B-PHE
and O
dim B-PHE
vision I-PHE
, O
red B-PHE
eyes I-PHE
, O
night B-PHE
blindness I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
fecal B-PHE
stoppage I-PHE
, O
hemorrhoids B-PHE
. O

-DOCSTART- O


warm B-PHE
malaria I-PHE
; O

pyrexial B-PHE
malaria I-PHE

-DOCSTART- O


Enduring O
cough B-PHE
and O
asthma B-PHE
, O
bronchitis B-PHE
, O
lumbago B-PHE
and O
limp O
leg B-PHE
, O
frequent O
urination B-PHE
, O
enuresis B-PHE
, O
impotence B-PHE
, O
emission B-PHE
, O
intestinal B-PHE
dry I-PHE
and O
constipation B-PHE
, O
stone B-PHE
strangury I-PHE
, O
sores B-PHE
and O
scrofula B-PHE
. O

-DOCSTART- O


Cancer B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
effuse O
sweat B-PHE
, O
dissipate O
cold B-PHE
and O
dry O
damp B-PHE
. O

-DOCSTART- O


snake-bite B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


To O
astringe O
intestines B-PHE
and O
check O
diarrhea B-PHE
, O
resolve O
toxin B-PHE
, O
relieve O
itch B-PHE
. O

-DOCSTART- O


Ritonavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
proteinase I-PHE
enzyme I-PHE
which O
prevents O
cleavage B-PHE
of I-PHE
the I-PHE
gag-pol I-PHE
polyprotein I-PHE
, O
resulting O
in O
noninfectious O
, O
immature O
viral B-PHE
particles I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
aching B-PHE
pain I-PHE
in O
joints O
, O
arthritis B-PHE
, O
dysmenorrhea B-PHE
, O
skin B-PHE
numbness I-PHE
, O
weakness B-PHE
in I-PHE
limbs I-PHE
, O
jaundice B-PHE
, O
cough B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
sores B-PHE
, O
zoster B-PHE
, O
scalds B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hemorrhoids B-PHE
( O
2 O
) O
polyp B-PHE

-DOCSTART- O


damp B-PHE
Pi O
arthritis B-PHE
due O
to O
dampness B-PHE
. O

damp B-PHE
stroke I-PHE
; O

attack O
of O
dampness B-PHE
syndrome I-PHE
due O
to O
attack O
of O
pathogenic B-PHE
factors I-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
the O
growth O
of O
leukemia615 B-PHE
, O
sarcoma180 B-PHE
and O
cervial B-PHE
carcinoma14 I-PHE
in O
mice O
. O
2 O
Relieving O
iodine B-PHE
deficiency I-PHE
and O
goiter B-PHE
in O
experimental O
animals O
. O

-DOCSTART- O


swelling B-PHE
of O
the O
cheek O
; O
parotitis B-PHE

-DOCSTART- O


Bone B-PHE
Marrow I-PHE
Suppression I-PHE

-DOCSTART- O


Eum O
deficiency O
of O
liver O
and O
kidney O
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver O
and O
kidney O

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE

-DOCSTART- O


Chronic B-PHE
Viral I-PHE
Hepatitis I-PHE
B I-PHE
Without I-PHE
Delta-agent I-PHE

-DOCSTART- O


prolapse B-PHE
of I-PHE
the I-PHE
rectum I-PHE

-DOCSTART- O


Hypertension B-PHE
. O

-DOCSTART- O


Menopausal B-PHE
syndrome I-PHE
marked O
by O
afternoon O
fever B-PHE
, O
excessive B-PHE
sweating I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
insomnia B-PHE
and O
unsteady B-PHE
blood I-PHE
pressure I-PHE
. O

-DOCSTART- O


Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O


nausea B-PHE
without O
vomiting B-PHE
. O

-DOCSTART- O


1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-PHE
and O
decrease O
the O
level B-PHE
of I-PHE
cGMP I-PHE
in O
plasma O
and O
in O
leukocytes O
. O
Protect O
the O
liver B-PHE
from O
damage O
. O
Hypotensive B-PHE
. O

-DOCSTART- O


Drug B-PHE
Induced I-PHE
Hepatotoxicity I-PHE

-DOCSTART- O


12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-PHE
component I-PHE
. O

-DOCSTART- O


To O
desolve O
phlegm B-PHE
and O
soften O
hardness O
; O
To O
revitalize O
blood B-PHE

-DOCSTART- O


Some O
patients O
with O
major B-PHE
depressive I-PHE
disorder I-PHE
( O
MDD B-PHE
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
associated O
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-PHE
or O
weakness B-PHE
of O
the O
lower O
abdomen O
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O


Treament O
of O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Kidney B-PHE
Diseases I-PHE

-DOCSTART- O


Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-PHE
sensation I-PHE
and O
numbness B-PHE
after O
stroke B-PHE
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke B-PHE
patients O
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
bladder B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


Thoracic O
Surgery O

-DOCSTART- O


wind B-PHE
syndrome I-PHE

-DOCSTART- O


Carotid B-PHE
Artery I-PHE
Stenosis I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


Infant B-PHE
, I-PHE
Diabetic I-PHE
Mother I-PHE

-DOCSTART- O


Treament O
of O
heat B-PHE
in O
the O
lung O
with O
cough B-PHE
, O
sticky B-PHE
and I-PHE
bloody I-PHE
sputum I-PHE
, O
and O
distress B-PHE
in I-PHE
the I-PHE
chest I-PHE
. O

-DOCSTART- O


HGS-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-PHE
and O
has O
anti-tumor B-PHE
activity I-PHE
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGS-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody B-PHE
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-PHE
human I-PHE
tumors I-PHE
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-PHE
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O


Tiagabine O
blocks O
GABA O
uptake O
into O
presynaptic O
neurons O
, O
permitting O
more O
GABA O
to O
be O
available O
for O
receptor O
binding O
on O
the O
surfaces O
of O
post-synaptic O
cells O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated O
N-type O
calcium O
ion O
channels O
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent O
calcium O
channel O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

-DOCSTART- O


wind B-PHE
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease B-PHE
in O
association O
with O
other O
pathogenic O
agent O
. O

It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic O
material O
. O

2 O
To O
clear O
liver-heat B-PHE
to O
treat O
eye B-PHE
disease I-PHE
. O

3 O
To O
clear O
dampness-heat B-PHE
. O

-DOCSTART- O


Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O


exogenous O
exogenous B-PHE
febrile I-PHE
disease I-PHE
; O

syndrome B-PHE
of I-PHE
T'aeyang I-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE

affection O
by O
cold B-PHE
; O

common B-PHE
cold I-PHE

-DOCSTART- O


Glomerulonephritis O

-DOCSTART- O


blurred B-PHE
vision I-PHE

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
qi O
; O
To O
soothe O
liver B-PHE
and O
modulate O
qi O
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Treament O
of O
abdomen B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
worms I-PHE
, O
sores B-PHE
, O
uterine B-PHE
bleeding I-PHE
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O


irregular O
chills B-PHE
and I-PHE
fever I-PHE

-DOCSTART- O


unblock O
blood B-PHE

-DOCSTART- O


Treatment O
of O
chills B-PHE
, O
fever B-PHE
and O
headache B-PHE
in O
colds B-PHE
and O
influenza B-PHE
, O
vexation B-PHE
, O
oppressed B-PHE
feeling I-PHE
in O
the O
chest O
and O
insomnia B-PHE
. O

-DOCSTART- O


Kidney B-PHE
Failure I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


This O
is O
an O
external B-PHE
wound I-PHE
in I-PHE
muscle I-PHE
of I-PHE
waist I-PHE
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute B-PHE
hepatitis I-PHE
with O
jaundice B-PHE
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
activities I-PHE
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
infections I-PHE
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-PHE
than O
against O
HSV-1 B-PHE
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-PHE
infection I-PHE
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-PHE
infection I-PHE
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-PHE
infectivity I-PHE
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection B-PHE
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections B-PHE
by O
HSV-1 B-PHE
and O
HSV-2 B-PHE
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-PHE
infectivity I-PHE
. O

-DOCSTART- O


red-white O
dysentery B-PHE

-DOCSTART- O


To O
control O
the O
essence O
; O

To O
astringe O
the O
intestines B-PHE
and O
stop O
diarrhea B-PHE
; O

To O
decrease O
urination B-PHE

-DOCSTART- O


Treatment O
of O
edema B-PHE
with O
oliguria B-PHE
, O
dizziness B-PHE
and O
palpitation B-PHE
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-PHE
marked O
by O
anorexia B-PHE
, O
loose O
stools B-PHE
or O
diarrhea B-PHE
, O
restlessness B-PHE
and O
insomnia B-PHE
. O

-DOCSTART- O


disperse O
stasis B-PHE

-DOCSTART- O


clear O
( O
pathogenic O
) O
fire B-PHE
and O
invigorate O
blood B-PHE

-DOCSTART- O


Intravenous O
Anesthetic O
Interaction O
Unrecognized B-PHE
Condition I-PHE

-DOCSTART- O


Coronary B-PHE
heart I-PHE
disease I-PHE
, O
angina B-PHE
pectoris I-PHE
, O
hypercholesterolemia B-PHE
, O
Parkinson B-PHE
disease I-PHE
, O
peripheral B-PHE
arterial I-PHE
diseases I-PHE
, O
chest B-PHE
impediment I-PHE
and O
heart B-PHE
pain I-PHE
, O
cough B-PHE
of O
phlegm B-PHE
asthma B-PHE
, O
diarrhea B-PHE
and O
dysentery B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
emission B-PHE
, O
retinal B-PHE
insufficiency I-PHE
syndrome I-PHE
. O

-DOCSTART- O


nine O
kinds O
of O
illness B-PHE
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O


Endometriosis B-PHE

-DOCSTART- O


Treatment O
of O
scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
lower O
abdominal B-PHE
pain I-PHE
and O
cold B-PHE
sensation I-PHE
, O
distending B-PHE
pain I-PHE
in I-PHE
the I-PHE
epigastrium I-PHE
with O
anorexia B-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
, O
hydrocele B-PHE
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
caused O
by O
cold B-PHE
. O

-DOCSTART- O


Woman O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Small O
dosage O
of O
berberine O
enhances O
the O
action B-PHE
of I-PHE
acetylcholine I-PHE
on O
animals' O
hearts O
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O


To O
contract O
uterus O
and O
stanch O
bleeding O
, O
relieve O
pain O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
itching B-PHE
of O
the O
throat O
and O
profuse O
expectoration B-PHE
in I-PHE
colds I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
and O
epigastric B-PHE
distension I-PHE
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O


Hepatocellular B-PHE
Carcinoma I-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
with O
chest B-PHE
congested I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-PHE
, O
spleen B-PHE
and O
stomach B-PHE
, O
and O
to O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


Treatment O
of O
fever B-PHE
due O
to O
deficiency B-PHE
of O
yin O
, O
consumptive O
fever B-PHE
, O
fever B-PHE
in O
infantile O
malnutrition B-PHE
. O

-DOCSTART- O


The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic B-PHE
bile I-PHE
acids I-PHE
in O
the O
gastrointestinal B-PHE
tract I-PHE
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O


For O
the O
treatment O
of O
Tuberculosis B-PHE
and O
Tuberculosis-related O
mycobacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Breast B-PHE
Neoplasms I-PHE

-DOCSTART- O


a O
mass O
amount O
of O
phlegm B-PHE
, O
and O
dyspnea B-PHE
and O
cough B-PHE

-DOCSTART- O


damp B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthritis B-PHE
due O
to O
dampness B-PHE
; O
damp B-PHE
impediment O
[ O
blockage B-PHE
] O

-DOCSTART- O


distension B-PHE
and O
fullness B-PHE

-DOCSTART- O


To O
arrest O
discharges O
, O
promote O
healing O
of O
wounds B-PHE
and O
tissue B-PHE
regeneration I-PHE
, O
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-PHE
, O
bruises B-PHE
and O
arthritis B-PHE
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery I-PHE
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' B-PHE
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone B-PHE
injury I-PHE
and O
regulates O
bone B-PHE
metabolism I-PHE
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
spinal B-PHE
compression I-PHE
fracture I-PHE
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain O
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-PHE
began O
promptly O
after O
administration O
and O
the O
pain B-PHE
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-PHE
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-PHE
of O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
one O
spinal B-PHE
compression I-PHE
fracture I-PHE
. O

-DOCSTART- O


Treament O
of O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
amenorrhea B-PHE
with O
blood O
stasis O
, O
arthralgia B-PHE
, O
traumatic O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


1 O
To O
clear O
the O
lungs B-PHE
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-PHE
and O
promote O
the O
production B-PHE
of I-PHE
body I-PHE
fluids I-PHE

-DOCSTART- O


Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 O
receptors O
. O

Naproxen O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
enzymes I-PHE
cyclo-oxygenase I-PHE
I I-PHE
and I-PHE
II I-PHE
, O
resulting O
in O
a O
decreased O
formation B-PHE
of I-PHE
precursors I-PHE
of I-PHE
prostaglandins I-PHE
and I-PHE
thromboxanes I-PHE
. O

-DOCSTART- O


Melphalan O
alkylates O
DNA B-PHE
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA B-PHE
inter-strand I-PHE
cross-linkages I-PHE
, O
resulting O
in O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cytotoxicity B-PHE
against O
both O
dividing O
and O
non-dividing O
tumor B-PHE
cells I-PHE
. O

-DOCSTART- O


1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O
and O
NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


restrain O
acid B-PHE

-DOCSTART- O


warm O
the O
lumbus B-PHE
and O
knees B-PHE

-DOCSTART- O


night O
fever B-PHE
and O
chilling B-PHE
in O
the O
morning O

-DOCSTART- O


strengthen O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

GSK2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-PHE
of I-PHE
leukotrienes I-PHE
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ETE O
) O
. O

-DOCSTART- O


Others O

-DOCSTART- O


Quality O
of O
life O
, O
Others O

-DOCSTART- O


To O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-PHE
, O
disperse O
swelling B-PHE
toxin I-PHE
. O

-DOCSTART- O


Pneumonia B-PHE
, O
pyothorax B-PHE
, O
sore B-PHE
pharynx I-PHE
, O
oral B-PHE
ulcer I-PHE
, O
vesical B-PHE
calculus I-PHE
, O
swollen O
welling O
abscess B-PHE
. O

-DOCSTART- O


Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase B-PHE
II I-PHE
activity I-PHE
by O
stabilizing O
the O
DNA-topoisomerase B-PHE
II I-PHE
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase B-PHE
II I-PHE
catalyzes I-PHE
. O

-DOCSTART- O


Gout B-PHE

-DOCSTART- O


Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-PHE
, O
insomnia B-PHE
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-PHE
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor O
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor O
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors O
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor O
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor O
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O


Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-PHE
deficiency I-PHE
( O
TD B-PHE
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100 O
- O
500 O
microg O
/ O
ml O
) O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-PHE
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration O
- O
dependent O
manner O
. O

These O
substances O
inhibited O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-PHE
activity I-PHE
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O


Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O


warm O
the O
lung B-PHE

-DOCSTART- O


This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O


support O
five O
viscera B-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Atrophy B-PHE

-DOCSTART- O


Taxation B-PHE
damage I-PHE
and O
sinew B-PHE
bone I-PHE
pain I-PHE
, O
impotence B-PHE
, O
stomachache B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
knife B-PHE
wound I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Kids O
, O
Others O
, O
Fetus O

-DOCSTART- O


Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-PHE
artery I-PHE
significantly O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O


abdominal B-PHE
fullness I-PHE
; O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
nourish O
blood B-PHE

-DOCSTART- O


Its O
alcoholic O
extract O
inhibits O
the O
heart B-PHE
and O
lowers O
blood B-PHE
pressure I-PHE
in O
anesthetized O
cats O
. O

-DOCSTART- O


fever B-PHE
with O
dysphoria B-PHE
; O
dysphoria B-PHE
with O
smothery O
sensation O
; O
smothery O
fever B-PHE

-DOCSTART- O


ceruminal B-PHE
impaction I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
is O
lumped O
at O
the O
neck O

-DOCSTART- O


dizziness B-PHE

-DOCSTART- O


Organophosphate B-PHE
Poisoning I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
after O
phlegm B-PHE
due O
to O
Wind B-PHE
sidesae O
blocked O
Gi O
. O

-DOCSTART- O


Both O
acted O
at O
the O
same O
active O
site O
of O
penicillinbinding O
protein O
2A O
but O
at O
relatively O
high O
MICs O
of O
32 O
g/ml O
. O

The O
relatively O
high O
MICs O
make O
it O
less O
likely O
for O
both O
drugs O
to O
saturate O
target O
sites O
, O
thereby O
maintaining O
additive O
antibacterial B-PHE
effect I-PHE
. O

-DOCSTART- O


blood B-PHE
wind I-PHE
of O
female O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


Dim B-PHE
vision I-PHE
, O
flooding B-PHE
and O
spotting I-PHE
, O
bleeding I-PHE
due O
to O
external B-PHE
injury I-PHE
, O
sore B-PHE
toxin I-PHE
and O
intractable O
lichen B-PHE
. O

-DOCSTART- O


skin B-PHE
disease I-PHE
on O
palms O
. O

-DOCSTART- O


Ankylosing B-PHE
Spondylitis I-PHE

-DOCSTART- O


hoarseness B-PHE
due O
to O
singing O

-DOCSTART- O


dyspnea B-PHE
with O
coughing B-PHE

-DOCSTART- O


dry O
phlegm B-PHE
; O
dry-phlegm B-PHE
( O
syndrome O
) O

-DOCSTART- O


Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O


Water O
extract O
of O
Samultang O
reduces O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
h(2)o(2)-induced O
oxidative B-PHE
injury I-PHE
in O
sk-N-mc O
cells O
. O

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE
of O
the O
back O
; O

carbuncle B-PHE
on O
the O
back O

-DOCSTART- O


To O
eliminate O
fluid B-PHE
and O
relieve O
edema B-PHE
( O
sthenia-syndrome B-PHE
with O
edema B-PHE
and O
ascites B-PHE
) O
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE
; O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE

-DOCSTART- O


Wind-evil O
attacked O
meridian O
, O
facial B-PHE
paralysis I-PHE
, O
muscle B-PHE
numbness I-PHE
, O
pain B-PHE
of I-PHE
tendons I-PHE
and I-PHE
bone I-PHE
. O

-DOCSTART- O


For O
ascariasis B-PHE
and O
taeniasis B-PHE
. O

For O
constipation B-PHE
due O
to O
dryness B-PHE
of O
intestine O
. O

-DOCSTART- O


( O
1 O
) O
hematochezia B-PHE
( O
2 O
) O
viginal B-PHE
bleeding I-PHE

-DOCSTART- O


wind B-PHE
rash I-PHE
; O
German B-PHE
measles I-PHE
; O
rubella B-PHE
; O
urticaria B-PHE

-DOCSTART- O


traumatic B-PHE
cataract I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


eliminate O
vacuity O
and O
clod O
of O
the O
spleen O
and O
the O
stomach O

-DOCSTART- O


To O
dispel O
wind-damp B-PHE
, O
quicken O
blood B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Pregnancy B-PHE

-DOCSTART- O


To O
expel O
wind B-PHE
and O
heat B-PHE
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels O
. O

-DOCSTART- O


cool O
blood B-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Memory B-PHE

-DOCSTART- O


Hepatoma B-PHE

-DOCSTART- O


bloody B-PHE
stool I-PHE
; O
hematochezia B-PHE

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
stop O
pain B-PHE
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Perennial B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


Apical B-PHE
Ballooning I-PHE
Syndrome I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O
, O
Evacuation B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE
( O
OAB B-PHE
) O

-DOCSTART- O


For O
activating O
blood B-PHE
and O
modulating O
period O

-DOCSTART- O


To O
invigorate O
the O
function B-PHE
of I-PHE
the I-PHE
kidney I-PHE
, O
to O
alleviate O
asthma B-PHE
, O
and O
to O
relieve O
diarrhea B-PHE
. O

-DOCSTART- O


It O
may O
also O
bind O
to O
bacterial B-PHE
potassium I-PHE
transporters I-PHE
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O


Deficiency O
of O
yin O
of O
the O
liver B-PHE
and O
the O
kidney B-PHE
marked O
by O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
, O
dizziness B-PHE
and O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


sore B-PHE
of I-PHE
scrotum I-PHE

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

By O
binding O
to O
the O
ATP-binding O
site O
, O
enzastaurin O
selectively O
inhibits O
protein B-PHE
kinase I-PHE
C I-PHE
beta I-PHE
, O
which O
appears O
to O
be O
cytotoxic O
in O
cells O
with O
DNA B-PHE
alterations O
or O
DNA O
damage O
which O
may O
decrease O
tumor B-PHE
blood I-PHE
supply I-PHE
, O
preventing O
growth B-PHE
. O

-DOCSTART- O


RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-PHE
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O


deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-PHE

-DOCSTART- O


Schizophrenia B-PHE
Prodrome I-PHE

-DOCSTART- O


For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-PHE
associated O
with O
chronic B-PHE
renal I-PHE
failure I-PHE
( O
CRF B-PHE
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-PHE
and O
reduction B-PHE
of I-PHE
transfusion I-PHE
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-PHE
tumours I-PHE
, O
malignant B-PHE
lymphoma I-PHE
or O
multiple B-PHE
myeloma I-PHE
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia B-PHE
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-PHE
blood I-PHE
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Breast I-PHE

-DOCSTART- O


dissipate O
depression B-PHE

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE
due O
to O
visceral O
cold B-PHE

-DOCSTART- O


Motivation O
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Others O
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-PHE
circulation. I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE

-DOCSTART- O


epiphora B-PHE
; O
lacrimation B-PHE

-DOCSTART- O


Cardiovascular B-PHE
Disorder I-PHE

-DOCSTART- O


terminate O
delivery O

-DOCSTART- O


To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
promote O
eruption B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
resolve O
phlegm B-PHE
and O
benefit O
throat B-PHE

-DOCSTART- O


1 O
Aloperine O
inhibits O
exudative B-PHE
inflammation I-PHE
and O
hemolysis B-PHE
of O
red O
blood B-PHE
cells O
2 O
. O

Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-PHE
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O

3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 B-PHE
in O
vitro O
. O

-DOCSTART- O


Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-PHE
activities I-PHE
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-PHE
activity I-PHE
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-PHE
activity I-PHE
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity O
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


Decompensated B-PHE
Cirrhosis I-PHE

-DOCSTART- O


Cough B-PHE
and O
asthma B-PHE
, O
fright O
epilepsy B-PHE
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of I-PHE
rectum I-PHE
, O
knocks B-PHE
and O
falls B-PHE
. O

-DOCSTART- O


Cardiovascular B-PHE
Diseases I-PHE

-DOCSTART- O


1 O
Its O
decoction O
enhances O
th O
intestinal B-PHE
contraction I-PHE
and O
tensity O
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O

2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-PHE
180 I-PHE
in O
mice O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
, O
deprive O
dampness B-PHE
and O
kill O
parasites B-PHE
. O

For O
sorethroat B-PHE
, O
dysentery B-PHE
, O
trichomonas B-PHE
enteritis I-PHE
, O
toothache B-PHE
, O
stomachache B-PHE
and O
leucorrhagia B-PHE
, O
external O
use O
for O
tinea B-PHE
and O
eczema B-PHE
. O

2 O
To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
. O

3 O
Anticarcinogenic B-PHE
. O
For O
malignant B-PHE
hydatidiform I-PHE
mole I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
and O
leukemia B-PHE
. O

-DOCSTART- O


Knee B-PHE
Osteoarthritis I-PHE

-DOCSTART- O


Malignancy B-PHE

-DOCSTART- O


Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O


Crohn's B-PHE
Disease I-PHE

-DOCSTART- O


Swelling B-PHE
and O
pain B-PHE
due O
to O
blood B-PHE
stagnation I-PHE
caused O
by O
external B-PHE
injuries I-PHE
. O

-DOCSTART- O


Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
arthritis I-PHE
with O
muscular B-PHE
contracture I-PHE
, O
aching B-PHE
of O
the O
loins O
and O
knees O
, O
inflammation B-PHE
of O
the O
throat O
, O
carbuncle B-PHE
and O
boils O
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-PHE
of I-PHE
MTIC I-PHE
is O
due O
primarily O
to O
methylation B-PHE
of I-PHE
DNA I-PHE
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition B-PHE
of I-PHE
DNA I-PHE
replication I-PHE
. O

-DOCSTART- O


Growth B-PHE

-DOCSTART- O


Treatment O
of O
: O
1 O
Hemorrhages B-PHE
due O
to O
external B-PHE
injuries I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O


A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-PHE
pain I-PHE
and O
general O
fatigue B-PHE
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-PHE
pain I-PHE
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain B-PHE
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-PHE
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced B-PHE
pneumonitis I-PHE
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic B-PHE
pneumonitis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Alzheimer B-PHE
Disease I-PHE

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
subdue O
hyperactivity B-PHE
of I-PHE
the I-PHE
liver I-PHE
, O
and O
improve O
eyesight B-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
depression B-PHE
. O

-DOCSTART- O


To O
stop O
bleeding B-PHE
and O
promote O
the O
healing B-PHE
of I-PHE
wounds I-PHE
. O

-DOCSTART- O


seven O
injuries B-PHE
; O
seven O
kinds O
of O
impairments B-PHE

-DOCSTART- O


Regulation O
of O
qi O

-DOCSTART- O


Eye B-PHE
pain I-PHE
, O
eye B-PHE
swelling I-PHE
, O
red B-PHE
eyes I-PHE
and O
tearing B-PHE
. O

-DOCSTART- O


Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-PHE
coli I-PHE
. O

-DOCSTART- O


phthisical B-PHE
cough I-PHE
due O
to O
Eum O
deficiency O

-DOCSTART- O


swollen O
check O
, O
mumps B-PHE
; O
epidemic B-PHE
parotitis I-PHE

-DOCSTART- O


Infection B-PHE

-DOCSTART- O


Behavioral B-PHE
and I-PHE
psychological I-PHE
symptoms I-PHE
of I-PHE
dementia I-PHE
( O
BPSD B-PHE
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-PHE
disease I-PHE
( O
AD B-PHE
) O
and O
other O
forms O
of O
senile B-PHE
dementia I-PHE
. O

BPSD B-PHE
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-PHE
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-PHE
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-PHE
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-PHE
of I-PHE
the I-PHE
serotonin I-PHE
( O
5-HT B-PHE
) O
system O
such O
as O
5-HT2A O
receptors O
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-PHE
of O
AD B-PHE
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A O
receptors O
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced B-PHE
head-twitch I-PHE
response I-PHE
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch B-PHE
response I-PHE
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced B-PHE
head-twitch I-PHE
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-PHE
system I-PHE
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O


Obesity B-PHE

-DOCSTART- O


relieve O
pain B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
and O
relieve O
cough B-PHE
. O

For O
acute O
and O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Non-Small B-PHE
Cell I-PHE
Lung I-PHE
Cancer I-PHE

-DOCSTART- O


To O
regulate O
the O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of O
the O
ear O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


Retention B-PHE
of I-PHE
milk I-PHE
in O
babies O
, O
profuse O
sputum B-PHE
and O
infantile B-PHE
convulsions I-PHE
. O

-DOCSTART- O


To O
stablize O
liver B-PHE
and O
suppress O
dizziness B-PHE
; O
To O
soothe O
neck B-PHE
and O
wake-up O
brain B-PHE

-DOCSTART- O


burn B-PHE

-DOCSTART- O


Melanoma B-PHE

-DOCSTART- O


reddish B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
and O
nocturnal B-PHE
emission I-PHE

-DOCSTART- O


urinary B-PHE
incontinence I-PHE
; O
galacturia B-PHE
; O
stranguria B-PHE
with O
chyluria B-PHE
; O
stranguria B-PHE
marked O
by O
chyluria B-PHE

-DOCSTART- O


To O
dissipate O
stasis B-PHE
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


replenish O
essence-marrow O

-DOCSTART- O


( O
1 O
) O
diarrhea B-PHE
( O
2 O
) O
diarrhea B-PHE
and O
urination B-PHE
( O
3 O
) O
diarrhea B-PHE
and O
dysentery B-PHE

-DOCSTART- O


A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O


Ureteral B-PHE
Stent I-PHE
Occlusion I-PHE

-DOCSTART- O


De O
Novo O
Kidney O
Transplant O
Patients O

-DOCSTART- O


Glaucoma B-PHE

-DOCSTART- O


excessive O
drinking O
of O
water O
due O
to O
thirst B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews B-PHE
and O
free O
network O
vessels B-PHE
. O

-DOCSTART- O


Ovarian B-PHE
Hyperstimulation I-PHE
Syndrome I-PHE

-DOCSTART- O


Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-PHE
. O

-DOCSTART- O


moisten O
the O
liver B-PHE

-DOCSTART- O


vomiting B-PHE
of O
milk O

-DOCSTART- O


Oxcarbazepine O
produces O
blockade B-PHE
of I-PHE
voltage-sensitive I-PHE
sodium I-PHE
channels I-PHE
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-PHE
membranes I-PHE
, O
inhibition O
of O
repetitive B-PHE
neuronal I-PHE
firing I-PHE
, O
and O
diminution O
of O
propagation B-PHE
of I-PHE
synaptic I-PHE
impulses I-PHE
. O

These O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-PHE
spread I-PHE
in O
the O
intact O
brain O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated B-PHE
N-type I-PHE
calcium I-PHE
ion I-PHE
channels I-PHE
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-PHE
calcium I-PHE
channel I-PHE
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O


Toxoplasmosis B-PHE

-DOCSTART- O


white B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


nourish O
essence-marrow B-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


warm O
the O
menses B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
resolve O
phlegm B-PHE
and O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
obstruction B-PHE
in I-PHE
the I-PHE
channels I-PHE
. O

-DOCSTART- O


Atrophic B-PHE
Vaginitis I-PHE

-DOCSTART- O


Treatment O
of O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
with O
epigastric B-PHE
distension I-PHE
, O
diarrhea B-PHE
and O
abdominal B-PHE
pain I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
epigastric B-PHE
pain I-PHE
or O
abdominal B-PHE
colic I-PHE
, O
after O
childbirth O
, O
heraial O
pain B-PHE
, O
hyperlipemia B-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
dryness B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


profuse B-PHE
bleeding I-PHE
after O
delivery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Inv(16)(p13.1q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


secure O
the O
essence O

-DOCSTART- O


Septic B-PHE
Shock I-PHE

-DOCSTART- O


Sore B-PHE
Throat I-PHE
Due O
to O
a O
Common O
Cold B-PHE

-DOCSTART- O


Neuropathic B-PHE
pain I-PHE

-DOCSTART- O


cool O
blood B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


close O
sores B-PHE

-DOCSTART- O


Kids O
, O
Protective B-PHE
immunity I-PHE
, O
Metabolism B-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
motility B-PHE
, O
Others O

-DOCSTART- O


Parasite O
worms B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
chronic B-PHE
hepatitis I-PHE
B O
in O
adult O
and O
adolescent O
patients O
??6 O
years O
of O
age O
with O
evidence O
of O
viral O
replication O
and O
either O
evidence O
of O
persistent O
elevations O
in O
serum O
aminotransferases O
( O
ALT O
or O
AST O
) O
or O
histologically O
active O
disease O
. O

-DOCSTART- O


Unspecified O
Adult O
Solid B-PHE
Tumor I-PHE
, O
Protocol O
Specific O

-DOCSTART- O


fever B-PHE
of O
juvenile O
Gamjeck O

-DOCSTART- O


Its O
solution O
may O
kill O
the O
oncomelania O
. O

-DOCSTART- O


Photoaging B-PHE

-DOCSTART- O


Myelomeningocele B-PHE

-DOCSTART- O


Treatment O
of O
attack O
of O
damp-heat B-PHE
manifested O
by O
stuffiness B-PHE
and O
fullness B-PHE
sensation O
in O
the O
abdomen O
, O
or O
causing O
acute O
dysentery B-PHE
of I-PHE
jaundice I-PHE
, O
high B-PHE
fever I-PHE
accompained O
by O
impairment B-PHE
of I-PHE
conciousness I-PHE
, O
fidgetness B-PHE
and O
insomnia B-PHE
due O
to O
exuberant B-PHE
fire I-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
and O
epistaxis B-PHE
caused O
by O
heat B-PHE
in I-PHE
the I-PHE
blood I-PHE
, O
inflammation B-PHE
of O
the O
eye O
, O
acid B-PHE
regurgitation I-PHE
, O
toothache B-PHE
, O
diabetes B-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
, O
external O
use O
for O
eczema B-PHE
and O
other O
skin B-PHE
diseases I-PHE
with O
exudation B-PHE
, O
purulent B-PHE
discharge I-PHE
from O
the O
ear O
. O

-DOCSTART- O


Dimethindene O
can O
also O
be O
used O
as O
an O
adjuvant O
in O
eczema B-PHE
and O
other O
pruriginous B-PHE
dermatoses I-PHE
of O
allergic O
origin O
. O

-DOCSTART- O


For O
the O
treatment O
of O
mild O
to O
moderate O
infections B-PHE
in O
adults O
and O
adolescents O
( O
12 O
years O
of O
age O
or O
older O
) O
which O
are O
caused O
by O
susceptible O
strains B-PHE
of O
microorganisms O
in O
acute B-PHE
bacterial I-PHE
exacerbation I-PHE
of O
chronic B-PHE
bronchitis I-PHE
, O
community-acquired B-PHE
pneumonia I-PHE
, O
pharyngitis/tonsillitis B-PHE
, O
and O
uncomplicated O
skin O
and O
skin-structure B-PHE
infections I-PHE
. O

-DOCSTART- O


sweating O
head O
; O
perspiration B-PHE
on O
forehead O
; O
morbid O
perspiration B-PHE
on O
the O
head O

-DOCSTART- O


This O
is O
bursting O
a O
carbuncle B-PHE
and O
cellulites B-PHE
after O
decaying O
. O

It O
is O
occurred O
in O
thick O
skin O
and O
region O
which O
have O
a O
lot O
of O
glandulae B-PHE
sebaceae I-PHE
and O
follicular B-PHE
. O

-DOCSTART- O


To O
replenish O
the O
kidney B-PHE
, O
to O
strengthen O
the O
bones B-PHE
, O
to O
promote O
the O
healing B-PHE
of I-PHE
fracture I-PHE
, O
and O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


blood B-PHE
stagnation I-PHE
caused O
by O
falling B-PHE
or O
strike B-PHE

-DOCSTART- O


Fatigue B-PHE

-DOCSTART- O


flaccidity B-PHE
and O
limping B-PHE

-DOCSTART- O


black B-PHE
hair I-PHE

-DOCSTART- O


Denosumab O
is O
designed O
to O
target O
RANKL B-PHE
( O
RANK B-PHE
ligand I-PHE
) O
, O
a O
protein O
that O
acts O
as O
the O
primary O
signal O
to O
promote O
bone B-PHE
removal/resorption I-PHE
. O

In O
many O
bone B-PHE
loss I-PHE
conditions O
, O
RANKL B-PHE
overwhelms O
the O
body's O
natural O
defense O
against O
bone B-PHE
destruction I-PHE
. O

Denosumab O
prevents O
RANKL B-PHE
from O
activating O
its O
receptor O
, O
RANK B-PHE
, O
on O
the O
surface O
of O
osteoclasts B-PHE
and O
their O
precursors O
. O

Prevention O
of O
the O
RANKL/RANK B-PHE
interaction O
inhibits O
osteoclast B-PHE
formation I-PHE
, O
function O
, O
and O
survival O
, O
thereby O
decreasing O
bone B-PHE
resorption I-PHE
and O
increasing O
bone B-PHE
mass I-PHE
and O
strength O
in O
both O
cortical B-PHE
and I-PHE
trabecular I-PHE
bone I-PHE
. O

-DOCSTART- O


mental B-PHE
confusion I-PHE

-DOCSTART- O


Counteracting O
the O
arrhythmias B-PHE
induced O
pituitrin B-PHE
in O
rabbits. O
. O

-DOCSTART- O


To O
relieve O
rheumatic B-PHE
conditions I-PHE
, O
and O
to O
remove O
damp-heat B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
flooding B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
pharyngolaryngitis B-PHE
, O
mammary B-PHE
welling I-PHE
abscess I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
poisonous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


move O
Gi(Qi O
) O
and O
blood B-PHE

-DOCSTART- O


Omeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-PHE
acid I-PHE
secretion I-PHE
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

By O
acting O
specifically O
on O
the O
proton O
pump O
, O
omeprazole O
blocks O
the O
final O
step O
in O
acid O
production O
, O
thus O
reducing O
gastric B-PHE
acidity I-PHE
. O

-DOCSTART- O


Tuberculosis B-PHE

-DOCSTART- O


diarrhea B-PHE
due O
to O
damp-heat B-PHE

-DOCSTART- O


Amenorrhea B-PHE
, O
concretion O
and O
conglomeration O
, O
knocks O
and O
falls O
, O
abdominal B-PHE
pain I-PHE
, O
asthma B-PHE
( O
raw O
) O
, O
blood B-PHE
ejection I-PHE
, O
hematuria B-PHE
, O
hematochezia B-PHE
, O
prolapse B-PHE
of O
rectum O
( O
scorch-fry O
) O
. O

-DOCSTART- O


Carcinoma B-PHE
, I-PHE
Renal I-PHE
Cell I-PHE

-DOCSTART- O


somnolence B-PHE

-DOCSTART- O


Neck B-PHE
bone I-PHE
problems I-PHE
and O
inflammation B-PHE

-DOCSTART- O


To O
remove O
heat B-PHE
and O
counteract O
toxicity B-PHE
, O
to O
nourish O
liver B-PHE
and O
stomach B-PHE
, O
curing O
sore B-PHE
, O
to O
improve O
consciousness B-PHE
, O
to O
tonify B-PHE
the I-PHE
body I-PHE
. O

-DOCSTART- O


Other O
Nutritional B-PHE
Deficiencies I-PHE

-DOCSTART- O


expel O
pus B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Stagnation O
of O
qi O
and O
blood B-PHE
marked O
by O
chest B-PHE
pain I-PHE
; O
dry B-PHE
cough I-PHE
with O
shortness B-PHE
of I-PHE
breath I-PHE
; O
insomnia B-PHE
. O

-DOCSTART- O


An O
active O
component O
pachyman O
promotes O
macrophage B-PHE
phagocytosis I-PHE
in O
mice O
, O
and O
enhances O
lymphocyte-blastogensis B-PHE
rate O
in O
vitro O
. O

Preventing O
the O
formation O
of O
gastric B-PHE
ulcer I-PHE
under O
stress B-PHE
in O
rats O
. O

Diuretic B-PHE
and O
liver-protective B-PHE
. O

-DOCSTART- O


toothache B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
motility B-PHE
, O
Evacuation B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


For O
dispersing O
wind-coldness B-PHE

-DOCSTART- O


Chlorpheniramine O
binds O
to O
the O
histamine O
H1 O
receptor O
, O
which O
blocks O
the O
action B-PHE
of I-PHE
endogenous I-PHE
histamine I-PHE
, O
which O
subsequently O
leads O
to O
temporary O
relief O
of O
the O
negative B-PHE
symptoms I-PHE
brought O
on O
by O
histamine O
. O

-DOCSTART- O


cosolidate O
bones B-PHE

-DOCSTART- O


Ipilimumab O
blocks O
the O
CTLA-4 B-PHE
inhibitory I-PHE
signal I-PHE
, O
and O
allows O
the O
Cytotoxic B-PHE
T I-PHE
lymphocytes I-PHE
to O
destroy O
the O
cancer B-PHE
cells I-PHE
. O

Fotemustine O
alkylates O
guanine O
by O
forming O
chloroethyl O
adducts O
at O
the O
6 O
position O
of O
guanine O
, O
resulting O
in O
N1-guanine O
and O
N3-cytosine O
cross O
linkages O
, O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
, O
cell B-PHE
cycle I-PHE
arrest I-PHE
, O
and O
finally O
apoptosis B-PHE
. O

-DOCSTART- O


malaria B-PHE
with O
mass O
under O
left O
hypochondrium O

-DOCSTART- O


phlegm-retention B-PHE
syndrome I-PHE
; O
congested O
fluids O
; O
retention O
of O
phlegm B-PHE
and O
fluid O
( O
1 O
) O
morbid O
conditions O
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, I-PHE
spleen I-PHE
md I-PHE
kidney I-PHE
or O
from O
disturbance O
of O
water O
circulation O
in O
the O
passage O
of O
Triple O
Ch'o(? O
. O

The O
thicker O
dampness O
is O
called O
phlegm B-PHE
, O
while O
the O
thinner O
fluid O
. O

Retention O
of O
phlegm B-PHE
and O
fluid O
can O
give O
rise O
to O
various O
diseases B-PHE
, O
one O
of O
the O
four O
kinds O
of O
fluid O
retention O
. O

( O
2 O
) O
a O
morbid O
condition O
due O
to O
fluid O
retention O
in O
the O
stomach B-PHE
and O
intestines B-PHE
. O

-DOCSTART- O


white-haired B-PHE

-DOCSTART- O


bluish B-PHE
blindness I-PHE
; O
optic B-PHE
atrophy I-PHE
; O
glaucoma B-PHE

-DOCSTART- O


deficiency O
of O
Gi O
( O
vital O
energy O
) O
of O
the O
stomach O

-DOCSTART- O


To O
nourish O
yin O
and O
clear O
away O
heat B-PHE
, O
relieve O
restlessness B-PHE
and O
tranquilize O
the O
mind B-PHE
, O
regulate O
the O
equilibrium O
of O
the O
human B-PHE
body I-PHE
, O
improve O
health B-PHE
and O
prolong B-PHE
life I-PHE
. O

-DOCSTART- O


Simultaneous O
quantitative O
analyses O
of O
indole O
and O
oxindole O
alkaloids O
of O
Uncaria O
Hook O
in O
rat O
plasma O
and O
brain O
after O
oral O
administration O
of O
the O
traditional O
Japanese O
medicine O
Yokukansan O
using O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest B-PHE
and O
a O
middle O
part O
of O
the O
stomach B-PHE
are O
full O
and O
uncomfortable O
. O

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
and O
blood B-PHE
, O
to O
relieve O
cough B-PHE
, O
and O
to O
induce O
tranquilization B-PHE
. O

-DOCSTART- O


Haemorrhage B-PHE

-DOCSTART- O


move O
stasis B-PHE

-DOCSTART- O


To O
arrest O
spontaneous O
emission O
, O
to O
reduce O
excessive B-PHE
urination I-PHE
, O
and O
to O
cure O
turbid B-PHE
discharge I-PHE
from O
the O
urethra O
. O
cturnal B-PHE
emission I-PHE
, O
spermatorrhea B-PHE
, O
enuresis B-PHE
, O
frequent B-PHE
urination I-PHE
, O
turbid B-PHE
discharge I-PHE
with O
urine O
. O

-DOCSTART- O


Pregnancy B-PHE
in I-PHE
Diabetics I-PHE

-DOCSTART- O


the O
heat B-PHE
from O
bones O
without O
sweating B-PHE

-DOCSTART- O


Eum O
in O
its O
extreme O
rise O
to O
agitation B-PHE

-DOCSTART- O


wind-cold B-PHE
; O

wind-cold B-PHE
pathogen I-PHE
wind B-PHE
and O
cold B-PHE
blended O
as O
a O
pathogenic O
facto O

-DOCSTART- O


Hemostatic O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
transform O
damp B-PHE
, O
disperse O
accumulation O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation B-PHE
of I-PHE
AMP-activated I-PHE
protein I-PHE
kinase I-PHE
( O
AMPK B-PHE
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin B-PHE
signaling I-PHE
, O
whole O
body B-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and O
fats O
. O

Rosiglitazone O
acts O
as O
a O
highly O
selective O
and O
potent O
agonist O
at O
peroxisome O
proliferator O
activated O
receptors O
( O
PPAR O
) O
in O
target O
tissues O
for O
insulin B-PHE
action I-PHE
such O
as O
adipose O
tissue O
, O
skeletal O
muscle O
, O
and O
liver O
and O
enhances O
tissue B-PHE
sensitivity I-PHE
to O
insulin O
. O

-DOCSTART- O


Pi B-PHE
syndrome I-PHE
due O
to O
pathogenic B-PHE
wind I-PHE
, O
cold B-PHE
and O
damp B-PHE

-DOCSTART- O


diabetes B-PHE
; O
wasting B-PHE
( O
emaciation B-PHE
) O
and O
thirsting B-PHE
syndrome I-PHE

-DOCSTART- O


The O
functional O
group O
of O
the O
anion O
exchange O
resin O
is O
a O
quaternary O
ammonium O
group O
attached O
to O
an O
inert O
styrene-divinylbenzene O
copolymer O
. O

-DOCSTART- O


Used O
to O
numb B-PHE
the I-PHE
skin I-PHE
, O
or O
surfaces O
of O
the O
penis O
or O
vagina O
, O
in O
preparation O
for O
a O
medical O
procedure O
or O
to O
lessen O
the O
pain B-PHE
of O
inserting O
a O
medical O
instrument O
such O
as O
a O
tube O
or O
speculum O
. O

-DOCSTART- O


fever B-PHE
; O
feverishness B-PHE

-DOCSTART- O


Heat B-PHE
in O
the O
heart O
, O
insufficient O
yin O
in O
kidney B-PHE
, O
frightening B-PHE
and O
madness B-PHE
, O
frequent O
talk O
and O
smile O
, O
driness B-PHE
in O
the O
mouth O
, O
red B-PHE
tong I-PHE
, O
loss B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
yellow B-PHE
body I-PHE
due O
to O
blood B-PHE
deficiency I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
dry O
damp B-PHE
and O
kill O
worms B-PHE
. O

-DOCSTART- O


invigorate O
blood B-PHE
and O
unblock O
the O
network B-PHE
vessels B-PHE

-DOCSTART- O


cough B-PHE

-DOCSTART- O


Ureterostomy O
; O
Functional B-PHE
Disturbance I-PHE

-DOCSTART- O


anal B-PHE
fistula I-PHE
hemorrhoids I-PHE
complicated O
by O
anal B-PHE
fistula I-PHE
. O

-DOCSTART- O


Hypercholesterolemia B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
cancer B-PHE
patients O
with O
severe O
pain B-PHE
that O
breaks O
through O
their O
regular O
narcotic O
therapy O
. O

-DOCSTART- O


1 O
flaccidity B-PHE
of I-PHE
lower I-PHE
limbs I-PHE
2 O
leg O
Gi O
; O
beriberi B-PHE

-DOCSTART- O


Treatment O
of O
amenorrhea B-PHE
with O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE
, O
swelling B-PHE
of I-PHE
breast I-PHE
after O
childbirth O
, O
rubella B-PHE
red O
in O
colour O
, O
itching B-PHE
, O
acne B-PHE
. O

-DOCSTART- O


diarrhea B-PHE

-DOCSTART- O


irritability B-PHE
and O
restlessness B-PHE
; O

dysphoria B-PHE

-DOCSTART- O


Lupus B-PHE
Nephritis I-PHE

-DOCSTART- O


Second-degree B-PHE
Burn I-PHE

-DOCSTART- O


Heartburn B-PHE

-DOCSTART- O


In O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
NF-kB B-PHE
activation I-PHE
and O
apoptotic B-PHE
pathways I-PHE
. O

-DOCSTART- O


difficult B-PHE
delivery I-PHE
; O

dystocia B-PHE

-DOCSTART- O


nourish O
Eum(Yin O
) O
blood B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
diabetes B-PHE
mellitus I-PHE
( O
type O
2 O
) O
. O

-DOCSTART- O


( O
1 O
) O
cold-type B-PHE
hernia I-PHE
; O
periumbilical B-PHE
colic I-PHE
due O
to O
invasion B-PHE
of I-PHE
cold I-PHE
( O
2 O
) O
testalgia B-PHE
due O
to O
pathogenic B-PHE
cold I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Body B-PHE
fat I-PHE
deposition I-PHE
( O
total O
amount O

-DOCSTART- O


diabetics B-PHE
; O
emaciation-thirst B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
edema B-PHE
, O
toxin B-PHE
swelling B-PHE
of O
sores O
. O

-DOCSTART- O


Stage O
II O
Non-Contiguous O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Memory O

-DOCSTART- O


For O
prophylaxis O
of O
respiratory B-PHE
diseases I-PHE
casued O
by O
respiratory B-PHE
syncytial I-PHE
virus I-PHE
. O

-DOCSTART- O


wind-heat B-PHE
; O
wind B-PHE
and O
heat B-PHE
; O
wind-heat B-PHE
pathogene I-PHE
wind I-PHE
and O
heat B-PHE
blended O
as O
a O
pathogenic O
factor O
. O

-DOCSTART- O


a O
disease O
of O
periumbilical B-PHE
sharp I-PHE
pain I-PHE
and O
cold B-PHE
hand I-PHE
and I-PHE
foot I-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Maturation O

-DOCSTART- O


unconsciousness B-PHE

-DOCSTART- O


Conservative O
treatment O
of O
benign B-PHE
prostatic I-PHE
hypertrophy I-PHE
- O
clinical O
effects O
of O
increased O
administration O
of O
Hachimijiogan O
and O
the O
relation O
between O
these O
effects O
and O
the O
Sho O
of O
Chinese O
medicine O
. O

-DOCSTART- O


OBJECTIVE O
: O
The O
purpose O
of O
this O
clinical O
trial O
was O
to O
assess O
the O
efficacy O
of O
Goshuyuto O
, O
a O
typical O
Kampo O
formula O
, O
in O
preventing O
episodes O
of O
headache B-PHE
in O
chronic B-PHE
headache I-PHE
patients O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
Because O
the O
treatment O
target O
of O
a O
Kampo O
formula O
is O
decided O
on O
a O
basis O
different O
to O
that O
of O
Western O
medicine O
, O
we O
first O
selected O
patients O
belonging O
to O
a O
subgroup O
that O
responded O
to O
goshuyuto O
before O
conducting O
the O
usual O
randomized O
controlled O
trial O
. O

During O
stage O
1, O
the O
subjects O
were O
instructed O
to O
orally O
consume O
goshuyuto O
for O
4 O
weeks O
. O

Only O
those O
subjects O
judged O
as O
responders O
advanced O
to O
stage O
2, O
during O
which O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
conducted O
. O

The O
subjects O
consumed O
the O
same O
dose O
of O
goshuyuto O
or O
placebo O
for O
12 O
weeks O
. O

RESULTS O
: O
Of O
the O
91 O
subjects O
enrolled O
in O
stage O
1, O
60 O
were O
judged O
as O
responders O
. O

Of O
these O
, O
53 O
advanced O
to O
stage O
2; O
28 O
were O
assigned O
to O
the O
goshuyuto O
group O
and O
25 O
to O
the O
placebo O
group O
. O

The O
decrease O
in O
the O
number O
of O
days O
on O
which O
headache B-PHE
episodes O
occurred O
was O
greater O
in O
the O
goshuyuto O
group O
than O
in O
the O
placebo O
group O
( O
2.6 O
+/- O
3.7 O
vs O
. O
0.3 O
+/- O
4 O
days O
, O
p O
= O
0.034 O
) O
; O
no O
difference O
was O
observed O
with O
regard O
to O
the O
reduction O
in O
the O
frequency O
of O
consuming O
reliever O
medications O
( O
2.2 O
+/- O
4 O
vs O
. O
1.4 O
+/- O
8.2 O
, O
p O
= O
0.672 O
) O
. O

Improvement O
in O
the O
associated O
symptoms O
was O
observed O
in O
more O
than O
0.5 O
of O
the O
subjects O
in O
the O
goshuyuto O
group O
. O

CONCLUSION O
: O
Goshuyuto O
is O
useful O
in O
preventing O
episodes O
of O
headache B-PHE
in O
chronic B-PHE
headache I-PHE
patients O
. O

Responder-limited O
design O
is O
a O
candidate O
for O
evaluating O
Kampo O
medicine O
. O

-DOCSTART- O


Essential B-PHE
Hypertension I-PHE

-DOCSTART- O


DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Blood B-PHE
pressure I-PHE

-DOCSTART- O


In O
addition O
, O
dalbavancin O
alters O
bacterial O
- O
cell O
- O
membrane O
permeability O
and O
RNA B-PHE
synthesis I-PHE
. O

-DOCSTART- O


NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


For O
the O
symptomatic B-PHE
relief I-PHE
of O
pain B-PHE
, O
burning B-PHE
, O
urgency B-PHE
, O
frequency O
, O
and O
other O
discomforts B-PHE
arising O
from O
irritation B-PHE
of O
the O
lower B-PHE
urinary I-PHE
tract I-PHE
mucosa I-PHE
caused O
by O
infection B-PHE
, O
trauma B-PHE
, O
surgery O
, O
endoscopic O
procedures O
, O
or O
the O
passage O
of O
sounds O
or O
catheters O
. O

-DOCSTART- O


Lenalidomide O
inhibits O
TNF-alpha B-PHE
production I-PHE
, O
stimulates O
T B-PHE
cells I-PHE
, O
reduces O
serum O
levels O
of O
the O
cytokines O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
, O
and O
inhibits O
angiogenesis B-PHE
. O

Acetylsalicylic O
acid O
binds O
to O
and O
acetylates O
serine O
residues O
in O
cyclooxygenases O
, O
resulting O
in O
decreased O
synthesis B-PHE
of I-PHE
prostaglandin I-PHE
, O
platelet O
aggregation O
, O
and O
inflammation B-PHE
. O

Dexamethasone O
is O
a O
glucocorticoid O
agonist O
. O

In O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
NF-kB B-PHE
activation I-PHE
and O
apoptotic O
pathways O
. O

Bendamustine O
acts O
as O
an O
alkylating O
agent O
causing O
intra-strand O
and O
inter-strand O
cross-links O
between O
DNA O
bases O
. O

-DOCSTART- O


erysipelas B-PHE
acute I-PHE
infection I-PHE
of I-PHE
the I-PHE
skin I-PHE
characterized O
by O
sudden O
onset O
of O
local O
bright O
red O
coloration O
and O
swelling B-PHE
with O
rapid O
spreading O
. O

-DOCSTART- O


1 O
Analgeic O
. O
2 O
Sedative O
. O
3 O
Antispasmodic O

-DOCSTART- O


Gastroesophageal B-PHE
Reflux I-PHE
Disease I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O
, O
Reproductive B-PHE
systems I-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


Stage O
II O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


1 O
For O
cases O
of O
apoplexy B-PHE
with O
sudden O
onset O
of O
face B-PHE
distortion I-PHE
, O
dysphasia B-PHE
, O
numbness B-PHE
of I-PHE
the I-PHE
limbs I-PHE
, O
or O
even O
hemiplegia B-PHE
, O
rigidity B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
white B-PHE
and I-PHE
greasy I-PHE
fur I-PHE
on O
the O
tongue O
, O
floating O
and O
smooth O
pulse B-PHE
, O
which O
are O
attributive O
to O
attack O
of O
wind-phlegm B-PHE
to O
the O

-DOCSTART- O


distribution O
) O
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE

-DOCSTART- O


Sleep B-PHE
Disturbance I-PHE

-DOCSTART- O


furuncle B-PHE
and O
swelling B-PHE
of I-PHE
carbuncle I-PHE

-DOCSTART- O


dirty B-PHE
face I-PHE
; O

dirty B-PHE
complexion I-PHE
; O

grimy B-PHE
facial I-PHE
complexion I-PHE
a O
face O
appearing O
as O
if O
covered O
with O
dirt O
, O
as O
often O
seen O
in O
hepatic B-PHE
disease I-PHE
, O
disease O
due O
to O
damp-heat B-PHE
. O

-DOCSTART- O


Eye B-PHE
health I-PHE
, O
Eye B-PHE

-DOCSTART- O


For O
desolving O
stasis B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Genz-112638 O
, O
a O
novel O
ceramide O
analog O
given O
orally O
, O
is O
designed O
to O
inhibit O
the O
enzyme B-PHE
glucosylceramide I-PHE
synthase I-PHE
, O
which O
results O
in O
reduced O
production O
of O
glucocerebroside B-PHE
. O

This O
is O
the O
substance O
that O
builds O
up O
in O
the O
cells O
and O
tissues O
of O
people O
with O
Gaucher B-PHE
disease I-PHE
. O

In O
preclinical O
studies O
, O
the O
molecule O
has O
shown O
high O
potency O
and O
specificity O
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation O
of O
AMP-activated B-PHE
protein I-PHE
kinase I-PHE
( O
AMPK B-PHE
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin O
signaling O
, O
whole O
body B-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and O
fats B-PHE
. O

Sulfonylureas O
such O
as O
glyburide O
bind O
to O
ATP-sensitive B-PHE
potassium I-PHE
channels I-PHE
on O
the O
pancreatic O
cell O
surface O
, O
raising O
intracellular O
concentrations B-PHE
of I-PHE
calcium I-PHE
ions O
, O
which O
induces O
the O
secretion B-PHE
, O
or O
exocytosis B-PHE
, O
of O
insulin B-PHE
. O

-DOCSTART- O


( O
1 O
) O
tangling O
up O
of O
intestine O
; O
accumulation O
of O
pathogenic O
factor O
in O
viscera O
( O
2 O
) O
Accumulation O
of O
Eum O
Cold B-PHE
in O
Viscera O
one O
of O
the O
symptoms O
in O
Soeumin O
( O
marked O
by O
hard O
mass O
on O
the O
right O
side O
of O
the O
epigastrium O
. O
The O
prognosis O
is O
not O
hopeful O
. O

-DOCSTART- O


having O
a O
yellow B-PHE
or I-PHE
reddish I-PHE
urine I-PHE
due O
to O
blocking O
the O
circulation B-PHE
of I-PHE
bile I-PHE
by O
epidemic B-PHE
toxin I-PHE
, O
fail O
to O
control O
food O
, O
and O
damp-heat B-PHE
and O
cold-damp B-PHE
blocked O
in O
the O
middle O
heater O

-DOCSTART- O


Nervous B-PHE
System I-PHE
Diseases I-PHE
, O
Sympathetic O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cancer/tumors B-PHE
( O
unspecified O
) O
. O

-DOCSTART- O


To O
provide O
some O
insights O
how O
herbal O
medicines O
affect O
deoxyribonucleic B-PHE
acid I-PHE
( I-PHE
DNA I-PHE
) I-PHE
synthesis I-PHE
in O
the O
uterus O
, O
the O
DNA B-PHE
polymerase I-PHE
activities I-PHE
( O
alpha O
and O
beta O
) O
in O
uterine O
samples O
taken O
from O
rats O
were O
measured O
. O

DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
with O
respect O
to O
DNA O
content O
revealed O
alpha O
cyclic O
change O
with O
the O
highest O
level O
on O
proestrus O
, O
while O
DNA B-PHE
polymerase I-PHE
beta I-PHE
activity I-PHE
showed O
no O
significant O
changes O
during O
the O
estrous O
cycle O
. O

The O
increased O
period O
of O
the O
activity O
coincided O
with O
that O
of O
17 B-PHE
beta-estradiol I-PHE
( O
E2 B-PHE
) O
but O
not O
progesterone B-PHE
( O
P4 B-PHE
) O
in O
the O
blood O
. O

Injection O
of O
10 O
IU O
pregnant B-PHE
mare I-PHE
serum I-PHE
gonadotropin I-PHE
( O
PMS B-PHE
) O
on O
day O
27 O
of O
age O
gradually O
increased O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
, O
while O
concomitant O
treatment O
with O
PMS B-PHE
and O
200 O
micrograms O
Tokishakuyakusan O
( O
TS O
) O
, O
Keishibukuryogan O
( O
KB O
) O
or O
Unkeito O
( O
UT O
) O
suppressed O
the O
enzyme B-PHE
activity I-PHE
, O
with O
a O
most O
remarkable O
effect O
of O
KB O
. O

These O
results O
suggest O
that O
TS O
, O
KB O
or O
UT O
suppresses O
in O
vivo O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
induced O
by O
PMS B-PHE
in O
the O
rat O
uterus O
. O

-DOCSTART- O


Angina B-PHE
pectoris I-PHE
, O
cerebral B-PHE
atherosclerosis I-PHE
, O
diffusive O
intravascular B-PHE
clotting I-PHE
, O
thrombophlebitis B-PHE
, O
hepatitis B-PHE
, O
acute B-PHE
surgical I-PHE
infection I-PHE
, O
mastitis B-PHE
, O
erysipelas B-PHE
, O
otitis B-PHE
media I-PHE
, O
tonsillitis B-PHE
, O
bone B-PHE
marrow I-PHE
infection I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
dysmenorrhea O
, O
amenorrhea B-PHE
, O
postpartum B-PHE
stasis I-PHE
stagnation I-PHE
abdominal I-PHE
pain I-PHE
, O
pain B-PHE
in I-PHE
heart I-PHE
and I-PHE
abdomen I-PHE
, O
concretion B-PHE
conglomeration I-PHE
accumulation I-PHE
and O
gathering O
, O
heat B-PHE
impediment O
swelling B-PHE
and O
pain B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
heat B-PHE
entering O
construction-blood B-PHE
, O
vexation B-PHE
and O
agitation B-PHE
, O
insomnia B-PHE
and O
vexation B-PHE
, O
swelling B-PHE
toxin O
of O
welling O
abscess B-PHE
and O
sore B-PHE
, O
zoster B-PHE
, O
neurodermatitis B-PHE
, O
psoriasis B-PHE
. O

-DOCSTART- O


Treatment O
of O
cough B-PHE
with O
profuse O
expectoration B-PHE
, O
indigestion B-PHE
, O
stagnancy B-PHE
of I-PHE
food I-PHE
with O
abdominal O
pain B-PHE
, O
traumatic O
swelling B-PHE
and O
ecchymoses B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


stabilize O
pain B-PHE

-DOCSTART- O


Ipilimumab O
is O
a O
fully O
human O
IgG1 B-PHE
antibody I-PHE
that O
binds O
to O
CTLA-4 B-PHE
( O
cytotoxic B-PHE
T I-PHE
lymphocyte-associated I-PHE
antigen I-PHE
4 I-PHE
) O
, O
a O
molecule O
on O
T-cells O
that O
is O
indicated O
for O
unresectable B-PHE
or I-PHE
metastatic I-PHE
melanoma I-PHE
. O

The O
absence O
or O
presence O
of O
CTLA-4 O
can O
augment O
or O
suppress O
the O
immune B-PHE
system's I-PHE
T-cell O
response O
in O
fighting O
disease B-PHE
. O

Ipilimumab O
is O
designed O
to O
block O
the O
activity O
of O
CTLA-4 O
, O
thereby O
sustaining O
an O
active B-PHE
immune I-PHE
response I-PHE
in O
its O
attack O
on O
cancer B-PHE
cells I-PHE
. O

The O
proposed O
mechanism O
of O
action O
is O
indirect O
, O
and O
may O
be O
through O
T-cell O
- O
mediated O
anti-tumor B-PHE
immune I-PHE
responses I-PHE
. O

-DOCSTART- O


This O
is O
a O
syndrome O
that O
children O
wet O
their O
pants O
regardless O
of O
time O
. O

-DOCSTART- O


1 O
Applicable O
to O
cases O
of O
diarrhea B-PHE
in O
summer O
time O
, O
manifested O
as O
watery B-PHE
diarrhea I-PHE
, O
abdominal B-PHE
fullness I-PHE
, O
increased O
borborygmus B-PHE
, O
nausea B-PHE
, O
feeling O
of O
oppression O
over O
the O
chest O
, O
fatigue B-PHE
, O
white O
and O
smooth O
fur O
on O
the O
tongue O
, O
soft O
and O
floating O
, O
slow B-PHE
pulse I-PHE
, O
which O
are O
attribut O

-DOCSTART- O


For O
the O
treatment O
of O
moderate O
and O
severe O
hypertension B-PHE
, O
either O
alone O
or O
as O
an O
adjunct O
, O
and O
for O
the O
treatment O
of O
renal B-PHE
hypertension I-PHE
. O

-DOCSTART- O


wind B-PHE
invaded O
Chang O
organ O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
exhaustion I-PHE
syndrome I-PHE

-DOCSTART- O


Hydrochlorothiazide O
allows O
the O
blood B-PHE
vessels I-PHE
to O
relax O
and O
causes O
kidneys B-PHE
to O
remove O
more O
salt B-PHE
and I-PHE
water I-PHE
from I-PHE
the I-PHE
blood I-PHE
in O
order O
to O
reduce O
blood B-PHE
volume I-PHE
. O

Valsartan O
is O
in O
a O
group O
of O
drugs O
called O
angiotensin O
II O
receptor O
antagonists O
. O

Valsartan O
keeps O
blood B-PHE
vessels I-PHE
from O
narrowing O
, O
which O
lowers O
blood B-PHE
pressure I-PHE
and O
improves O
blood B-PHE
flow I-PHE
. O

-DOCSTART- O


Relief O
of O
mild O
to O
moderate O
pain B-PHE
of O
acte B-PHE
musculoskeletal I-PHE
disorders I-PHE
. O

-DOCSTART- O


nourish O
blood B-PHE

-DOCSTART- O


The O
exact O
mechanism O
of O
action O
of O
ingenol O
mebutate O
in O
actinic B-PHE
keratosis I-PHE
is O
unknown O
. O

It O
is O
presumed O
to O
involve O
primary O
necrosis B-PHE
then O
neutrophil-mediated B-PHE
inflammation I-PHE
and O
antibody-dependent B-PHE
cell I-PHE
death I-PHE
of O
residual O
disease B-PHE
cells I-PHE
. O

Additionally O
in O
early O
studies O
, O
PEP005 O
was O
shown O
to O
be O
an O
effective O
activator O
of O
PKC-delta O
and O
PKC-delta O
translocation O
into O
nucleus B-PHE
and O
membranes B-PHE
. O

PEP005 O
also O
downregulates O
the O
expression B-PHE
and I-PHE
activity I-PHE
of I-PHE
PKC-alpha I-PHE
. O

PEP005 O
induced O
modulation O
of O
PKCs O
leads O
to O
Ras B-PHE
/ O
Raf B-PHE
/ O
MAPK B-PHE
and O
p38 B-PHE
activation O
and O
AKT B-PHE
/ O
PKB B-PHE
inhibition O
. O

-DOCSTART- O


Treatment O
of O
measles B-PHE
without O
adequate O
eruption B-PHE
, O
urticaria B-PHE
with O
itching B-PHE
, O
edema B-PHE
with O
oliguria B-PHE
. O

-DOCSTART- O


Amenorrhea B-PHE
, O
menstrual B-PHE
disorders I-PHE
, O
difficult O
labour O
, O
retention B-PHE
of I-PHE
placenta I-PHE
, O
postpartum O
abdominal B-PHE
pain I-PHE
due O
to O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Organic O
iodine O
compounds O
attenuate O
x-rays O
as O
they O
pass O
through O
the O
body O
, O
thereby O
allowing O
the O
body O
structures O
containing O
iodine O
to O
be O
delineated O
in O
contrast O
to O
those O
structures O
that O
do O
not O
contain O
iodine O
. O

The O
degree O
of O
opacity O
produced O
by O
these O
compounds O
is O
directly O
proportional O
to O
the O
total O
amount O
( O
concentration O
and O
volume O
) O
of O
the O
iodinated O
contrast O
agent O
in O
the O
path O
of O
the O
x-rays O
. O

After O
intravascular O
administration O
, O
iodixanol O
makes O
opaque O
those O
internal O
structures O
in O
its O
path O
of O
flow O
, O
allowing O
their O
visualization O
until O
significant O
hemodilution B-PHE
and O
elimination O
occur O
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Others O

-DOCSTART- O


Muscle B-PHE
Spasticity I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
C I-PHE

-DOCSTART- O


clear O
the O
head B-PHE
and O
eyes B-PHE

-DOCSTART- O


Prevent O
pregnancy B-PHE

-DOCSTART- O


[ O
Treatment O
of O
breast B-PHE
proliferation I-PHE
disease I-PHE
with O
modified O
Xiao O
Yao O
San O
and O
er O
chen O
decoction O
] O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


regenerate O
blood B-PHE

-DOCSTART- O


We O
reported O
previously O
that O
cholesterol O
feeding O
induced O
an O
increase O
in O
hepatic B-PHE
secretion I-PHE
of O
VLDL B-PHE
and O
a O
decrease O
in O
that O
of O
LDL B-PHE
, O
especially O
LDL-apo B-PHE
B100 I-PHE
, O
using O
monkey O
liver O
perfusion O
. O

In O
the O
present O
study O
we O
conducted O
rat O
liver O
perfusion O
using O
the O
HMG O
Co O
A O
reductase O
inhibitor O
( O
CS-514 O
) O
and O
Kampo O
medicine O
( O
Daisaikoto O
) O
to O
elucidate O
the O
mechanism O
of O
the O
effect O
of O
dietary O
cholesterol O
on O
hepatic B-PHE
lipoprotein I-PHE
and O
apolipoprotein B-PHE
synthesis I-PHE
. O

Although O
the O
secretion B-PHE
of I-PHE
VLDL I-PHE
was O
increased O
by O
cholesterol O
feeding O
, O
that O
of O
LDL B-PHE
and O
especially O
of O
apo B-PHE
B100 I-PHE
of I-PHE
LDL I-PHE
were O
markedly O
decreased O
, O
and O
apo B-PHE
E I-PHE
of I-PHE
the I-PHE
LDL I-PHE
was O
increased O
as O
observed O
in O
the O
monkey O
liver O
perfusion O
experiments O
. O

The O
effect O
of O
CS-514 O
was O
clearly O
different O
from O
the O
effect O
of O
dietary B-PHE
cholesterol I-PHE
in O
spite O
of O
the O
suppression O
of O
hepatic O
cholesterogenesis O
which O
was O
comparable O
to O
that O
induced O
by O
cholesterol O
feeding O
, O
suggesting O
that O
the O
decrease O
in O
secretion B-PHE
of I-PHE
LDL-apo I-PHE
B100 I-PHE
induced O
by O
the O
dietary O
cholesterol O
is O
not O
due O
to O
suppressed O
cholesterogenesis O
. O

Daisaikoto O
, O
which O
was O
added O
to O
the O
diet O
together O
with O
cholesterol B-PHE
, O
diminished O
the O
effects O
of O
dietary B-PHE
cholesterol I-PHE
on O
the O
plasma B-PHE
and I-PHE
hepatic I-PHE
cholesterol I-PHE
levels I-PHE
. O

When O
the O
liver O
treated O
with O
Daisaikoto O
was O
perfused O
, O
the O
effect O
of O
dietary B-PHE
cholesterol I-PHE
on O
the O
production O
of O
lipoprotein B-PHE
and O
apolipoprotein B-PHE
was O
markedly O
diminished O
. O

This O
evidence O
indicates O
that O
the O
decrease O
in O
LDL-apo B-PHE
B100 I-PHE
and O
the O
increase O
in O
apo B-PHE
E I-PHE
were O
mediated O
by O
the O
hepatic B-PHE
cholesterol I-PHE
level I-PHE
. O

-DOCSTART- O


dispel O
wind-damp B-PHE

-DOCSTART- O


Diabetes B-PHE

-DOCSTART- O


a O
lumbago B-PHE
pain I-PHE
. O

Occur O
by O
invasion B-PHE
of I-PHE
wind-heat I-PHE
in O
kidney O
meridian O
. O

-DOCSTART- O


Methotrexate B-PHE
anti-tumor I-PHE
activity I-PHE
is O
a O
result O
of O
the O
inhibition O
of O
folic B-PHE
acid I-PHE
reductase I-PHE
, O
leading O
to O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
and O
inhibition O
of O
cellular B-PHE
replication I-PHE
. O

Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes B-PHE
in I-PHE
gene I-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased O
cell B-PHE
proliferation I-PHE
, O
and O
inhibition O
of O
tumorigenesis B-PHE
. O

Mercaptopurine O
inhibits O
nucleotide B-PHE
interconversions I-PHE
and O
de O
novo O
purine B-PHE
synthesis I-PHE
, O
thereby O
blocking O
the O
formation B-PHE
of I-PHE
purine I-PHE
nucleotides I-PHE
and O
inhibiting O
DNA B-PHE
synthesis I-PHE
. O

Idarubicin O
intercalates O
into O
DNA B-PHE
and O
interferes O
with O
the O
activity B-PHE
of I-PHE
topoisomerase I-PHE
II I-PHE
, O
thereby O
inhibiting O
DNA B-PHE
replication I-PHE
, O
RNA B-PHE
transcription I-PHE
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent O
RNA B-PHE
polymerase I-PHE
, O
leading O
to O
a O
suppression O
of O
RNA B-PHE
synthesis I-PHE
and O
cell O
death O
. O

-DOCSTART- O


profuse B-PHE
nasal I-PHE
bleeding I-PHE
; O
brandy B-PHE
nose I-PHE
; O
rosacea B-PHE

-DOCSTART- O


Gumiganghwaltang O
( O
GMGHT O
) O
is O
an O
Oriental O
herbal O
prescription O
, O
which O
has O
been O
commonly O
used O
to O
treat O
a O
cold B-PHE
and O
inflammatory B-PHE
diseases I-PHE
in O
Korea O
. O

However O
, O
the O
mechanism O
of O
GMGHT O
is O
not O
clear O
. O

In O
this O
study O
, O
we O
investigated O
the O
anti-inflammatory B-PHE
mechanism I-PHE
of O
GMGHT O
in O
mouse O
peritoneal O
macrophages O
. O

GMGHT O
exerted O
an O
anti-inflammatory B-PHE
action I-PHE
through O
inhibiting O
lipopolysaccaride O
( O
LPS)-induced O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
and O
interleukin O
( O
IL)-6 O
production O
in O
mouse O
peritoneal O
macrophages O
. O

The O
maximal O
inhibition O
rate O
of O
TNF-alpha O
, O
and O
IL-6 O
production O
by O
GMGHT O
(1 O
mg/ml O
) O
was O
52.31+/-2.8% O
and O
56.31+/-3.1% O
, O
respectively O
. O

In O
the O
inflammatory B-PHE
process I-PHE
, O
cyclooxygenase B-PHE
2 I-PHE
( O
COX-2 B-PHE
) O
and O
inducible O
nitric B-PHE
oxide I-PHE
synthase I-PHE
( O
iNOS B-PHE
) O
increased O
in O
peritoneal O
macrophages O
. O

GMGHT O
decreased O
the O
protein O
level O
of O
COX-2 B-PHE
and O
iNOS B-PHE
in O
LPS-stimulated O
mouse O
peritoneal O
macrophages O
. O

In O
addition O
, O
GMGHT O
inhibited O
nuclear B-PHE
factor-kappaB I-PHE
activation I-PHE
and O
IkappaB-alpha B-PHE
degradation I-PHE
. O

Our O
study O
suggests O
that O
an O
important O
molecular O
mechanism O
by O
GMKHT O
reduce O
inflammation B-PHE
, O
which O
might O
explain O
its O
beneficial O
effect O
in O
the O
regulation O
of O
inflammatory B-PHE
reactions I-PHE
. O

-DOCSTART- O


Ulcer B-PHE

-DOCSTART- O


These O
cross-links O
result O
in O
apoptosis B-PHE
and O
cell B-PHE
growth I-PHE
inhibition I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


Lymphoma B-PHE

-DOCSTART- O


loosen O
the O
chest B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
felling B-PHE
of I-PHE
cold I-PHE
and O
a O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE
. O

-DOCSTART- O


astringe O
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
benefit O
vital O
energy O
, O
lift O
yang O
and O
activate O
vital O
energy O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Mood O
, O
Quality O
of O
life O
, O
Endocrine B-PHE
system I-PHE
, O
activation O
, O
attention O
, O
sleep B-PHE
, O
Arousal B-PHE
, O
vigilance B-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Lipid O
profile O
, O
motility B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


To O
replenish O
the O
kidney B-PHE
and O
subdue O
hyperactivity O
of O
the O
liver B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
pain B-PHE
in O
stomach O
duct O
, O
wound O
swelling B-PHE
from O
knocks B-PHE
and O
falls B-PHE
, O
fracture B-PHE
, O
bleeding B-PHE
due O
to O
external O
injury B-PHE
. O

-DOCSTART- O


Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
ulcers B-PHE
in O
the O
mouth O
. O

-DOCSTART- O


painful O
urinary B-PHE
dysfunction I-PHE
; O
stranguria B-PHE
a O
syndrome O
characterized O
by O
frequent O
, O
painful B-PHE
and I-PHE
dripping I-PHE
urination I-PHE
. O

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
. O

-DOCSTART- O


Acetaminophen O
acts O
primarily O
in O
the O
CNS B-PHE
, O
by O
increasing O
the O
pain B-PHE
threshold I-PHE
by O
inhibiting O
both O
isoforms B-PHE
of I-PHE
cyclooxygenase I-PHE
, O
COX-1 B-PHE
, O
COX-2 B-PHE
, O
and O
COX-3 B-PHE
enzymes O
involved O
in O
prostaglandin B-PHE
( I-PHE
PG I-PHE
) I-PHE
synthesis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Strength O
and O
power O
, O
Others O
, O
Quality O
of O
life O
, O
Protective O
immunity B-PHE
, O
Body B-PHE
fat I-PHE
deposition I-PHE
( O
total O
amount O

-DOCSTART- O


Liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
determination O
of O
arsenic O
species O
in O
dog O
plasma O
and O
its O
application O
to O
a O
pharmacokinetic O
study O
after O
oral O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
. O

-DOCSTART- O


Human B-PHE
Immunodeficiency I-PHE
Virus I-PHE
Infection I-PHE

-DOCSTART- O


Spasticity B-PHE

-DOCSTART- O


Digestant O
. O

-DOCSTART- O


To O
purge O
pathogenic B-PHE
fire I-PHE
and O
lessen O
virulence O
of O
any O
pathogenic O
organism O
. O

-DOCSTART- O


delirium B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
dampness B-PHE
, O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
: O
For O
jaundice B-PHE
of O
dampness-heat B-PHE
type O
and O
abdominal B-PHE
mass I-PHE
. O

Recently O
used O
for O
acute B-PHE
and I-PHE
chronic I-PHE
hepatitis I-PHE
, O
cirrhosis B-PHE
, O
cholecysitis B-PHE
, O
etc O
. O
, O
also O
for O
diarrhea B-PHE
, O
desentery B-PHE
and O
leucorrhagia B-PHE
of O
dampness-heat B-PHE
type O
, O
ough O
of O
lung-heat B-PHE
type O
, O
sorethroat B-PHE
, O
silicosis B-PHE
, O
and O
tumors B-PHE
such O
as O
lung B-PHE
cancer I-PHE
, O
nasopharyngeal B-PHE
carcinoma I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
, O
tumor B-PHE
of O
the O
digestive O
tract O
, O
etc O
. O
2 O
To O
stop O
bleeding B-PHE
. O

For O
hematemesis B-PHE
, O
hemafecia B-PHE
, O
hemoptysis B-PHE
and O
epistaxis B-PHE
. O

External O
use O
for O
bleeding B-PHE
after O
trauma B-PHE
and O
after O
separation O
of O
umbilical O
cord O
in O
infants O
. O

-DOCSTART- O


polydipsia B-PHE
due O
to O
high B-PHE
fever I-PHE

-DOCSTART- O


To O
nourish O
vital O
energy O
, O
strengthen O
spleen B-PHE
, O
invigorate O
the O
heart B-PHE
and O
nourish O
blood B-PHE
. O

-DOCSTART- O


To O
induce O
diaphoresis B-PHE
, O
to O
ease O
the O
mind B-PHE
, O
and O
to O
relieve O
fever B-PHE
. O

-DOCSTART- O


The O
coldness B-PHE
of O
hands O
and O
feet O

-DOCSTART- O


Thioridazine O
blocks O
postsynaptic O
mesolimbic O
dopaminergic O
D1 O
and O
D2 O
receptors O
in O
the O
brain B-PHE
; O
blocks O
alpha-adrenergic O
effect O
, O
depresses O
the O
release O
of O
hypothalamic O
and O
hypophyseal O
hormones O
and O
is O
believed O
to O
depress O
the O
reticular B-PHE
activating I-PHE
system I-PHE
thus O
affecting O
basal O
metabolism B-PHE
, O
body B-PHE
temperature I-PHE
, O
wakefulness B-PHE
, O
vasomotor B-PHE
tone I-PHE
, O
and O
emesis B-PHE
. O

-DOCSTART- O


Used O
for O
the O
treatment O
of O
individual O
patients O
with O
certain O
filarial B-PHE
diseases I-PHE
including O
tropical B-PHE
pulmonary I-PHE
eosinophilia I-PHE
, O
loiasis B-PHE
, O
and O
lymphatic B-PHE
filariasis I-PHE
caused O
by O
infection O
with O
Wuchereria B-PHE
bancrofti I-PHE
, O
Brugia B-PHE
malayi I-PHE
, O
or O
Brugia B-PHE
timori I-PHE
. O

-DOCSTART- O


arrest O
vomiting B-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Strength O
and O
power O
, O
Others O
, O
Protective O
immunity B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Metabolism B-PHE
, O
Man O

-DOCSTART- O


Hyperkalemia B-PHE

-DOCSTART- O


diarrhea B-PHE

dysentery B-PHE

-DOCSTART- O


1 O
Its O
decoction O
can O
lower O
blood B-PHE
pressure I-PHE

2 O
. O
Inhibiting O
the O
growth B-PHE
of I-PHE
(a)-streptococcus I-PHE

3 O
. O
Shortening O
the O
bleeding B-PHE
time O
. O

4 O
. O
Anti-inflammatory B-PHE

5 O
. O
Diuretic O
. O

-DOCSTART- O


To O
nourish O
yin O
; O
To O
relieve O
fire O
; O
To O
smooth O
heart B-PHE
and O
kidney B-PHE

-DOCSTART- O


To O
lessen O
contracture B-PHE
, O
regulate O
stomach B-PHE
function I-PHE
, O
and O
dispel O
contracture B-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Hypersensitivity B-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Kidney O
Transplantation O

-DOCSTART- O


Linezolid O
selectively O
inhibits O
bacterial B-PHE
protein I-PHE
synthesis I-PHE
through O
binding O
to O
sites O
on O
the O
bacterial O
ribosome O
and O
prevents O
the O
formation B-PHE
of I-PHE
a I-PHE
functional I-PHE
70S-initiation I-PHE
complex I-PHE
. O

Isoniazid O
appears O
to O
block O
the O
synthesis B-PHE
of I-PHE
mycolic I-PHE
acids I-PHE
, O
major O
components O
of O
the O
mycobacterial O
cell O
wall O
. O

This O
agent O
is O
only O
active O
against O
actively O
growing O
mycobacteria B-PHE
because O
, O
as O
a O
pro-drug O
, O
it O
requires O
activation O
in O
susceptible O
mycobacterial O
species O
. O

Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent B-PHE
RNA I-PHE
polymerase I-PHE
, O
leading O
to O
a O
suppression B-PHE
of I-PHE
RNA I-PHE
synthesis I-PHE
and O
cell B-PHE
death I-PHE
. O

-DOCSTART- O


For O
tonifying O
weakness B-PHE
. O

-DOCSTART- O


To O
break O
qi O
and O
move O
phlegm B-PHE
, O
harmonize O
stomach B-PHE
and O
disperse O
accumulation B-PHE
. O

-DOCSTART- O


vomiting B-PHE
due O
to O
dysphagia B-PHE

-DOCSTART- O


Sarcoma B-PHE

-DOCSTART- O


morbid B-PHE
leukorrhea I-PHE
; O

gynecological B-PHE
diseases I-PHE
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O


Sermorelin O
binds O
to O
the O
growth O
hormone O
releasing O
hormone O
receptor O
and O
mimics O
native O
GRF O
in O
its O
ability O
to O
stimulate O
growth B-PHE
hormone I-PHE
secretion I-PHE
. O

-DOCSTART- O


1 O
Broad-spectrum O
antibacteric O
. O
Its O
antibacterial O
components O
are O
para-hydroxyphenylacetic O
acid O
, O
salicylic O
acid O
, O
vanillic O
acid O
, O
pyromucic O
acid O
and O
hydroquinone O
. O

2 O
. O
Its O
1/1800-1/1600 O
decoction O
inhibits O
the O
growth B-PHE
of I-PHE
leptospira I-PHE
. O

3 O
. O
Anti-trichomonas B-PHE
vaginalis I-PHE
in O
vitro O
. O

4 O
. O
Its O
component O
, O
senecionine O
, O
is O
anticarcinogenic O
on O
Walker O
sarcoma256 O
. O

-DOCSTART- O


heavy B-PHE
sensation I-PHE
of O
the O
body O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
HIV B-PHE
infection I-PHE
. O

-DOCSTART- O


dysenteric B-PHE
disorder I-PHE
; O
dysentery B-PHE

-DOCSTART- O


Propranolol O
competes O
with O
sympathomimetic B-PHE
neurotransmitters I-PHE
such O
as O
catecholamines O
for O
binding O
at O
beta(1)-adrenergic O
receptors O
in O
the O
heart O
, O
inhibiting O
sympathetic O
stimulation O
. O

Hydrochlorothiazide O
, O
a O
thiazide O
diuretic O
, O
inhibits O
water B-PHE
reabsorption I-PHE
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-PHE
symporter I-PHE
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
0.05 O
of O
total O
sodium B-PHE
reabsorption I-PHE
. O

-DOCSTART- O


Adult B-PHE
Erythroleukemia I-PHE

-DOCSTART- O


Ocular B-PHE
Hypertension I-PHE

-DOCSTART- O


Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-PHE
of I-PHE
serotonin I-PHE
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-PHE
of I-PHE
serotonin I-PHE
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism O
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O


To O
remove O
blood B-PHE
stasis I-PHE
, O
promote O
the O
subsidence O
of O
swelling B-PHE
, O
relieve O
pain B-PHE
and O
arrest O
bleeding B-PHE
. O

-DOCSTART- O


Treatment O
of O
anorexia B-PHE
, O
lassitude B-PHE
and O
loose B-PHE
stools I-PHE
in O
deficiency B-PHE
syndrome I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
hysteria O
in O
women O
. O

-DOCSTART- O


Metastatic B-PHE
Cancer I-PHE

-DOCSTART- O


Bone O
metabolism/density B-PHE
, O
Intelligence O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Overall O
CVD B-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


1 O
Inhibiting O
experimental O
arthritis B-PHE
in O
mice O
and O
decreasing O
capillary B-PHE
permeability I-PHE
. O

2 O
. O
Anti-allergric B-PHE
. O

3 O
. O
Inducing O
transient O
hypotensive B-PHE
effect I-PHE
. O

-DOCSTART- O


Type B-PHE
2 I-PHE
Diabetes I-PHE
Mellitus I-PHE

-DOCSTART- O


expel O
worm B-PHE

-DOCSTART- O


An O
inhibition O
of O
DNA B-PHE
polymerase I-PHE
. O

-DOCSTART- O


For O
the O
treatment O
of O
documented O
ventricular B-PHE
arrhythmias I-PHE
, O
such O
as O
sustained O
ventricular B-PHE
tachycardia I-PHE
, O
that O
, O
in O
the O
judgment O
of O
the O
physician O
, O
are O
life-threatening O
. O

-DOCSTART- O


bleeding B-PHE
in O
the O
hemorrhoids O

-DOCSTART- O


Familial B-PHE
Adenomatous I-PHE
Polyposis I-PHE

-DOCSTART- O


furuncle B-PHE
; O
boil B-PHE

-DOCSTART- O


disperse O
goiter B-PHE
core O

-DOCSTART- O


Kworeum O
headache B-PHE
caused O
by O
disorders O
of O
Kworeum O
channel O
and O
aching B-PHE
along O
the O
Kworeum O
channel O
over O
the O
head O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
Overall O
CVD B-PHE
, O
Others O

-DOCSTART- O


Promoting O
phagocytosis B-PHE
of I-PHE
macrophage I-PHE
. O

-DOCSTART- O


fullness B-PHE
of O
chest O
and O
abdomen O
. O

Indigestion B-PHE
caused O
by O
that O
cold O
pathogen B-PHE
of O
the O
middle-Cho O
disturb O
function O
of O
stomach B-PHE
and O
spleen B-PHE
. O
Feel O
tiring B-PHE
and O
heavy O
, O
pain B-PHE
in O
joint O
due O
to O
damp O
pathogen B-PHE

-DOCSTART- O


Croup B-PHE

-DOCSTART- O


Interferon O
alpha O
binds O
to O
type O
I O
interferon O
receptors O
which O
activate O
two O
Jak1 O
and O
Tyk2 O
and O
activate O
multiple O
dowmstream O
immunomodulatory B-PHE
and O
antiviral O
proteins O
. O

Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine B-PHE
monophosphate I-PHE
dehydrogenase I-PHE
, O
viral B-PHE
RNA I-PHE
polymerase I-PHE
and O
mRNA B-PHE
guanylyltransferase I-PHE
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Telaprevir O
is O
an O
inhibitor O
of O
the O
HCV B-PHE
NS3/4A I-PHE
serine I-PHE
protease I-PHE
, O
necessary O
for O
the O
proteolytic O
cleavage O
of O
the O
HCV O
encoded O
polyprotein O
into O
mature O
forms O
of O
the O
NS4A O
, O
NS4B O
, O
NS5A O
and O
NS5B O
proteins O
and O
essential O
for O
viral O
replication O
. O

-DOCSTART- O


a O
disease O
with O
dry B-PHE
cough I-PHE
with O
little O
amount O
of O
phlegm B-PHE

-DOCSTART- O


Tsumura O
Hachimijiogan O
, O
7.5 O
g O
a O
day O
, O
was O
administered O
to O
30 O
patients O
with O
benign B-PHE
prostatic I-PHE
hypertrophy I-PHE
( O
BPH B-PHE
) O
. O

Clinical O
effects O
were O
estimated O
based O
on O
subjective O
symptoms O
and O
objective O
findings O
obtained O
by O
uroflowmetry O
. O

Twenty O
patients O
( O
0.667 O
) O
showed O
improvement O
of O
subjective O
symptoms O
and O
14 O
patients O
( O
0.467 O
) O
showed O
good O
response O
in O
uroflowmetry O
. O

An O
improvement O
of O
overall O
clinical O
efficacy O
was O
observed O
in O
21 O
patients O
( O
0.7 O
) O
. O

These O
results O
were O
better O
than O
those O
obtained O
with O
5 O
g O
a O
day O
doses O
of O
Tsumura O
Hachimijiogan O
. O

No O
significant O
relation O
between O
the O
Sho O
in O
Chinese O
medicine O
and O
the O
clinical O
effects O
of O
Hachimijiogan O
was O
detected O
. O

No O
side O
effects O
or O
abnormal O
laboratory O
data O
were O
found O
in O
any O
of O
these O
30 O
patients O
. O

-DOCSTART- O


Dental B-PHE
Plaque I-PHE

-DOCSTART- O


Phlegm B-PHE
stagnation I-PHE
in O
chest O
and O
diaphragm O
, O
glomus B-PHE
in I-PHE
chest I-PHE
, O
distention B-PHE
in I-PHE
rib-side I-PHE
, O
food B-PHE
accumulation I-PHE
, O
retching B-PHE
counterflow I-PHE
. O

-DOCSTART- O


Its O
decoction O
in O
1:3000-1:200 O
concentration B-PHE
inhibits O
the O
growth O
of O
influenzae B-PHE
virus I-PHE
and O
Bacillus B-PHE
dysenteriae I-PHE
in O
vitr O
. O

Promoting O
the O
secretion O
of O
gastric B-PHE
juice I-PHE
and O
enhancing O
the O
digestive B-PHE
function I-PHE
, O
also O
as O
an O
astringent B-PHE
. O

-DOCSTART- O


Hyperlipidemia B-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE

-DOCSTART- O


all O
kinds O
of O
pain B-PHE
due O
to O
disorder O
of O
Gi O

-DOCSTART- O


major O
cold B-PHE
and O
heat B-PHE

-DOCSTART- O


pain B-PHE
in O
throat O
and O
hypochondrium O

-DOCSTART- O


promote O
the O
small B-PHE
intestine I-PHE

-DOCSTART- O


edema B-PHE
edema B-PHE
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, I-PHE
spleen I-PHE
and I-PHE
kidney I-PHE
. O

-DOCSTART- O


Postpartum B-PHE
Depressive I-PHE
Mood I-PHE

-DOCSTART- O


muscular B-PHE
twitching I-PHE
and O
cramp B-PHE
; O

twitching B-PHE
of I-PHE
muscles I-PHE

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
psoriasis B-PHE
and O
psoriatic B-PHE
disorders I-PHE
. O

-DOCSTART- O


HIV B-PHE
Infections I-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Infection I-PHE

-DOCSTART- O


Cough B-PHE
in O
phthisis B-PHE
, O
dyspnea B-PHE
in O
the O
aged O
, O
depressed B-PHE
sensation I-PHE
and O
stuffiness B-PHE
in O
the O
chest O
. O

-DOCSTART- O


bald B-PHE
white I-PHE
scalp I-PHE
sore I-PHE
; O
tinea B-PHE
alba I-PHE
; O
white B-PHE
ringworm I-PHE

-DOCSTART- O


Since O
it O
is O
not O
degraded O
in O
the O
neuromuscular O
junction O
, O
the O
depolarized O
membrance O
remains O
depolarized O
and O
unresponsive O
to O
any O
other O
impulse O
, O
causing O
muscle B-PHE
paralysis I-PHE
. O

-DOCSTART- O


frequent B-PHE
urination I-PHE

-DOCSTART- O


Trachoma B-PHE

-DOCSTART- O


Ticarcillin's O
antibiotic O
properties O
arise O
from O
its O
ability O
to O
prevent O
cross-linking O
of O
peptidoglycan O
during O
cell B-PHE
wall I-PHE
synthesis I-PHE
when O
the O
bacteria O
tries O
to O
divide O
, O
causing O
death B-PHE
. O

-DOCSTART- O


The O
symptom O
of O
disease O
where O
the O
skin B-PHE
turns I-PHE
yellow I-PHE
because O
dampness O
and O
heat O
tangle O
together O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Mood O
, O
Quality O
of O
life O
, O
Inflammation B-PHE
, O
Other B-PHE
system I-PHE
health I-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


disease O
due O
to O
wind-dampness B-PHE
; O
rheumatism B-PHE

-DOCSTART- O


This O
is O
kinds O
of O
consciousness B-PHE
disorder I-PHE
with O
a O
light O
stupor B-PHE
. O

It O
is O
sleeping O
at O
nights O
and O
days O
, O
and O
responding O
with O
opening O
an O
eye O
. O

It O
is O
cause O
by O
palsy B-PHE
. O

-DOCSTART- O


Prostate B-PHE
Cancer I-PHE

-DOCSTART- O


Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
has O
been O
used O
to O
cure O
neuropsychological B-PHE
disorders I-PHE
. O

In O
the O
present O
study O
, O
the O
effect O
of O
Yokukansan O
on O
social B-PHE
isolation I-PHE
- I-PHE
induced I-PHE
aggressive I-PHE
behavior I-PHE
was O
examined O
in O
zinc-deficient O
mice O
, O
which O
were O
fed O
a O
zinc-deficient O
diet O
and O
a O
drinking O
water O
containing O
Yokukansan O
for O
2 O
weeks O
. O

In O
the O
resident-intruder O
test O
, O
the O
rate O
of O
mice O
that O
exhibited O
aggressive B-PHE
behavior I-PHE
in O
zinc-deficient O
mice O
, O
which O
was O
significantly O
higher O
than O
that O
in O
the O
control O
mice O
, O
was O
significantly O
decreased O
by O
administration O
of O
Yokukansan O
. O

The O
basal O
level O
of O
serum B-PHE
glucocorticoid I-PHE
, O
which O
was O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
was O
lowered O
by O
administration O
of O
Yokukansan O
. O

On O
the O
other O
hand O
, O
serum B-PHE
glucocorticoid I-PHE
levels I-PHE
after O
the O
resident-intruder O
test O
were O
almost O
the O
same O
between O
the O
control O
and O
zinc-deficient O
mice O
. O

However O
, O
administration O
of O
Yokukansan O
to O
zinc-deficient O
mice O
significantly O
increased O
serum B-PHE
glucocorticoid I-PHE
level I-PHE
after O
the O
resident-intruder O
test O
and O
the O
significant O
difference O
in O
the O
rate O
of O
serum B-PHE
corticosterone I-PHE
level I-PHE
after O
the O
test O
to O
the O
basal O
level O
between O
the O
control O
and O
zinc-deficient O
mice O
was O
abolished O
. O

Dietary O
zinc O
deficiency O
increases O
the O
basal O
levels B-PHE
of I-PHE
serum I-PHE
glucocorticoid I-PHE
, O
while O
may O
insufficiently O
increase O
serum B-PHE
glucocorticoid I-PHE
levels I-PHE
in O
the O
resident-intruder O
test O
. O

The O
concentrations O
of O
glutamate B-PHE
and O
GABA B-PHE
( O
y-aminobutyric B-PHE
acid I-PHE
) O
in O
the O
brain O
were O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
while O
Yokukansan O
ameliorated O
the O
significant O
increases O
. O

These O
results O
indicate O
that O
Yokukansan O
ameliorates O
social B-PHE
isolation-induced I-PHE
aggressive I-PHE
behavior I-PHE
of O
zinc-deficient O
mice O
, O
probably O
via O
amelioration O
of O
abnormal B-PHE
glucocorticoid I-PHE
secretion I-PHE
. O

The O
ameliorative O
effect O
seems O
to O
be O
linked O
to O
the O
modification O
of O
glutamatergic B-PHE
neuron I-PHE
activity I-PHE
after O
administration O
of O
Yokukansan O
. O

-DOCSTART- O


dissipate O
stasis B-PHE

-DOCSTART- O


Nephrotic B-PHE
Syndrome I-PHE

-DOCSTART- O


retention B-PHE
or I-PHE
stagnancy I-PHE
of I-PHE
undigested I-PHE
food I-PHE

-DOCSTART- O


Eldery O
, O
Others O

-DOCSTART- O


Chronic B-PHE
ulcers I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
for O
external O
use O
. O

-DOCSTART- O


Clarithromycin O
is O
first O
metabolized O
to O
14-OH O
clarithromycin O
, O
which O
is O
active O
and O
works O
synergistically O
with O
its O
parent O
compound O
. O

-DOCSTART- O


The O
target O
of O
LX6171 O
is O
a O
membrane B-PHE
protein I-PHE
that O
is O
expressed O
exclusively O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

Its O
activity O
is O
associated O
with O
synaptic B-PHE
vesicles I-PHE
and O
presynaptic B-PHE
membranes I-PHE
. O

-DOCSTART- O


To O
relieve O
exterior B-PHE
syndrome I-PHE
. O

-DOCSTART- O


invigorate O
blood B-PHE
and O
regulate O
menstruation B-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Mood O

-DOCSTART- O


Imipenem O
acts O
as O
an O
antimicrobial O
through O
the O
inhibition O
of O
cell B-PHE
wall I-PHE
synthesis I-PHE
which O
leads O
to O
rapid O
cell B-PHE
lysis I-PHE
and O
death O
without O
filament B-PHE
formation I-PHE
. O

Cilastatin O
helps O
imipenem O
work O
more O
effectively O
by O
preventing O
the O
breakdown O
of O
the O
antibiotic O
in O
the O
kidneys O
. O

-DOCSTART- O


aversion B-PHE
to I-PHE
heat I-PHE
during O
fever B-PHE

-DOCSTART- O


resolve O
phlegm B-PHE
and O
relieve O
cough B-PHE

-DOCSTART- O


Delta1-dihydrotestosterone O
binds O
to O
the O
androgen O
receptor O
, O
a O
nuclear O
receptor O
which O
binds O
the O
androgenic B-PHE
hormones I-PHE
testosterone I-PHE
and O
dihydrotestosterone B-PHE
. O

-DOCSTART- O


Used O
as O
an O
analgesic O
adjunct O
in O
anesthesia O
and O
as O
a O
primary O
anesthetic O
drug O
in O
procedures O
requiring O
assisted O
ventilation O
and O
in O
the O
relief O
of O
pain B-PHE
. O

-DOCSTART- O


diabetics B-PHE
due O
to O
interior O
heat B-PHE

-DOCSTART- O


Pain B-PHE
in O
joints O
due O
to O
rheumatalgia B-PHE
, O
aching B-PHE
in O
lumbus O
and O
legs O
, O
kidney B-PHE
vacuity I-PHE
and O
edema B-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
knocks O
and O
falls O
, O
fracture O
, O
pain O
in O
stomach O
duct O
, O
blood B-PHE
ejection I-PHE
, O
spontaneous O
external B-PHE
bleeding I-PHE
, O
malaria B-PHE
, O
lacquer O
sore B-PHE
, O
medullitis B-PHE
, O
deep O
pus B-PHE
ulcer I-PHE
. O

-DOCSTART- O


Used O
to O
prolong O
the O
time O
to O
recurrence O
of O
paroxysmal B-PHE
atrial I-PHE
fibrillation/flutter I-PHE
( O
PAF B-PHE
) O
associated O
with O
disabling O
symptoms O
in O
patients O
without O
structural B-PHE
heart I-PHE
disease I-PHE
. O

Also O
used O
for O
the O
treatment O
of O
life-threatening O
documented O
ventricular B-PHE
arrhythmias I-PHE
, O
such O
as O
sustained B-PHE
ventricular I-PHE
tachycardia I-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
to O
remove O
damp B-PHE
, O
to O
clear O
the O
stuffed B-PHE
nose I-PHE
, O
to O
relieve O
pain B-PHE
, O
and O
to O
promote O
the O
subsidence O
of O
swelling B-PHE
and O
drainage O
of O
pus B-PHE
. O

-DOCSTART- O


To O
dissipate O
wind-cold B-PHE
, O
quicken O
network O
vessels B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Liver B-PHE
, O
Liver B-PHE
health I-PHE

-DOCSTART- O


expel O
malign B-PHE
blood I-PHE

-DOCSTART- O


This O
is O
having O
a O
lot O
of O
phlegm B-PHE
due O
to O
carbuncle B-PHE
and O
cellulites B-PHE
. O

-DOCSTART- O


Doxapram O
produces O
respiratory B-PHE
stimulation I-PHE
mediated O
through O
the O
peripheral O
carotid O
chemoreceptors O
. O

It O
is O
thought O
to O
stimulate O
the O
carotid B-PHE
body I-PHE
by O
inhibiting O
certain B-PHE
potassium I-PHE
channels I-PHE
. O

-DOCSTART- O


Injury B-PHE
of I-PHE
Bladder I-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Monoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


move O
drug O
effect O

-DOCSTART- O


Hypertension B-PHE

-DOCSTART- O


Eye B-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Lipid O
profile O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Inflammation B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
absorption B-PHE
, O
UV O
protection O
, O
motility B-PHE
, O
Others O
, O
Urinary B-PHE
systems I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Eye B-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


Dextromethorphan O
is O
an O
opioid-like O
drug O
that O
binds O
to O
and O
acts O
as O
antagonist O
to O
the O
NMDA O
glutamatergic O
receptor O
, O
and O
targets O
the O
serotonin O
reuptake O
pump O
. O

-DOCSTART- O


hematemesis B-PHE
and O
epistaxis B-PHE

-DOCSTART- O


clear O
the O
liver B-PHE

-DOCSTART- O


Multiple B-PHE
Sclerosis I-PHE

-DOCSTART- O


Dihydroergotamine O
is O
a O
5-HT1D O
receptor O
agonists O
used O
for O
migraine B-PHE
, O
activation O
of O
5-HT1D O
receptors O
located O
on O
intracranial O
blood O
vessels O
, O
leads O
to O
vasoconstriction B-PHE
; O
activation O
of O
5-HT1D O
receptors O
on O
sensory O
nerve O
endings O
of O
the O
trigeminal B-PHE
system I-PHE
results O
in O
the O
inhibition O
of O
pro-inflammatory B-PHE
neuropeptide I-PHE
release I-PHE
. O

-DOCSTART- O


normalize O
Gi O
( O
Qi O
) O
and O
relieve O
pain B-PHE

-DOCSTART- O


1 O
Applicable O
to O
summer B-PHE
fever I-PHE
in O
children O
manifested O
as O
prolonged B-PHE
fever I-PHE
, O
restlessness B-PHE
, O
thirst B-PHE
, O
fatigue B-PHE
, O
red B-PHE
tongue I-PHE
with O
little O
fur O
, O
hollow O
and O
rapid B-PHE
pulse I-PHE
, O
which O
is O
attributed O
to O
comsumption O
of O
both O
vital B-PHE
energy I-PHE
and O
body B-PHE
fluid I-PHE
by O
summer-heat O
evil O
. O

In O
this O
case O
, O

-DOCSTART- O


menstrual B-PHE
irregularities I-PHE
; O
menstrual B-PHE
disorders I-PHE
; O
abnormal B-PHE
menstruation I-PHE

-DOCSTART- O


The O
bactericidal O
action O
of O
lomefloxacin O
results O
from O
interference O
with O
the O
activity B-PHE
of I-PHE
the I-PHE
bacterial I-PHE
enzymes I-PHE
DNA I-PHE
gyrase I-PHE
and O
topoisomerase B-PHE
IV I-PHE
, O
which O
are O
needed O
for O
the O
transcription O
and O
replication O
of O
bacterial O
DNA O
, O
as O
a O
result O
of O
inhibition O
of O
DNA B-PHE
replication I-PHE
and I-PHE
transcription I-PHE
. O

Furosemide O
blocks O
the O
Na-K-Cl B-PHE
cotransporter I-PHE
( O
NKCC B-PHE
) O
in O
the O
luminal O
membrane O
of O
the O
thick O
ascending O
limb O
of O
the O
loop O
of O
Henle O
in O
the O
kidney O
, O
by O
binding O
to O
the O
Cl-binding O
site O
located O
in O
the O
cotransporter's O
transmembrane O
domain O
, O
thereby O
inhibiting O
reabsorption B-PHE
of I-PHE
sodium I-PHE
, O
chloride B-PHE
, O
potassium B-PHE
ions I-PHE
and O
water O
. O

This O
agent O
reduces O
plasma B-PHE
and O
extracellular B-PHE
fluid I-PHE
volume I-PHE
resulting O
in O
decreased O
blood B-PHE
pressure I-PHE
and O
cardiac B-PHE
output I-PHE
. O

-DOCSTART- O


Methdilazine O
binds O
to O
the O
histamine O
H O
1 O
receptor O
. O

-DOCSTART- O


ecchymosis B-PHE

-DOCSTART- O


The O
bactericidal O
action O
of O
dalbavancin O
results O
primarily O
from O
inhibition O
of O
cell-wall B-PHE
biosynthesis I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Quality O
of O
life O
, O
Endocrine B-PHE
system I-PHE
, O
Others O
, O
Memory O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


aphasia B-PHE
with O
stiffness B-PHE
of I-PHE
the I-PHE
tongue I-PHE

-DOCSTART- O


Relaxing O
the O
smooth B-PHE
muscles I-PHE
of I-PHE
blood I-PHE
vessels I-PHE
and O
stimulating O
those O
of O
uterus B-PHE
, O
urinary B-PHE
bladder I-PHE
bronchus B-PHE
and O
gastrointestines B-PHE
. O

-DOCSTART- O


slight O
thirst B-PHE
and O
redness B-PHE
of I-PHE
the I-PHE
face I-PHE

-DOCSTART- O


For O
induction O
and O
maintenance O
in O
the O
treatment O
of O
cytomegalovirus B-PHE
( O
CMV B-PHE
) O
retinitis B-PHE
in O
immunocompromised O
patients O
, O
including O
patients O
with O
acquired B-PHE
immunodeficiency I-PHE
syndrome I-PHE
( O
AIDS B-PHE
) O
. O

Also O
used O
in O
the O
treatment O
of O
severe O
cytomegalovirus B-PHE
( O
CMV B-PHE
) O
disease B-PHE
, O
including O
CMV B-PHE
pneumonia I-PHE
, O
CMV B-PHE
gastrointestinal I-PHE
disease I-PHE
, O
and O
disseminated O
CMV B-PHE
infections I-PHE
, O
in O
immunocompromised O
patients O
. O

-DOCSTART- O


Non B-PHE
Small I-PHE
Cell I-PHE
Lung I-PHE
Carcinoma I-PHE

-DOCSTART- O


numbness B-PHE
of O
the O
limbs O

-DOCSTART- O


a O
symptom O
of O
pruritis B-PHE
due O
to O
smallpox B-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
; O
night B-PHE
sweating I-PHE
spontaneous B-PHE
sweating I-PHE
during O
asleep O
and O
no B-PHE
sweating I-PHE
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-PHE
of I-PHE
vital I-PHE
essence I-PHE
and O
presence B-PHE
of I-PHE
internal I-PHE
heat I-PHE
. O

-DOCSTART- O


Acute B-PHE
Gastroenteritis I-PHE
in O
Adult O
Travelers O

-DOCSTART- O


Pain B-PHE
in O
lumbus O
and O
legs O
. O

-DOCSTART- O


Urgency B-PHE
Incontinence I-PHE

-DOCSTART- O


stop O
sweating B-PHE

-DOCSTART- O


Purging O

-DOCSTART- O


Wind-damp B-PHE
bone I-PHE
pain I-PHE
, O
knocks O
and O
falls O
, O
bleeding B-PHE
due O
to O
external O
injury B-PHE
, O
child O
gan O
accumulation O
. O

-DOCSTART- O


dry B-PHE
heat I-PHE
and O
cough B-PHE
with O
much O
expectoration B-PHE

-DOCSTART- O


cool O
the O
blood B-PHE

-DOCSTART- O


Keishibukuryogan O
, O
one O
of O
the O
traditional O
herbal O
formulations O
, O
is O
used O
clinically O
to O
improve O
blood B-PHE
circulation I-PHE
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
keishibukuryogan O
on O
glucose B-PHE
and I-PHE
lipids I-PHE
metabolism I-PHE
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
, O
an O
animal O
model O
of O
type B-PHE
2 I-PHE
diabetes I-PHE
. O

Forty-five-week-old O
male O
OLETF O
rats O
were O
divided O
into O
three O
groups O
: O
diabetic O
control O
rats O
given O
a O
standard O
chow O
; O
diabetic O
rats O
given O
keishibukuryogan O
( O
0.03 O
, O
w/w O
in O
chow O
) O
; O
diabetic O
rats O
given O
pioglitazone O
( O
0.0001 O
, O
w/w O
in O
chow O
) O
. O

Oral O
administration O
of O
keishibukuryogan O
produced O
significant O
improvement O
against O
impaired B-PHE
glucose I-PHE
tolerance I-PHE
. O

On O
the O
other O
hand O
, O
fasting O
serum B-PHE
glucose I-PHE
and I-PHE
insulin I-PHE
levels I-PHE
, O
and O
the O
homeostasis B-PHE
index I-PHE
of O
insulin B-PHE
resistance I-PHE
did O
not O
change O
by O
keishibukuryogan O
treatment O
. O

Against O
lipid O
parameters O
, O
keishibukuryogan O
significantly O
lowered O
serum B-PHE
total I-PHE
cholesterol I-PHE
and O
triglyceride B-PHE
levels I-PHE
, O
and O
the O
hepatic B-PHE
total I-PHE
cholesterol I-PHE
level I-PHE
. O

Keishibukuryogan O
treatment O
also O
significantly O
reduced O
the O
serum B-PHE
leptin I-PHE
level I-PHE
, O
but O
it O
had O
no O
effect O
on O
the O
serum B-PHE
adiponectin I-PHE
level I-PHE
. O

Additionally O
, O
keishibukuryogan O
showed O
significant O
effects O
on O
epididymal B-PHE
adipose I-PHE
tissue I-PHE
by O
decreasing O
the O
size O
of O
fat B-PHE
cells I-PHE
and O
on O
skeletal B-PHE
muscle I-PHE
by O
reducing O
TNF-alpha B-PHE
protein I-PHE
content I-PHE
. O

From O
these O
results O
, O
it O
was O
suggested O
that O
keishibukuryogan O
exerts O
beneficial O
effects O
on O
the O
features O
associated O
with O
type B-PHE
2 I-PHE
diabetes I-PHE
. O

-DOCSTART- O


To O
cool O
blood B-PHE
and O
stanch O
bleeding B-PHE
, O
quicken O
blood B-PHE
and O
transform O
stasis O
. O

-DOCSTART- O


Bofutsushosan O
( O
BOF O
) O
, O
a O
traditional O
Chinese O
formulation O
( O
Kampo O
formulation O
in O
Japanese O
) O
, O
is O
widely O
used O
for O
patients O
with O
obesity B-PHE
and O
hyperlipidemia B-PHE
resulting O
from O
long-term O
inappropriate O
lifestyles O
. O

Since O
atherosclerosis B-PHE
, O
a O
lifestyle-related B-PHE
disease I-PHE
, O
is O
accompanied O
by O
an O
abnormal O
accumulation O
of O
vascular B-PHE
smooth I-PHE
muscle I-PHE
cells I-PHE
( O
VSMCs B-PHE
) O
in O
the O
intimal O
area O
of O
the O
artery O
, O
we O
investigated O
the O
preventive O
effect O
of O
BOF O
on O
intimal O
thickening O
. O

Oral O
administration O
of O
BOF O
extracts O
3 O
d O
before O
and O
7 O
d O
after O
balloon O
endothelial O
denudation O
dose O
dependently O
suppressed O
the O
intimal O
thickening O
and O
proliferation O
of O
VSMCs B-PHE
in O
the O
intimal O
area O
in O
rat O
carotid O
arteries O
. O

This O
model O
has O
a O
similar O
pathologic O
process O
to O
atherosclerosis B-PHE
and O
is O
considered O
to O
be O
an O
accelerated O
atherosclerosis B-PHE
model O
. O

BOF O
extract O
also O
dose O
dependently O
inhibited O
the O
migration O
of O
cultured O
VSMCs B-PHE
. O

BOF O
extract O
suppressed O
serum B-PHE
lipid I-PHE
levels I-PHE
, O
which O
are O
a O
major O
risk O
factor O
for O
atherosclerosis B-PHE
. O

These O
findings O
clarified O
the O
usefulness O
of O
BOF O
in O
cardiovascular O
risk-reduction O
therapy O
. O

-DOCSTART- O


Treatment O
of O
headache B-PHE
, O
particularly O
pain B-PHE
in O
the O
forehead O
, O
and O
stuffed B-PHE
nose I-PHE
due O
to O
colds B-PHE
, O
sinusitis B-PHE
, O
toothache B-PHE
, O
excessive O
leukorrhea B-PHE
, O
swelling B-PHE
and O
pain B-PHE
of O
sores B-PHE
and O
wounds B-PHE
. O

-DOCSTART- O


cool O
the O
blood B-PHE
and O
move O
the O
blood B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
move O
water O
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


amenorrhea B-PHE
; O
menstrual B-PHE
block I-PHE
absence I-PHE
or O
suppression B-PHE
of I-PHE
menstruation I-PHE
. O

-DOCSTART- O


distribution O
) O
, O
absorption B-PHE
, O
Endurance B-PHE
, O
Body B-PHE
weight I-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Mimmuietabolic B-PHE
rate I-PHE
/ I-PHE
energy I-PHE
expenditure I-PHE
, O
motility B-PHE
, O
Others O

-DOCSTART- O


hematemesis B-PHE
; O
blood B-PHE
vomiting I-PHE
; O
spitting B-PHE
blood I-PHE
; O
blood B-PHE
vomiting I-PHE

-DOCSTART- O


harmonize O
blood B-PHE
vessel I-PHE

-DOCSTART- O


To O
promote O
diuresis B-PHE
, O
treat O
stranguria B-PHE
, O
remove O
urinary B-PHE
calculus I-PHE
. O

-DOCSTART- O


Chai O
Hu O
( O
Radix O
Burpleuri O
) O
, O
a O
major O
ingredient O
in O
many O
traditional O
Chinese O
medicine O
formulas O
, O
such O
as O
Xiao O
Yan O
Wan O
, O
is O
used O
in O
the O
treatment O
of O
liver B-PHE
stagnation I-PHE
and O
spleen B-PHE
deficiency I-PHE
syndrome I-PHE
( O
LSSDS B-PHE
) O
. O

The O
objectives O
of O
this O
study O
were O
to O
examine O
the O
effects O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
changes O
of O
plasma B-PHE
indices I-PHE
in O
patients O
with O
LSSDS B-PHE
. O

Fifty-eight O
cases O
of O
LSSDS B-PHE
were O
randomly O
divided O
into O
two O
groups O
: O
41 O
cases O
in O
the O
experimental O
group O
were O
treated O
with O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
and O
17 O
cases O
in O
the O
control O
group O
were O
treated O
with O
Zhi O
Bai O
Di O
Huang O
Wan O
for O
one O
consecutive O
month O
in O
a O
single O
blind O
design O
. O

Before O
and O
after O
treatment O
, O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
was O
applied O
to O
determine O
the O
changes O
of O
plasma B-PHE
norepinephrine I-PHE
( O
NE B-PHE
) O
, O
epinephrine B-PHE
( O
E B-PHE
) O
and O
dopamine B-PHE
( O
DA B-PHE
) O
. O

Radioimmunoassay O
was O
performed O
to O
measure O
the O
amount O
of O
plasma B-PHE
beta-endorphin I-PHE
( O
beta-EP B-PHE
) O
, O
adrenocorticotropin B-PHE
hormone I-PHE
( O
ACTH B-PHE
) O
, O
estradiol B-PHE
( O
E2 B-PHE
) O
and O
testosterone B-PHE
( O
T B-PHE
) O
, O
and O
laser O
nephelometry O
was O
also O
conducted O
to O
measure O
plasma B-PHE
immunoglobulin I-PHE
A I-PHE
( O
Ig B-PHE
A) I-PHE
and O
G O
( O
Ig B-PHE
G I-PHE
) O
. O

Compared O
to O
baseline O
levels O
, O
plasma B-PHE
beta-EP I-PHE
was O
significantly O
increased O
(p O
< O
0.01 O
) O
, O
while O
E B-PHE
and O
DA B-PHE
were O
markedly O
decreased O
(p O
< O
0.01 O
) O
after O
the O
administration O
of O
Xiao O
Yao O
Wan O
in O
the O
experimental O
group O
. O

The O
other O
indices O
did O
not O
change O
. O

This O
is O
the O
first O
evidence O
showing O
that O
the O
effect O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
treatment O
of O
patients O
with O
LSSDS B-PHE
may O
be O
through O
enhancing O
plasma B-PHE
beta-EP I-PHE
and O
decreasing O
E B-PHE
and O
DA B-PHE
release O
. O

We O
conclude O
that O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
regulates O
nervous B-PHE
and I-PHE
endocrine I-PHE
systems I-PHE
and O
contributes O
to O
the O
improvement O
of O
the O
clinical O
status O
of O
patients O
with O
LSSDS B-PHE
. O

-DOCSTART- O


This O
study O
was O
conducted O
to O
evaluate O
the O
importance O
of O
intraoperative O
smear O
examinations O
for O
the O
final O
diagnosis O
of O
intracerebral O
stereotaxic O
procedures O
. O

125 O
consecutive O
patients O
with O
suspect O
intracerebral B-PHE
lesions I-PHE
underwent O
stereotaxic O
frame-based O
biopsies O
after O
acquisition O
of O
computer O
tomographic O
and O
magnetic O
resonance O
images O
. O

After O
secondary O
image O
processing O
, O
including O
multiplanar O
visualization O
of O
the O
target O
region O
and O
target O
definition O
, O
a O
serial O
biopsy O
was O
realized O
using O
an O
aspiration O
Sedan O
needle O
. O

Biopsy O
taking O
was O
repeated O
as O
long O
as O
pathological O
tissue O
samples O
were O
obtained O
according O
to O
the O
visual O
impression O
of O
the O
neurosurgeon O
( O
group O
I) O
or O
to O
the O
first O
neuropathological O
result O
of O
a O
smear O
examination O
( O
group O
II O
) O
. O

Retrospective O
analysis O
of O
all O
cases O
showed O
that O
intraoperative O
microscopic O
diagnostics O
could O
improve O
the O
conditions O
for O
a O
definitive O
neuropathological O
diagnosis O
from O
0.918 O
( O
56/61 O
patients O
, O
group O
I) O
to O
0.969 O
( O
62/64 O
patients O
, O
group O
II O
) O
( O
t>0.05 O
) O
. O

The O
number O
of O
biopsy O
specimens O
and O
the O
rate O
of O
CT-detectable O
small B-PHE
bleedings I-PHE
differed O
slightly O
between O
both O
groups O
and O
were O
higher O
in O
group O
II O
. O

The O
duration O
of O
surgery O
and O
anaesthesia O
as O
well O
as O
the O
final O
neurological O
outcomes O
were O
comparable O
in O
both O
groups O
. O

In O
conclusion O
, O
intraoperative O
smear O
examination O
as O
a O
kind O
of O
bedside O
diagnostics O
confers O
a O
better O
diagnostic O
safety O
and O
improves O
the O
reliability O
of O
this O
minimal O
invasive O
manoeuvre O
. O

-DOCSTART- O


lubricate O
the O
intestines B-PHE

-DOCSTART- O


Patients O
with O
squamous B-PHE
cell I-PHE
carcinoma I-PHE
of O
the O
head O
and O
neck O
. O

-DOCSTART- O


Objectives O
Mycobacterium B-PHE
avium I-PHE
subspecies I-PHE
paratuberculosis I-PHE
( O
MAP B-PHE
) O

-DOCSTART- O


Sirolimus O
inhibits O
T B-PHE
lymphocyte I-PHE
activation I-PHE
and I-PHE
proliferation I-PHE
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-PHE
( O
Interleukin B-PHE
IL-2 B-PHE
, O
IL-4 B-PHE
, O
and O
IL-15 B-PHE
) O
stimulation O
by O
a O
mechanism O
that O
is O
distinct O
from O
that O
of O
other O
immunosuppressants O
. O

-DOCSTART- O


To O
nourish O
blood B-PHE
. O

-DOCSTART- O


It O
is O
designed O
to O
mimic O
the O
molecular O
shape O
of O
adrenaline O
. O

It O
binds O
to O
alpha-adrenergic O
receptors O
in O
the O
nasal O
mucosa O
. O

Here O
it O
can O
, O
therefore O
, O
cause O
vasoconstriction B-PHE

-DOCSTART- O


bloody B-PHE
dysentery I-PHE

-DOCSTART- O


A O
traditional O
Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
is O
a O
well-known O
Kampo O
formula O
, O
and O
has O
been O
found O
to O
enhance O
antigen-specific B-PHE
antibody I-PHE
response I-PHE
in O
not O
only O
local O
mucosal B-PHE
immune I-PHE
system I-PHE
in O
upper O
respiratory O
tract O
, O
but O
also O
systemic B-PHE
immune I-PHE
system I-PHE
through O
upper O
respiratory B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
. O

Although O
this O
immunopharmacological O
effect O
has O
been O
proposed O
to O
express O
by O
modulation O
of O
intestinal B-PHE
immune I-PHE
system I-PHE
including O
Peyer's B-PHE
patches I-PHE
and O
intestinal B-PHE
epithelial I-PHE
cells I-PHE
, O
active O
ingredients O
are O
not O
known O
. O

TJ-41 O
directly O
affected O
the O
production O
of O
bone B-PHE
marrow I-PHE
cell I-PHE
- O
proliferative O
growth B-PHE
factors I-PHE
from O
murine O
Peyer's O
patch O
immunocompetent O
cells O
in O
vitro O
. O

Among O
low O
molecular O
, O
intermediate O
size O
and O
macromolecular O
weight O
fractions O
prepared O
from O
TJ-41 O
, O
only O
fraction O
containing O
macromolecular O
weight O
ingredients O
showed O
Peyer's B-PHE
patch I-PHE
- O
mediated O
bone B-PHE
marrow I-PHE
cell I-PHE
- O
proliferation O
enhancing O
activity O
. O

Anion-exchange O
chromatography O
and O
gel O
filtration O
gave O
17 O
subfractions O
comprising O
polysaccharides O
and O
lignins O
from O
the O
macromolecular O
weight O
fraction O
of O
TJ-41 O
, O
and O
some O
of O
the O
subfractions O
showed O
significant O
enhancing O
activities O
having O
different O
degrees O
. O

Some O
of O
the O
subfractions O
also O
expressed O
stimulating O
activity O
on O
G-CSF B-PHE
- I-PHE
production I-PHE
from O
colonic O
epithelial O
cells O
, O
and O
statistically O
significant O
positive O
correlation O
was O
observed O
among O
enhancing O
activities O
of O
the O
subfractions O
against O
Peyer's B-PHE
patch I-PHE
immunocompetent I-PHE
cells I-PHE
and O
epithelial B-PHE
cells I-PHE
. O

Among O
the O
fractions O
from O
TJ-41 O
oral O
administration O
of O
macromolecular O
weight O
ingredient O
fraction O
to O
mice O
succeeded O
to O
enhance O
antigen-specific B-PHE
antibody I-PHE
response I-PHE
in O
systemic B-PHE
immune I-PHE
system I-PHE
through O
upper O
respiratory B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
, O
but O
all O
the O
separated O
fractions O
failed O
to O
enhance O
the O
in O
vivo O
antibody B-PHE
response I-PHE
in O
upper O
respiratory O
tract O
. O

-DOCSTART- O


Native O
Americans O
residing O
in O
a O
broad O
region O
downwind O
from O
the O
Nevada O
Test O
Site O
during O
the O
1950s O
and O
1960s O
received O
significant O
radiation O
exposures O
from O
nuclear O
weapons O
testing O
. O

Because O
of O
differences O
in O
diet O
, O
activities O
, O
and O
housing O
, O
their O
radiation O
exposures O
are O
only O
very O
imperfectly O
represented O
in O
the O
Department O
of O
Energy O
dose O
reconstructions O
. O

There O
are O
important O
missing O
pathways O
, O
including O
exposures O
to O
radioactive O
iodine O
from O
eating O
small O
game O
. O

The O
dose O
reconstruction O
model O
assumptions O
about O
cattle O
feeding O
practices O
across O
a O
year O
are O
unlikely O
to O
apply O
to O
the O
native O
communities O
as O
are O
other O
model O
assumptions O
about O
diet O
. O

Thus O
exposures O
from O
drinking O
milk O
and O
eating O
vegetables O
have O
not O
yet O
been O
properly O
estimated O
for O
these O
communities O
. O

Through O
consultations O
with O
members O
of O
the O
affected O
communities O
, O
these O
deficiencies O
could O
be O
corrected O
and O
the O
dose O
reconstruction O
extended O
to O
Native O
Americans O
. O

An O
illustration O
of O
the O
feasibility O
of O
extending O
the O
dose O
reconstruction O
is O
provided O
by O
a O
sample O
calculation O
to O
estimate O
radiation O
exposures O
to O
the O
thyroid B-PHE
from O
eating O
radio-iodine-contaminated O
rabbit O
thyroids B-PHE
after O
the O
Sedan O
test O
. O

The O
illustration O
is O
continued O
with O
a O
discussion O
of O
how O
the O
calculation O
results O
may O
be O
used O
to O
make O
estimates O
for O
other O
tests O
and O
other O
locations O
. O

-DOCSTART- O


The O
antiinflammatory B-PHE
effects I-PHE
of O
tenoxicam O
may O
result O
from O
the O
inhibition O
of O
the O
enzyme O
cycooxygenase O
and O
the O
subsequent O
peripheral O
inhibition O
of O
prostaglandin B-PHE
synthesis I-PHE
. O

As O
prostaglandins O
sensitize O
pain B-PHE
receptors O
, O
their O
inhibition O
accounts O
for O
the O
peripheral O
analgesic O
effects O
of O
tenoxicam O
. O

Antipyresis O
may O
occur O
by O
central O
action O
on O
the O
hypothalamus B-PHE
, O
resulting O
in O
peripheral O
dilation O
, O
increased O
cutaneous O
blood B-PHE
flow O
, O
and O
subsequent O
heat B-PHE
loss I-PHE
. O

-DOCSTART- O


epilepsy B-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


Diaphragmatic B-PHE
Dysfunction I-PHE

-DOCSTART- O


moisten O
the O
lung B-PHE
and O
send O
Gi(Qi O
) O
downward O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Intelligence O
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Strength O
and O
power O
, O
Neurological B-PHE
systems I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Cardiac B-PHE
Output I-PHE
, I-PHE
Low I-PHE

-DOCSTART- O


Pancreatic B-PHE
cancer I-PHE

-DOCSTART- O


Inhibiting O
the O
growth O
of O
various O
kinds O
of O
dermatomyces B-PHE
. O

-DOCSTART- O


urticaria B-PHE

-DOCSTART- O


Swelling B-PHE
pain I-PHE
in O
throat O
, O
red O
eyes O
with O
gall O
, O
lung O
heat O
cough B-PHE
, O
mastitis B-PHE
, O
damp-heat B-PHE
jaundice B-PHE
, O
wind-damp B-PHE
impediment O
pain B-PHE
, O
bleeding B-PHE
due O
to O
external B-PHE
injury I-PHE
. O

-DOCSTART- O


Treatment O
of O
stroke B-PHE
with O
gurgling B-PHE
in I-PHE
the I-PHE
throat I-PHE
, O
deviation B-PHE
of I-PHE
the I-PHE
eye I-PHE
and I-PHE
the I-PHE
mouth I-PHE
, O
and O
impairment B-PHE
of I-PHE
speech I-PHE
, O
upward O
invasion O
of O
phlegm B-PHE
causing O
headache B-PHE
accompanied O
with O
dizziness B-PHE
, O
heaviness B-PHE
of I-PHE
the I-PHE
body I-PHE
, O
restlessness B-PHE
, O
fidgetness B-PHE
, O
nausea B-PHE
and O
cold B-PHE
extremities I-PHE
, O
or O
migraine B-PHE
, O
sore B-PHE
throat I-PHE
, O
tetanus B-PHE
, O
external O
use O
for O
scrofula B-PHE
, O
venomous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


hoarseness B-PHE

-DOCSTART- O


alleviate O
edema B-PHE
and O
toxin B-PHE

-DOCSTART- O


Juzentaihoto O
( O
JTT O
) O
is O
a O
well-known O
Japanese O
herbal O
medicine O
, O
which O
has O
been O
reported O
to O
modulate O
immune B-PHE
responses I-PHE
and O
enhance O
antitumor B-PHE
immunity I-PHE
in O
animal O
models O
. O

However O
, O
it O
is O
not O
clear O
whether O
JTT O
has O
similar O
effects O
on O
humans O
. O

In O
particular O
, O
there O
is O
little O
information O
on O
the O
effects O
of O
JTT O
in O
antigen-specific B-PHE
immunity I-PHE
in O
cancer B-PHE
patients O
. O

Here O
we O
conducted O
a O
randomized O
clinical O
study O
to O
investigate O
whether O
combined O
usage O
of O
JTT O
could O
affect O
antigen-specific B-PHE
immunity I-PHE
and O
clinical O
findings O
in O
advanced O
pancreatic B-PHE
cancer I-PHE
patients O
undergoing O
personalized O
peptide O
vaccination O
( O
PPV O
) O
, O
in O
which O
HLA-matched O
vaccine O
antigens O
were O
selected O
based O
on O
the O
preexisting B-PHE
host I-PHE
immunity I-PHE
. O

Fifty-seven O
patients O
were O
randomly O
assigned O
to O
receive O
PPV O
with O
(n O
= O
28 O
) O
or O
without O
(n O
= O
29 O
) O
JTT O
. O

Unexpectedly O
, O
JTT O
did O
not O
significantly O
affect O
cellular B-PHE
or I-PHE
humoral I-PHE
immune I-PHE
responses I-PHE
specific O
to O
the O
vaccine O
antigens O
, O
which O
were O
determined O
by O
antigen B-PHE
- I-PHE
specific I-PHE
interferon I-PHE
- I-PHE
y I-PHE
secretion I-PHE
in O
T B-PHE
cells I-PHE
and O
antigen B-PHE
- I-PHE
specific I-PHE
IgG I-PHE
titers I-PHE
in O
plasma O
, O
respectively O
. O

Nevertheless O
, O
JTT O
prevented O
deterioration O
of O
patients' O
conditions O
, O
such O
as O
anemia B-PHE
, O
lymphopenia B-PHE
, O
hypoalbuminemia B-PHE
, O
plasma B-PHE
IL-6 I-PHE
elevation I-PHE
, O
and O
reduction O
of O
performance O
status O
, O
which O
are O
frequently O
observed O
in O
advanced O
cancers B-PHE
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
clinical O
study O
that O
examined O
the O
immunological O
and O
clinical O
effects O
of O
JTT O
in O
cancer B-PHE
patients O
undergoing O
immunotherapy O
in O
humans O
. O

-DOCSTART- O


injury B-PHE
by O
wind B-PHE
pathogen I-PHE
and O
headache B-PHE

-DOCSTART- O


Measles B-PHE
papules O
with O
complicated O
pneumonia B-PHE
, O
throat B-PHE
erosion I-PHE
. O

-DOCSTART- O


spasmodic B-PHE
contraction I-PHE
of I-PHE
tendons I-PHE
and I-PHE
meridian I-PHE

-DOCSTART- O


Used O
to O
produce O
controlled B-PHE
hypotension I-PHE
during O
surgical O
procedures O
and O
in O
hypertensive B-PHE
crises I-PHE
. O

-DOCSTART- O


difficulty B-PHE
in I-PHE
feces I-PHE
and I-PHE
urine I-PHE

-DOCSTART- O


attack O
and O
expel O

-DOCSTART- O


( O
1 O
) O
morbid B-PHE
leukorrhea I-PHE
; O
( O
2 O
) O
gynecological B-PHE
diseases I-PHE
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Others O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Respiratory B-PHE
systems I-PHE
, O
Respiratory B-PHE
systems I-PHE
health I-PHE
, O
motility B-PHE
, O
absorption B-PHE
, O
Others O
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


Acute B-PHE
Mania I-PHE

-DOCSTART- O


To O
relax O
the O
bowels B-PHE
( O
sthenia-syndrome B-PHE
with O
constipation B-PHE
due O
to O
accumulation O
of O
cold B-PHE
, O
dysentery B-PHE
of I-PHE
cold I-PHE
type O
) O
. O

-DOCSTART- O


weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE

-DOCSTART- O


purge O
heat B-PHE
and O
treat O
gam B-PHE
( O
gan O
) O

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE
, O
Liver B-PHE

-DOCSTART- O


Its O
decoction O
promotes O
the O
secretion B-PHE
of I-PHE
pepsin I-PHE
and I-PHE
gastric I-PHE
juice I-PHE
. O

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
remove O
stagnation B-PHE
. O

-DOCSTART- O


Macular B-PHE
Edema I-PHE

-DOCSTART- O


illness B-PHE

-DOCSTART- O


Pharyngitis B-PHE
, O
excessive B-PHE
sputum I-PHE
blocking O
the O
windpipe O
, O
rapid B-PHE
breathing I-PHE
and O
even O
suffocation B-PHE
. O

-DOCSTART- O


ulcer B-PHE

-DOCSTART- O


ulceration B-PHE
in O
the O
gum O

-DOCSTART- O


metrorrhagia B-PHE
and O
metrostaxis B-PHE

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE

-DOCSTART- O


For O
promoting O
diuresis B-PHE
and O
desolving O
inflammation B-PHE

-DOCSTART- O


Used O
to O
provide O
skeletal B-PHE
muscle I-PHE
relaxation I-PHE
as O
an O
adjunct O
to O
general B-PHE
anesthesia I-PHE
, O
for O
endotracheal O
intubation O
or O
to O
facilitate O
mechanical O
ventilation O
. O

-DOCSTART- O


Cystic B-PHE
Fibrosis I-PHE

-DOCSTART- O


malaria B-PHE
; O
malarial B-PHE
disorder I-PHE
malaria B-PHE
and O
other O
disease O
characterized O
by O
intermittent O
rigor B-PHE
, O
high O
fever B-PHE
and O
sweating B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hernia B-PHE
( O
2 O
) O
diseases B-PHE
of I-PHE
genitalia I-PHE
( O
3 O
) O
severe O
pain B-PHE
in O
the O
lower O
abdomen O

-DOCSTART- O


Esophageal B-PHE
Varices I-PHE

-DOCSTART- O


nfantile O
malnutrition B-PHE
with O
diarrhea B-PHE

-DOCSTART- O


Polycystic B-PHE
Ovary I-PHE
Syndrome I-PHE

-DOCSTART- O


promote O
water O
and O
purge O
/ O
relieve O
toxicity B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
gastroesophageal B-PHE
reflux I-PHE
disease I-PHE
( O
GERD B-PHE
) O
. O

It O
is O
also O
used O
in O
treating O
nausea B-PHE
and O
vomiting B-PHE
, O
and O
to O
increase O
gastric B-PHE
emptying I-PHE
. O

Occasionally O
used O
in O
Cushing's B-PHE
syndrome I-PHE
. O

-DOCSTART- O


bloodshot B-PHE
eyes I-PHE
; O
congestion B-PHE
of I-PHE
the I-PHE
eye I-PHE
; O
red B-PHE
eyes I-PHE
; O
redness B-PHE
of I-PHE
the I-PHE
eye I-PHE

-DOCSTART- O


postpartum B-PHE
debility I-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
swelling B-PHE
pain I-PHE
in I-PHE
throat I-PHE
, O
scrofula B-PHE
, O
mammary B-PHE
welling I-PHE
abscess I-PHE
, O
sore B-PHE
and O
boil B-PHE
, O
eczema B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
poisonous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


insomnia B-PHE

-DOCSTART- O


Advanced B-PHE
Breast I-PHE
Cancer I-PHE

-DOCSTART- O


Cerebral B-PHE
thrombosis I-PHE

-DOCSTART- O


venomous O
snake-bite B-PHE

-DOCSTART- O


nourish O
the O
stomach B-PHE
stop O
dysentery B-PHE

-DOCSTART- O


Lymphoma B-PHE
, I-PHE
Lymphoblastic I-PHE

-DOCSTART- O


Binds O
to O
the O
nicotinic O
acetycholine O
receptors O
( O
by O
virtue O
of O
its O
similarity O
to O
acetylcholine O
) O
in O
the O
motor O
endplate O
and O
blocks O
access O
to O
the O
receptors O
. O

-DOCSTART- O


affection O
due O
to O
wind-cold B-PHE
; O
common O
cold B-PHE
caused O
by O
wind B-PHE
and O
cold B-PHE

-DOCSTART- O


cough B-PHE
due O
to O
phlegm B-PHE

-DOCSTART- O


1 O
An O
active O
component O
arcitiin O
is O
a O
vasodilator O
and O
hypotensive O
. O
2 O
. O
Over O
dosage O
of O
arctiin O
may O
lead O
to O
convulsion B-PHE
and O
respiratory B-PHE
failure I-PHE
. O

-DOCSTART- O


Dalbavancin O
has O
a O
spectrum O
and O
mechanism O
of O
action O
similar O
to O
vancomycin B-PHE
, O
a O
naturally O
formed O
glycopeptide B-PHE
antimicrobial I-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
thin O
due O
to O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


Chlorothiazide O
is O
indicated O
as O
adjunctive O
therapy O
in O
edema B-PHE
associated O
with O
congestive B-PHE
heart I-PHE
failure I-PHE
, O
hepatic B-PHE
cirrhosis I-PHE
, O
and O
corticosteroid O
and O
estrogen O
therapy O
. O

It O
is O
also O
indicated O
in O
the O
management O
of O
hypertension B-PHE
either O
as O
the O
sole O
therapeutic O
agent O
or O
to O
enhance O
the O
effectiveness O
of O
other O
antihypertensive O
drugs O
in O
the O
more O
severe O
forms O
of O
hypertension B-PHE
. O

-DOCSTART- O


Vaginal B-PHE
Atrophy I-PHE

-DOCSTART- O


abdominal B-PHE
pain I-PHE
due O
to O
stagnation O
of O
Gi O

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


Extemal O
use O
for O
carbuncle B-PHE
, O
pyogenic B-PHE
infection I-PHE
of O
skin O
, O
ulcera B-PHE
tive I-PHE
gingivitis I-PHE
and O
dental B-PHE
caries I-PHE
. O

Recently O
, O
also O
for O
carcinoma B-PHE
of I-PHE
breast I-PHE
, I-PHE
cervix I-PHE
and I-PHE
pancreas I-PHE
and O
malignant B-PHE
lymphoma I-PHE

-DOCSTART- O


Anemia B-PHE

-DOCSTART- O


cosolidate O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


